UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-K
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
or
For the transition period from to
Commission file number: 001-36182
Xencor, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of
Incorporation or Organization)
111 West Lemon Avenue, Monrovia, CA
(Address of Principal Executive Offices)
20-1622502
(I.R.S. Employer
Identification No.)
91016
(Zip Code)
Securities registered pursuant to Section 12(b) of the Act:
(626) 305-5900
(Registrant’s Telephone Number, Including Area Code)
Title of each class
Common Stock, par value $0.01 per share
Trading Symbol
XNCR
Name of each exchange on which registered
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒
No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange
Act.
Large accelerated filer ☒
Accelerated filer ☐
Non-accelerated filer ☐
Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ☐ No ☒
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last
sold as of June 28, 2019 was $2,291,908,831.
The number of outstanding shares of the registrant’s common stock, par value $0.01 per share, as of February 14, 2020 was 56,943,858.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s
2020 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be
filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant’s fiscal year ended December 31, 2019.
Table of Contents
PART I
Item 1
Item 1A
Item 1B
Item 2
Item 3
Item 4
PART II
Item 5
Item 6
Item 7
Item 7A
Item 8
Item 9
Item 9A
Item 9B
PART III
Item 10
Item 11
Item 12
Item 13
Item 14
PART IV
Item 15
Item 16
Signatures
Xencor, Inc.
FORM 10-K
For the Fiscal Year Ended December 31, 2019
Table of Contents
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Exhibits, Financial Statement Schedules
Form 10-K Summary
Page
4
25
57
57
57
57
57
59
60
81
81
115
115
116
116
116
116
116
116
117
121
122
The Xencor logo is a trademark of Xencor, Inc. XmAb, PDA and Protein Design Automation are also registered
trademarks of Xencor. All other product and company names are trademarks of their respective companies. References in
this Annual Report on Form 10-K to “we”, “our”, “us”, “Xencor” or “the Company” refer to Xencor, Inc.
2
Table of Contents
Forward-Looking Statements
PART I
This Annual Report on Form 10-K (Annual Report), may contain “forward-looking statements” within the meaning
of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. We have based these forward-looking statements largely on our current expectations and projections about future
events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read
as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which
such performance or results will be achieved. Forward-looking statements are based on information available at the time
those statements are made and/or management’s good faith belief as of that time with respect to future events, and are subject
to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or
suggested by the forward-looking statements. Our actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors, including those set forth below under Part I, Item 1A, “Risk
Factors” in this Annual Report. These statements, which represent our current expectations or beliefs concerning various
future events, may contain words such as “may,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate” or
other words indicating future results. Such statements may include, but are not limited to, statements concerning the
following:
● the initiation, cost, timing, progress and results of our research and development activities, preclinical studies
and future clinical trials;
● our ability to obtain and maintain regulatory approval of our future product candidates, and any related
restrictions, limitations, and/or warnings in the label of an approved product candidate;
● our ability to obtain funding for our operations;
● our plans to research, develop and commercialize our future product candidates;
● our strategic alliance partners’ election to pursue development and commercialization;
● our ability to attract collaborators with development, regulatory, and commercialization expertise;
● our ability to obtain and maintain intellectual property protection for our future product candidates;
● the size and growth potential of the markets for our future product candidates, and our ability to serve those
markets;
● our ability to successfully commercialize our future product candidates;
● the rate and degree of market acceptance of our future product candidates;
● our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;
● regulatory developments in the United States (U.S.) and foreign countries;
● the performance of our third-party suppliers and manufacturers;
● the success of competing therapies that are or become available;
● the loss of key scientific or management personnel;
● our failure to successfully execute our growth strategy including any delays in our planned future growth;
3
Table of Contents
● our failure to maintain effective internal controls; and
● the accuracy of our estimates regarding expenses, future revenues, capital requirements and need for additional
financing.
Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-
looking statements represent our estimates and assumptions only as of the date of this Annual Report, and except as required
by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new
information, future events, or otherwise after the date of this Annual Report. We qualify all of our forward-looking
statements by these cautionary statements.
Item 1. Business.
Our Business
We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal
antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. We are
developing a suite of clinical-stage drug candidates, ourselves and with our partners, from our proprietary XmAb®
technology platforms that are designed to treat cancer and autoimmune diseases. In contrast to conventional approaches to
antibody design, which focus on the segment of antibodies that interact with target antigens, our protein engineering efforts
and the XmAb technologies are focused on the parts of the antibody that interacts with multiple segments of the immune
system and controls antibody structure. This segment, referred to as the Fc domain, is constant and interchangeable among
antibodies. Our engineered Fc domains, the XmAb technology, can be readily substituted for natural Fc domains.
We believe our XmAb technologies enhance antibody performance by, for example, increasing immune inhibitory
activity, improving cytotoxicity, extending circulating half-life, or stabilizing novel antibody and other protein structures,
while maintaining 99.5% identity in structure and sequence to natural antibodies. By designing antibodies and other protein
molecules with improved function, we believe that our XmAb-engineered proteins offer innovative approaches to treating
disease and potential clinical advantages over other treatments. For example, our partner Alexion, used our Xtend™ Fc
technology to enhance the half-life of Ultomiris®, a complement inhibitor antibody, to allow for a longer duration of action,
less frequent dosing and reduced patient burden of therapy compared to the previous generation therapy, Soliris®. Ultomiris
is approved for marketing in the United States (U.S.), the European Union and Japan for the treatment of adult patients with
the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) and also approved in the US for the treatment of patients
with atypical hemolytic uremic syndrome (aHUS).
In December 2019, our partner MorphoSys AG submitted a Biologics License Application (BLA) to the US Food
and Drug Administration (FDA) for tafasitamab (MOR208/XmAb5574) for the treatment of patients with relapsed/refractory
diffuse large B cell lymphoma (DLBCL). Tafasitamab was initially developed by us and incorporates our Cytotoxic Fc
domain to enhance its tumor killing properties.
Our protein engineering capabilities allow us to continually explore new functionality in the Fc region, which
provides us with opportunities to:
● Identify new technology platforms;
● Identify new drug candidates for internal development; and
● Provide collaboration and licensing opportunities with partners for access to our technologies, to our drug
candidates, or a combination of both.
4
Table of Contents
The most recent expansion of our platform is the XmAb bispecific Fc domains, which enable the rapid design and
simplified development of antibodies and other protein structures that can bind two or more different targets simultaneously.
Our Strategy
Our goal is to become a leading biopharmaceutical company focused on developing and commercializing
engineered monoclonal antibodies and other proteins in oncology and autoimmune to treat patients with severe and life-
threatening diseases with unmet medical needs. Key elements of our strategy are to:
1. Advance the clinical development of our bispecific Fc domain development candidates. Our XmAb bispecific
technology and protein engineering capabilities allow us the opportunity to rapidly develop multiple drug
candidates with dual targeting mechanisms for the treatment of various cancers including hematologic
malignancies and solid tumors as well as autoimmune diseases. We and our partners have initiated Phase 1 studies
for six of these candidates and a seventh is expected to dose a Phase 1 study in early 2020, and we plan to
advance additional bispecific antibodies and cytokines, currently in preclinical development, in the future.
2. Build a large and diversified portfolio of product candidates. We aim to create new XmAb-engineered antibody
and cytokine product candidates that exploit the novel properties of our XmAb technology platform for
preclinical and clinical development by us or, if appropriate, license certain candidates to leading pharmaceutical
and biotechnology companies.
3. Continue to monetize and expand the use of our XmAb technology platform and XmAb candidates. We
continuously seek opportunities to maximize the value of our XmAb technologies and drug candidates and will
selectively license our drug candidates and access to certain of our technologies to leading pharmaceutical and
biotechnology companies.
Since we began focusing our efforts on the potential applications of our bispecific Fc domain, we and our partners
have advanced ten drug candidates using our bispecific Fc domain into clinical development, we have expanded
the functionality of our bispecific Fc technology and have entered into three collaborations with major
pharmaceutical companies that have generated over $340.0 million in total upfront and milestone payments.
In 2019, we received a total of $164.0 million in upfront payments, milestones and royalties from our partnerships
and collaborations including: upfront payments from Genentech and Astellas of $120.0 million and $15.0 million,
respectively; milestone payments from Novartis and Amgen of $10.0 million and $5.0 million, respectively; and a
total of $13.0 million in milestones and royalties from Alexion.
In early 2020, we will receive $16.0 million in licensing payments including an upfront payment of $6.0 million
from Gilead and $10.0 million from Aimmune, which includes a $5.0 million upfront payment and Aimmune
Common Stock having an aggregate value of $5.0 million.
4. Broaden the functionality of our XmAb technology platform. We are conducting further research into the
function and application of antibody Fc domains in order to expand the scope of our XmAb technology platform.
Our bispecific technology, which uses our heterodimeric Fc domain to enable molecules with dual target binding,
is the most recent example of the expanding functionality of our XmAb technology platform, and we have
applied it to create a wide range of novel therapeutic candidates.
5. Continue to expand our patent portfolio protecting our XmAb technologies and XmAb candidates. We seek to
expand and protect our development programs and product candidates by filing and prosecuting patents in the
United States and other countries.
5
Table of Contents
XmAb® Technologies
A distinguishing feature of our XmAb technologies is our modular approach to protein engineering. This provides
us with flexibility to seek out new applications of the bispecific Fc domain, allows us to design drug candidates with distinct
and novel mechanisms-of-action, and also allows for different variable target combinations. This approach is illustrated
through our expansion of our bispecific Fc platform and the novel candidates that we have designed.
CD3 candidates: the initial bispecific antibody candidates we designed were created with our engineered
heterodimer Fc domain, or bispecific Fc domain, and are dual-antigen targeting molecules, containing an anti-tumor
associated antigen binding domain and a second binding domain targeted to CD3, an activating receptor on T-cells. The goal
of the “CD3 bispecific” is to recruit or activate T cells against tumor cells expressing the antigen target. We are currently
conducting Phase 1 studies for three CD3 bispecific antibody candidates: XmAb14045, plamotamab (XmAb13676), and
XmAb18087.
TME activator candidates: we expanded the functionality of our bispecific Fc platform with a suite of tumor
microenvironment (TME) activators that have been designed to promote tumor-selective T-cell activation by targeting
multiple checkpoints or co-stimulating receptors. These TME activator candidates use our bispecific Fc domain and
incorporate our Xtend technology for longer half-life. We are currently conducting Phase 1 studies for three TME activator
candidates: XmAb20717, XmAb22841, and XmAb23104.
Cytokine candidates: the most recent expansion of our bispecific Fc platform is our novel cytokine candidates.
These cytokines are built on our bispecific Fc domain and have their potency tuned to improve therapeutic index. These
candidates also incorporate our Xtend technology for longer half-life. Our first cytokine candidate is XmAb24306, an IL-
15/IL-15Ra cytokine complex built with our bispecific Fc domain, which we believe is a promising candidate for oncology
combination therapies. In December 2019, the investigational new drug (IND) application submitted for XmAb24306 by our
partner Genentech was allowed by the FDA. Genentech plans to initiate a Phase 1 clinical study of XmAb24306 in 2020. Our
second cytokine candidate is XmAb27564, an IL-2 Fc fusion protein with our bispecific Fc domain, which is currently in
IND-enabling studies.
We continue to invest in our protein engineering efforts to identify additional novel technologies and drug
candidates.
Other XmAb Fc Technologies
Our business, research, and clinical efforts are in developing and advancing our bispecific Fc technology and
pipeline of drug candidates in oncology and autoimmune diseases. We have also designed additional Fc technologies and
XmAb drug candidates that we have partnered with other companies, and we will continue to seek additional partnering and
licensing opportunities for these technologies and candidates. Our Fc domains and technologies include:
1.
Immune Inhibitor Fc Domain – selective immune inhibition and rapid target clearance, targeting the
receptor FcγRIIb;
2. Cytotoxic Fc Domain – increased cytotoxicity, targeting the receptors FcγRIIIa on natural killer (NK) cells
and FcγRIIa on other immune system cells; and
3. Xtend™ Fc Domain – extended antibody half-life, targeting the receptor FcRn on endothelial cells.
XmAb Bispecific Fc Drug Candidates
There are currently ten drug candidates that have been engineered with our bispecific Fc domain in clinical
development: five candidates are wholly owned and are being evaluated by us in Phase 1 studies, two candidates are being
co-developed with our partners, and three candidates are being advanced into clinical studies by our partners. Eight of the
candidates are currently advancing in Phase 1 studies, and two additional candidates have IND applications that have been
allowed by the FDA and which expect to initiate clinical studies in 2020.
6
Table of Contents
Wholly Owned
Co-developed with Partners
Developed by Partners
Plamotamab (XmAb13676)
XmAb18087
XmAb20717
XmAb22841
XmAb23104
XmAb14045
XmAb24306
AMG 424
AMG 509
Novartis undisclosed
Drug candidates with our bispecific Fc domain in clinical development include:
1. XmAb14045 is a bispecific antibody that targets CD123, an antigen on acute myeloid leukemia (AML)
cells and leukemic stem cells, and CD3, an activating receptor on T cells. It is being developed in
collaboration with our partner Novartis Institutes for BioMedical Research, Inc. (Novartis) and is being
evaluated in a Phase 1 study. In September 2016, we dosed the first patient in an open-label, multiple-dose,
dose escalation study to assess the safety, tolerability, and preliminary anti-tumor activity of XmAb14045
in patients with relapsed or refractory AML and other CD123-expressing hematologic malignancies. We
presented initial data from the study in December 2018 at the American Society of Hematology (ASH)
Annual Meeting. The data presented indicated multiple complete remissions had been achieved with
weekly dosing of XmAb14045 in this heavily pretreated patient population.
In February 2019, we received notice from the FDA placing the XmAb14045 study on partial clinical hold
due to safety issues of cytokine release syndrome and pulmonary toxicities. In April 2019, the FDA lifted
the partial clinical hold following discussion and agreement on amendments to the study protocol,
including guidance on the monitoring and clinical management of cytokine release syndrome. In July 2019,
we resumed enrolling patients in the study based on the amended protocol. In 2020, pending agreement
with our partner, Novartis, we plan to initiate additional clinical studies evaluating XmAb14045.
2. Plamotamab (XmAb13676) is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and
CD3 for the treatment of B-cell malignancies. In February 2017, we dosed the first patient in an open-
label, Phase 1, multiple-dose, dose escalation study to assess the safety, tolerability, and preliminary anti-
tumor activity of plamotamab in patients with B-cell malignancies. This program was also partnered with
Novartis as part of our Novartis collaboration. In December 2018, as part of a strategic pipeline
reprioritization, Novartis notified us of its decision to return its rights to develop and commercialize
plamotamab, which became effective in June 2019.
At the ASH Annual Meeting in December 2019, we presented preliminary safety and anti-tumor activity of
plamotamab in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) and chronic
lymphocytic leukemia (CLL). As of November 8, 2019, the data cut-off for analysis, 53 patients were
treated with plamotamab monotherapy with 45 NHL patients and 8 CLL patients. Plamotamab was
generally well tolerated with safety events mild or moderate in severity. Cytokine release syndrome (CRS)
was reported in 53% (28 of 53) patients with most CRS occurring with the first dosing of the drug.
Plamotamab demonstrated clinical activity in DLBCL at doses of 80 mcg/kg and higher (the top dose
through the cut-off date was 170 mcg/kg) in a dose-dependent manner. In DLBCL, the objective response
rate (ORR) was 7/18 (38.0%), and the complete response rate (CRR) was 5/18 (27.8%).
We continue to enroll patients in the ongoing dose-escalation study, and we are planning to initiate
additional studies for plamotamab.
7
Table of Contents
3. XmAb18087 is a bispecific antibody that targets somatostatin receptor 2, or SSTR2, a target on
neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST), and CD3. In February 2018, we
dosed the first patient in an open-label, Phase 1, dose-escalation study to assess the safety, tolerability, and
preliminary anti-tumor activity of XmAb18087 in patients with NET or GIST. XmAb18087 is our first
CD3 bispecific antibody to be evaluated in solid tumors. We expect to provide initial data from this study
in 2020.
4. XmAb20717 is a bispecific antibody that targets PD-1 and CTLA-4, two immune checkpoint receptors, to
selectively activate the tumor microenvironment, and is being developed in broad oncology indications
including patients with solid tumors. In July 2018, we dosed the first patient in an open-label Phase 1 dose-
escalation study to assess the safety, tolerability, and preliminary anti-tumor activity of XmAb20717 in
patients with selected solid tumors. We expect to provide initial data from this study in 2020.
5. XmAb22841 is a bispecific antibody that targets CTLA-4 and LAG-3, also an immune checkpoint receptor,
and is being developed in multiple oncology indications. We are advancing XmAb22841 in combination
with an anti-PD-1 drug to create a triple checkpoint blockade. In May 2019, we dosed the first patient in an
open-label, Phase 1, dose-escalation study to assess the safety, tolerability, and preliminary anti-tumor
activity of XmAb22841 in patients with selected solid tumors.
6. XmAb23104 is a bispecific antibody that targets PD-1 and ICOS, an immune co-stimulatory receptor, and
is being developed in multiple oncology indications. In May 2019, we dosed the first patient in a an open-
label, Phase 1, dose-escalation study to assess the safety, tolerability, and preliminary anti-tumor activity of
XmAb23104 in patients with selected solid tumors.
7. XmAb24306, our initial cytokine candidate, is an IL15/IL15-receptor alpha complex fused to our bispecific
Fc domain (IL15/IL15Ra-Fc) and incorporates our Xtend technology for extended half-life. We believe a
broad combination development strategy will be critical to realize the potential of IL-15 cytokines like
XmAb24306. In February 2019, we entered into a research and license agreement with Genentech, Inc.
and F. Hoffmann-LaRoche Ltd. (collectively Genentech), to develop and commercialize novel IL-15
cytokine therapeutics, whereby the companies will co-develop XmAb24306 and other potential IL-15
programs. In December 2019, the IND application submitted for XmAb24306 by our partner Genentech
was allowed by the FDA. Genentech plans to initiate a Phase 1 clinical study of XmAb24306 in 2020.
8. Amgen-Xencor XmAb bispecific antibody candidates: Amgen, Inc. (Amgen) is advancing two bispecific
antibody candidates that were developed with our bispecific Fc technology under our collaboration with
them.
a. AMG 424 is a CD38 x CD3 bispecific antibody candidate that is currently in Phase 1 clinical
study that is enrolling patients with multiple myeloma.
b. AMG 509 is a STEAP1 (six transmembrane epithelial antigen of prostate 1) x CD3 bispecific
antibody candidate for the treatment of patients with prostate cancer. The FDA has allowed the
IND application to proceed, and Amgen has indicated it expects to initiate a Phase 1 study for this
candidate in 2020.
9. Novartis-Xencor XmAb bispecific antibody candidate: in December 2019, Novartis initiated a Phase 1
clinical study with an undisclosed bispecific antibody candidate that was developed with our bispecific Fc
technology under our collaboration with them.
8
Table of Contents
XmAb Immune Inhibitor Fc Candidate
Obexelimab (XmAb5871) uses our XmAb Immune Inhibitor Fc Domain and targets CD19 with its variable domain,
which is designed to inhibit the function of B cells, an important component of the immune system. We believe that
obexelimab has the potential to address a key unmet need in autoimmune diseases due to its combination of potent reversible
B-cell inhibition without B-cell depletion, enabling the immune system to resume natural function once treatment is no
longer needed. We have completed Phase 2 clinical trials for obexelimab in three autoimmune disease areas: Systemic Lupus
Erythematosus (SLE), IgG4-Related Disease (IgG4-RD), and Rheumatoid Arthritis (RA). We have also completed a Phase 1
bioequivalence trial using a subcutaneous (SC) formulation, and we expect that further clinical studies of obexelimab could
be conducted with the SC formulation. We believe that the clinical trials that we have conducted with obexelimab show the
potential of this molecule in treating B-cell mediated autoimmune indications. We are looking to continue developing
obexelimab in additional late-stage clinical trials with a partner that has the resources and infrastructure to maximize the
potential of this compound.
Collaborations
An important part of our business strategy is to leverage the value of our Fc technologies and drug candidates with
partnerships and collaborations. Our goal in such partnerships is to a retain a major economic interest in drug candidates that
we develop or, are developed with our XmAb technologies, in the form of retention of U.S. commercial rights, profit-sharing
interest, co-development opportunities, upfront payments, milestones, and royalties on approved drug candidates. We seek to
partner with companies that can provide infrastructure for late stage development, have a track record of developing and
commercializing oncology drug candidates, or have a pipeline of development and commercial compounds for potential
combination with our bispecific compounds. The plug-and-play nature of our technologies allows us to license access to our
bispecific Fc platform to partners with limited effort or resources on our part.
We primarily enter into three types of collaborations to broaden the use of our technology or to advance the
development of our drug candidates. We have co-development collaborations with Genentech for XmAb24306 and with
Novartis for XmAb14045, in which we share development activities and costs in order to bring significant resources to
develop the program. We have product candidate license agreements with MorphoSys for tafasitamab and with Aimmune
Therapeutics (Aimmune) for XmAb7195, in which they conduct all future development and commercialization and we
receive license fees, milestone payments and royalties on sales. We also have several XmAb technology license agreements
with a variety of partners that monetize limited access to one or more of our Fc technologies in return for license fees,
milestones and royalties.
A summary of our key collaboration and partnerships include:
Genentech
In February 2019, we entered into a research and license agreement with Genentech (the Genentech Agreement) to
develop and commercialize novel IL-15 cytokine therapeutics that use our bispecific Fc technology, including XmAb24306,
a Collaboration Product. We are jointly collaborating on the worldwide development of XmAb24306 and potentially other
IL-15 cytokine therapeutics, each a Collaboration Product, with Genentech maintaining worldwide commercialization rights,
subject to us having a co-promotion option in the U.S. We retain the right to perform clinical studies of Collaboration
Products at our sole expense in combination with other therapeutic agents, subject to certain restrictions. Genentech received
a worldwide exclusive license to XmAb24306 and other Collaboration Products. The key aspects of the agreement include:
● We received an upfront payment of $120.0 million and are eligible to receive up to $160.0 million in
clinical milestone payments for XmAb24306 and up to $180.0 million in clinical milestone payments for
each new Collaboration Product,
● We are eligible to receive a 45% share of net profits from sales of XmAb24306 and other Collaboration
Products, while also sharing in the net losses at the same percentage rate,
9
Table of Contents
● We are sharing in 45% of development and commercialization costs of XmAb24306, while Genentech will
pay for commercial launch costs, and
● We are conducting a two-year joint research program with Genentech to discover additional IL-15
programs, including ones targeted to specific immune cells, and we are eligible for clinical milestone
payments for new Collaboration Products developed under a research plan.
In December 2019, the IND application submitted for XmAb24306 by Genentech was allowed by the FDA.
Genentech plans to initiate a Phase 1 clinical study of XmAb24306 in 2020.
Astellas
In March 2019, we entered into a Research and License Agreement (Astellas Agreement) with Astellas Pharma Inc.
(Astellas) pursuant to which the Company and Astellas will conduct a discovery program to characterize compounds and
products for development and commercialization. Under the Astellas Agreement, Astellas was granted a worldwide
exclusive license, with the right to sublicense products in the field created by the research activities.
Pursuant to the Astellas Agreement, we are applying our bispecific Fc technology to an antigen pair provided by
Astellas to generate bispecific antibody candidates and are conducting limited testing and characterization of the bispecific
antibody candidates and will return the candidates to Astellas for development and commercialization. The activities are
being conducted under a research plan agreed to by both parties. Astellas will assume full responsibility for development and
commercialization of the antibody candidate. Pursuant to the Astellas Agreement, we received an upfront payment of $15.0
million, and we are eligible to receive up to $240.0 million in milestones which include $32.5 million in development
milestones, $57.5 million in regulatory milestones and $150.0 million in sales milestones and royalties on net sales that range
from the high-single to low-double digit percentages.
During 2019, we completed delivery of bispecific drug candidates to Astellas and are conducting testing and
characterization of the candidates.
Aimmune
In February 2020, we entered into a License, Development and Commercialization Agreement (the Aimmune
Agreement) with Aimmune, in which we granted them an exclusive worldwide license to XmAb7195, which was renamed
AIMab7195. Under the Aimmune Agreement, Aimmune will be responsible for all further development and
commercialization activities for XmAb7195. We will receive an upfront payment of $10.0 million which includes $5.0
million in cash proceeds and shares of Aimmune common stock with an aggregate value of $5.0 million, and we are eligible
to receive up to $385.0 million in milestones, which include $22.0 million in development milestones, $53.0 million in
regulatory milestones and $310.0 million in sales milestones, and tiered royalties on net sales of approved products from
high-single to mid-teen percent range.
Gilead
In January 2020, we entered into a Technology License Agreement (the Gilead Agreement) with Gilead Sciences,
Inc. (Gilead), in which we provided an exclusive license to our Cytotoxic Fc and Xtend Fc technologies for an initial
identified antibody and options for up to three additional compounds directed to the same molecular target. Xencor retains
the right to grant licenses for other antibodies directed to the target. These additional antibodies selected by Gilead are
subject to our approval. Gilead is responsible for all development and commercialization activities for all target candidates.
We received an upfront payment of $6.0 million and are eligible to receive up to $67.0 million in milestones, which include
$10.0 million in development milestones, $27.0 million in regulatory milestones and $30.0 million in sales milestones for
each antibody selected. In addition, we are eligible to receive royalties in the low-single digit percentage range on net sales of
approved products.
Gilead has advanced the initial compound GS-9722, into Phase 1 clinical studies.
10
Table of Contents
Novartis
In June 2016, we entered into a Collaboration and License Agreement (the Novartis Agreement) with Novartis to
develop and commercialize bispecific and other Fc engineered antibody drug candidates. Key aspects to the agreement
include:
● We received a $150.0 million upfront payment and are eligible to receive up to $2.1 billion in milestone
payments.
● We granted Novartis certain exclusive rights to research, develop and commercialize XmAb14045 and
plamotamab, our two lead bispecific clinical candidates. In December 2018, Novartis returned all their
rights to plamotamab to us. In November 2019, we and Novartis amended the Novartis Agreement and
Novartis paid us $1.4 million in settlement of its remaining projected cost-sharing obligations due for the
plamotamab program.
● We are eligible to receive up to $325.0 million in milestone payments in connection with the development
of XmAb14045, including $90.0 million in development milestones, $110.0 million in regulatory
milestones, and $125.0 million in sales milestones, and low-double digit royalties on sales of approved
products in all territories outside the United States (ex-U.S. rights). We retained the commercialization
rights to all XmAb14045 candidates in the U.S.
● We and Novartis are co-developing XmAb14045 worldwide and sharing development costs equally.
● We will also apply our bispecific technology to up to four target pair antibodies selected by Novartis,
subject to approval by us. Novartis is responsible for development and commercialization of each global
discovery product candidate. We are eligible to receive up to $250.0 million in milestone payments for
each global discovery program which includes $50.0 million in development milestones, $100.0 million in
regulatory milestones, and $100.0 million in sales milestones and royalties in the mid-single digit range on
global net sales of approved products.
● We have the right to participate in the development and commercialization of one of the global discovery
programs prior to submission of an IND for such program. If we elect to participate in development, we
will assume responsibility for 25% of the worldwide development costs for the program and 50% of
commercialization costs and will receive 50% of the U.S. profits on net sales of the product.
● We completed delivery of one bispecific antibody candidate for a global discovery program in 2017 and
one bispecific antibody candidate for a global discovery program in 2018. In December 2019, Novartis
dosed the first patient in a Phase 1 study of an undisclosed bispecific antibody candidate that was a target
pair antibody, and we received a $10.0 million milestone.
● We also granted Novartis a non-exclusive research license to our cytotoxic, Xtend, and Immune Inhibitor
Fc technologies to research, develop, commercialize and manufacture antibodies against up to 10 targets
selected by Novartis, subject to approval by us. For each program that advances to development, we are
eligible to receive up to $76.0 million in milestone payments and also low single-digit royalties on global
net sales of approved products.
11
Table of Contents
Amgen
In September 2015, we entered into a research and license agreement (the Amgen Agreement) with Amgen to
develop and commercialize products using our bispecific technology. Under the Amgen Agreement, we licensed the rights to
our internally developed, preclinical CD38 x CD3 bispecific antibody candidates to Amgen and also agreed to apply our
bispecific technology to five previously identified Amgen antibodies. We have received $60.5 million in upfront and
milestone payments and are eligible to receive up to an additional $600.0 million in milestone payments and royalties on
approved products. Amgen is responsible for all development of the bispecific antibody candidates under the Amgen
Agreement. Current programs in development from the Amgen collaboration include:
● AMG 424, a bispecific antibody that targets CD38 and CD3 and is in clinical development for multiple
myeloma. The program is currently in a Phase 1 clinical study, and we are eligible to receive up to $345.0
million in additional milestones payments and royalties from high-single to low-double digit percentage
range on the sale of approved products from this program, and
● AMG 509, a bispecific antibody that targets STEAP1 and CD3 and is being developed for patients with
prostate cancer. Amgen has received FDA allowance for its IND submission and plans to initiate a Phase 1
study for this candidate in 2020. We received a $5.0 million milestone related to allowance of the IND, and
we are eligible to receive up to $255.0 million in additional milestone payments and tiered royalties in the
mid-to-high-single digit percentage range on the sale of approved products.
Alexion
In 2013, we licensed Alexion Pharmaceuticals, Inc. (Alexion) the right to access our Xtend Fc domain, which
Alexion used to develop Ultomiris, an improved version of Alexion’s commercialized Soliris product. The Xtend technology
has increased the half-life of Ultomiris by over three-fold compared to Soliris and extended the dosing schedule to bimonthly
for Ultomiris compared to biweekly for Soliris.
In December 2018, Alexion received U.S. marketing approval for Ultomiris for the treatment of adult patients with
PNH. During 2019, Alexion received marketing approval in Europe and Japan for Ultomiris for the treatment of adult
patients with PNH and also marketing approval in the U.S. for the treatment of adult patients with atypical hemolytic uremic
syndrome (aHUS). During 2019, we received $8.0 million in milestone payments and recorded royalty revenue of $5.0
million from this partnership. We are eligible to receive an additional $30.0 million in sales milestones and a continued low-
single digit percent royalty on the sale of approved products.
MorphoSys
In June 2010, we entered into a collaboration and license agreement (the MorphoSys Agreement) with MorphoSys
AG (MorphoSys) to license the worldwide rights to tafasitamab (formerly MOR208 and XmAb5574). Tafasitamab is an anti-
CD19 antibody drug candidate initially developed by us, and it incorporates our XmAb Cytotoxic Fc domain.
MorphoSys submitted a BLA to the FDA in December 2019 for treating patients with DLBCL. We are eligible to
receive an additional $37.5 million in regulatory milestones related to DLBCL. We are also eligible to receive up to $98.0
million in additional milestones for development of tafasitamab in additional oncology indications and $50.0 million in sales
milestones across all indications. If licensed products are commercialized, we are entitled to receive tiered royalties in the
high-single digit to low-double digit percent range. The term of this agreement will continue until all of MorphoSys’ royalty
payment obligations have expired unless terminated earlier.
12
Table of Contents
Vir Biotechnology
In August 2019, we entered into a Patent License Agreement with Vir Biotechnology (VirBio), in which we
provided a non-exclusive license to our Xtend technology for up to two targets. We received an upfront payment, and we are
eligible to receive total milestones of $155.25 million, including $5.25 million of development milestones, $30.0 million of
regulatory milestones and $120.0 million of sales milestones and royalties on the net sales of approved products in the low
single digits.
VirBio has advanced a program using Xtend technology into a Phase 1 clinical study.
Boehringer Ingelheim
In February 2007, we entered into a research and option agreement (BI Agreement) with Boehringer Ingelheim
International GmbH (BI). Under the terms of the BI Agreement we provided a research license to our XmAb cytotoxic
technology and options to non-commercial licenses. In 2019, BI discontinued development of the last drug candidate under
the license and our license with them terminated.
NIH
In January 2016, we announced that the National Institutes of Health (NIH) initiated a Phase 1 clinical trial of
VRC01LS, a therapeutic antibody for the treatment of human immunodeficiency virus (HIV) that uses our Xtend technology
to enhance antibody half-life. VRC01LS is a humanized monoclonal antibody targeted to the CD4 binding site of HIV-1.
VRC01LS is a modification of the VRC01 monoclonal antibody, which demonstrated a suppression of HIV viral load in a
Phase 1 trial conducted by NIH. NIH has not entered into an agreement with us for this technology.
Our Research and Development Pipeline
We have used our XmAb Fc platforms and protein engineering capabilities to produce a growing pipeline of drug
candidates in clinical and preclinical development. These include multiple oncology candidates using our bispecific Fc
domain, including CD3 bispecific antibodies, TME activating bispecific antibodies and cytokine candidates. We have also
produced additional drug candidates using our immune inhibitor Fc domain. We will continue to progress these candidates as
additional options for clinical development by us or as out-licensing opportunities. We also from time to time in-license
antibody technologies and compounds from other companies which we believe may allow us to create potential product
candidates by incorporating our XmAb technology. These licenses may require us to pay upfront fees, development and
commercial milestone payments, and if commercial products are approved, royalties on net sales.
Human Capital Management
Our ability to develop XmAb technologies, advance our programs into late-stage development, position our
programs for commercialization and identify successful business partnerships is dependent on attracting and retaining
experienced leadership. In 2019, we identified certain gaps in the skillsets and experience provided by our senior
management and appointed executives into the newly created positions of vice president, regulatory affairs and quality
assurance; vice president, business development; and vice president, general counsel and corporate secretary.
Additionally, our former senior vice president and chief medical officer, retired effective at the end of October 2019.
In December 2019, we appointed Allen Yang, M.D., Ph.D., who had been serving as the acting chief medical officer of Jazz
Pharmaceuticals, as our senior vice president and chief medical officer. In this role, Dr. Yang is responsible for leading
development strategy and overseeing clinical operations for our portfolio of bispecific antibody and cytokine candidates.
13
Table of Contents
Market Opportunity
Our drug candidates that use the XmAb bispecific Fc domain, including XmAb14045, plamotamab, XmAb18087,
XmAb20717, XmAb22841, XmAb23104 and XmAb24306: We are pursuing the development of our bispecific antibody and
cytokine candidates for applications in oncology, whereby the immune system is modulated to treat cancer. Cancer is a broad
group of diseases in which cells divide and grow in an uncontrolled fashion, forming malignancies that can invade other parts
of the body, and it is the second leading cause of death in the United States (U.S.). The American Cancer Society estimates
that in 2020 there will be approximately 1.8 million new cases of cancer and approximately 606,500 deaths from cancer. The
National Institutes of Health (NIH) estimates that based on growth and aging of the U.S. population, medical expenditures
for cancer in the year 2020 are projected to reach at least $158.0 billion (in 2010 dollars).
Obexelimab: We have advanced development of obexelimab through Phase 2 trials for SLE, IgG4-RD, and other
autoimmune diseases. The unmet need in SLE remains high for the estimated 240,000 Americans with a lupus diagnosis.
SLE is a serious and potentially fatal disease that primarily affects women. It is an autoimmune disease that affects many
parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels and brain. Patients are often subject to
prolonged use of systemic corticosteroids and potent immunosuppressive agents with significant short- and long-term side
effects. Current biologic treatments are limited by their modest efficacy or safety risks. Because B cells play a significant role
in SLE pathogenesis, we believe that obexelimab is a potential treatment. IgG4-RD is a fibro-inflammatory autoimmune
disorder that we estimate impacts approximately 40,000 patients in the United States. IgG4-RD affects multiple organ
systems and we believe is characterized by the distinct pathologies in diseased organs, frequently including the presence of
IgG4-positive plasma blast cells. There are currently no approved therapies for IgG4-RD and glucocorticoids (hormone
steroids) are the current standard of care treatment.
Intellectual Property
The foundation for our XmAb technology and our product candidates and partnering is the generation and
protection of intellectual property for novel antibody and cytokine therapeutics. We combine proprietary computational
methods for amino acid sequence design with laboratory generation and testing of new antibody compositions. Our design
and engineering team prospectively assesses, with patent counsel, the competitive landscape with the goal of building broad
patent positions and avoiding third-party intellectual property.
As a pioneer in Fc domain engineering, we systematically scanned the structure of the Fc domain to discover Fc
variants. We have filed patent applications relating to thousands of specific Fc domain variants with experimental data on
specific improvements of immune function, pharmacokinetics, structural stability, and novel structural constructs. We have
filed additional patent applications derived from these applications as we discover new properties of the Fc variants and as
new business opportunities arise. We continually seek to expand the intellectual property coverage of our technology and
candidates and invest in discovering new Fc domain technologies, antibody product candidates and cytokine product
candidates.
Our patent estate, on a worldwide basis, includes over 1,000 issued patents and pending patent applications which
we own or for which we have a fully-paid exclusive license, with claims directed to XmAb Fc domains, all of our clinical
and preclinical stage antibodies and our computational protein design methods and platforms. We also have a large number
of issued patents and pending patent applications with claims directed specifically to our XmAb technology and candidates.
The patent expiration in the U.S. and major foreign countries for our key technologies and drug candidates is set
forth below. We have pending applications filed that may extend the exclusivity of some of our technology and products:
14
Table of Contents
Technology
Cytotoxic
Immune Inhibitor
Xtend
Bispecific
Company Products
Obexelimab (XmAb5871)
Plamotamab (XmAb13676)
XmAb18087
XmAb20717, XmAb22841, XmAb23104
Partnered Products
Tafasitamab (MOR208)
Ultomiris
AIMab7195 (XmAb7195)
XmAb14045
XmAb24306
Patent Expiry
2025 U.S.; 2024 Ex-U.S.
2028 U.S.; 2025 Ex-U.S.
2025 U.S.; 2028 Ex-U.S.
2034 U.S. and Ex-U.S.
Patent Expiry
2029 U.S.; 2028 Ex-U.S.
2035 U.S. and Ex-U.S.
2037 U.S. and Ex-U.S.
2037 U.S. and Ex-U.S.
Patent Expiry
2029 U.S.; 2027 Ex-U.S.
2025 U.S.; 2028 Ex-U.S.
2029 U.S. and Ex-U.S.
2035 U.S.; 2036 Ex-U.S.
2038 U.S.; 2037 Ex-U.S.
In addition to patent protection, we rely on trade secret protection and know-how to expand our proprietary position
around our technology and other discoveries and inventions that we consider important to our business. We seek to protect
this intellectual property in part by entering into confidentiality agreements with our employees, consultants, scientific
advisors, clinical investigators, and other contractors and also by requiring our employees, commercial contractors, and
certain consultants and investigators, to enter into invention assignment agreements that grant us ownership of certain
discoveries or inventions made by them.
Further, we seek trademark protection in the United States and in certain other jurisdictions where available and
when we deem appropriate. We have obtained registrations for the Xencor trademark, as well as certain other trademarks,
which we use in connection with our pharmaceutical research and development services and our clinical-stage products,
including XmAb, PDA and Protein Design Automation. We currently have registrations for Xencor and PDA in the United
States, Australia, Canada, the European Community, and Japan, for Protein Design Automation in the United States,
Australia, Canada and the European Community, and for XmAb in the United States, Australia, and the European
Community.
Manufacturing
We are able to internally manufacture the quantities of our product candidates required for relatively short
preclinical animal studies. We believe that this allows us to accelerate the drug development process by not having to rely on
third parties for all of our manufacturing needs. We have adopted a manufacturing strategy of contracting with third parties in
accordance with current good manufacturing practices (cGMPs) for the manufacture of drug substance and product,
including our pipeline of bispecific antibody and cytokine development candidates and also our obexelimab development
candidate. We have used third party manufacturers for all our bispecific antibody and cytokine candidates which include:
XmAb14045, plamotamab, XmAb18087, XmAb20717, XmAb22841, XmAb23104, and XmAb24306. Additional contract
manufacturers are used to fill, label, package and distribute investigational drug products. This allows us to maintain a more
flexible infrastructure while focusing our expertise on developing our products. Obexelimab is produced by mammalian cell
culture of a Chinese hamster ovary cell line that expresses the antibody, followed by multiple purification and filtration steps
typical of those used for monoclonal antibodies. We do not have any long-term manufacturing agreements in place and will
ultimately depend on contract manufacturers for the manufacture of our products for commercial sale, as well as for process
development. We have successfully completed clinical trials with subcutaneous formulations for obexelimab which have
been manufactured with third party contract manufacturers. In February 2020, we entered into a License, Development and
Commercialization Agreement for XmAb7195 (Aimmune Agreement) with Aimmune Therapeutics, Inc. (Aimmune). Under
the Aimmune Agreement, Aimmune will assume all future manufacturing of XmAb7195.
15
Table of Contents
KBI Biopharma, Inc.
In July 2014, we entered into a master services agreement (KBI Agreement) with KBI Biopharma, Inc. (KBI). We
have engaged KBI under the KBI Agreement for process development, clinical scale-up, analytical method development,
formulation development, and other services related to drug substance and drug product for our bispecific antibody and
cytokine development candidates: XmAb14045, plamotamab, XmAb18087, XmAb20717, XmAb22841, XmAb23104, and
XmAb24306 in accordance with cGMP regulations. For each bispecific program, we have entered into a separate agreement
with the terms and conditions of services and payment. The KBI Agreement is for a three-year term but is automatically
extended on an annual basis until the services are completed. The KBI Agreement may be terminated by either party for a
breach that is not remedied within 30 days after notice or 60 days after notice of the existence of an incurable scientific or
technical issue that renders KBI unable to render services under the KBI Agreement, by after 60 day notice, or in the event of
a bankruptcy of a party. For termination other than a material breach by KBI, we must pay for all services conducted prior to
the termination and to wind down the activities.
Cell Line Agreements with Selexis
In December 2015, we entered into a master service agreement (Selexis Agreement) with Selexis SA (Selexis) for
the manufacture of Selexis cell lines. Under the terms of the Selexis Agreement, Selexis will manufacture cell lines for the
antibody candidates provided by us and upon completion of the cell lines, we have the option to take an unrestricted
commercial license to the cell line. The terms of each commercial license require us to make payments upon achievement of
certain development and regulatory milestones and we will also pay royalties based on a percentage of net sales for products
that are derived from or utilize the Selexis cell line. The royalty percentage is less than 1%.
Selexis has manufactured cell lines for all our bispecific antibody and cytokine drug candidates, and we currently
have commercial licenses to the Selexis cell line for the following bispecific antibody and cytokine candidates: XmAb14045,
plamotamab, XmAb18087, XmAb20717, XmAb22841, XmAb23104, XmAb24306 and XmAb27564.
License Agreements with BIO-TECHNE
In February 2015, we entered into a license agreement with BIO-TECHNE Corporation (BIO-TECHNE) for a non-
exclusive license to certain antibody technology including monoclonal antibodies which recognize human somatostatin
receptor 2 (SSTR2). The variable domain of this antibody is incorporated in our XmAb18087 drug candidate.
Under the terms of this agreement, we made an upfront payment and are obligated to make payments upon the
achievement of certain development and regulatory milestones, and royalties based on a percentage of net sales from
products that are derived from the XmAb18087 program. The royalty percentage is less than 1%.
We entered into a second agreement with BIO-TECHNE effective February 2018 for a non-exclusive license to
certain recombinant monoclonal antibody reactive with human programmed death protein, PD-1 antibody. We expect to use
this protein in certain of our oncology drug candidates.
Under the terms of this agreement, we made an upfront payment and are obligated to make payments upon the
achievement of certain development, regulatory and sales milestones, and royalties based on a percentage of net sales from
products that are derived from the PD-1 antibody. The royalty percent is 1%.
Development and Manufacturing and Cell Line Sale Agreements with Catalent
In September 2005, we entered into a development and manufacturing services agreement (the Catalent
Manufacturing Agreement) with Catalent Pharma Solutions LLC (Catalent).
16
Table of Contents
We have also entered into separate cell line sale agreements (Cell Line Agreements) with Catalent for the
obexelimab and XmAb7195 cell lines. Catalent manufactured the cell lines for the obexelimab and XmAb7195 programs
using their proprietary GPEx® technology. Under the Catalent Manufacturing Agreement, we have an unrestricted license to
the GPEx cell lines provided that Catalent is manufacturing drug substance material from the cell line. The Cell Line
Agreements allow us to transfer the manufacturing processes for either obexelimab or XmAb7195 to a third party
manufacturer. In 2018, we transferred the manufacturing process for obexelimab from Catalent to a third party manufacturer.
In connection with the Aimmune Agreement, we sublicensed our rights to the XmAb7195 cell line to Aimmune who will
assume all our rights and obligations under our Cell Line Agreement with Catalent for XmAb7195.
Upon transfer of the obexelimab cell line to a third party manufacturer, we will be required to make payments to
Catalent based upon the achievement of certain development and regulatory milestones and will also pay royalties based on a
percentage of net sales for products that are derived from or utilize the GPEx cell line. The royalty percentages under each
Cell Line Agreement are less than 1.0%. We have not made any payments under the Cell Line Agreement to date.
We have the unilateral right to terminate the Catalent Manufacturing Agreement upon 30 days written notice to
Catalent. Absent early termination, the agreement will remain in effect. If we terminate the agreement without cause or if
Catalent terminates the agreement for our material breach of the agreement, our ownership rights in the cell line will
automatically terminate, and title will revert to Catalent.
Master Bioprocessing Services Agreement with FUJIFILM Diosynth Biotechnologies
In June 2017, we entered into a bioprocessing services agreement (FUJI Agreement) with FUJIFILM Diosynth
Biotechnologies U.S.A. (FUJI). We have engaged FUJI under the FUJI Agreement for manufacturing and development
services related to drug substance for our obexelimab program in accordance with cGMP regulations. The FUJI Agreement
may be terminated by either party for a breach or default that is not remedied within 45 days or for an additional 45 days if
such cure has commenced by the responsible party, but it is unable to cure it within the original 45-day notice period. If such
cure is not completed within the 90-day period, we have the right to terminate the FUJI Agreement. We have the unilateral
right to terminate the Agreement upon 30 days written notice to FUJI.
Umbrella Development Services Agreement with Patheon Biologics LLC
In September 2018, we entered into an Umbrella Development Services Agreement (Patheon Agreement) with
Patheon Biologics LLC (Patheon). Under the terms of the Patheon Agreement, any of the affiliates within the global network
of service sites in Thermo Fisher Scientific Inc.’s Pharma Services Group may perform clinical manufacturing and
development services for us in accordance with cGMP regulations. The Patheon Agreement includes a statement of work for
Patheon to provide process transfer, process development and cGMP manufacturing to support our obexelimab program. The
Patheon Agreement may be terminated by either party for a breach or default that is not remedied within 30 days, or such
other time period as may be reasonably necessary to remedy such breach after receiving notice of the breach from the non-
breaching party or if the other party is subject to an insolvency event. We have the unilateral right to terminate the Patheon
Agreement upon 30 days written notice to Patheon for any business reason, subject to cancellation fees. Patheon has the
unilateral right to terminate the Patheon Agreement if we request to reschedule work beyond 120 days, the project work is
not progressing according to our expectations and we cannot agree on appropriate changes, after six months of inactivity on a
project at our request or if Patheon determines it is unable to perform its obligations in a safe and effective way in
compliance with applicable regulatory requirements.
17
Table of Contents
Competition
We compete in an industry that is characterized by rapidly advancing technologies, intense competition, and a
strong emphasis on proprietary products. Our competitors include pharmaceutical companies, biotechnology companies,
academic institutions, and other research organizations. We compete with these parties for promising targets for antibody-
based therapeutics, new technology for optimizing antibodies, and in recruiting highly qualified personnel. Many competitors
and potential competitors have substantially greater scientific, research, and product development capabilities as well as
greater financial, marketing and sales, and human resources than we do. In addition, many specialized biotechnology firms
have formed collaborations with large, established companies to support the research, development, and commercialization
of products that may be competitive with ours. Accordingly, our competitors may be more successful than we may be in
developing, commercializing, and achieving widespread market acceptance. In addition, our competitors’ products may be
more effective, more effectively developed, or more effectively marketed and sold than any treatment we or our development
partners may commercialize, and may render our product candidates obsolete or noncompetitive before we can recover the
expenses related to developing and commercializing any of our product candidates.
Competition in the field of cancer drug development is intense, with hundreds of compounds in clinical trials by
large multinational pharmaceutical companies. We are aware of companies with competing bispecific and biologic
technologies. Several companies have competing bispecific molecules including CD20 x CD3 candidates and CD123 x CD3
candidates in clinical development . The field of oncology has multiple large pharmaceutical companies with competing
oncology programs, and several companies have immune checkpoint inhibitor candidates in clinical development or have
received marketing approval. In addition, we are aware of a number of other companies with development stage programs
that may compete with the drug candidates we and our licensees are developing in the future. We anticipate that we will face
intense and increasing competition as new treatments enter the market and advanced technologies become available.
Regulatory Overview
Our business and operations are subject to a variety of U.S. federal, state and local and foreign supranational,
national, provincial and municipal laws, regulations and trade practices. The FDA and comparable regulatory authorities in
state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies
involved in the clinical development, manufacture, marketing, and distribution of drugs and biologics. These agencies and
other federal, state and local entities regulate research and development activities and the testing, manufacture, quality
control, safety, effectiveness, labeling, storage, recordkeeping, approval, advertising and promotion, and export and import of
our product candidates.
U.S. Government Regulation
We are subject to extensive regulation by the U.S. and other countries. Regulation by government authorities is a
significant factor in the development, manufacture, distribution and ongoing research activities. All of our products in
development will require regulatory approval by government agencies prior to commercialization. In particular, drugs and
biologic products are subject to rigorous preclinical studies and clinical trials and other approval procedures of the FDA and
similar regulatory authorities in foreign countries. The process of obtaining these approvals and the subsequent compliance
with appropriate federal and state statutes and regulations require the expenditure of substantial time and financial resources.
Various federal and state statutes and regulation also govern or influence testing, manufacturing, safety, labeling, storage,
tracking, tracing and record-keeping of drugs and biologic products and their marketing.
18
Table of Contents
U.S. Drug Development Process
In the United States, the FDA regulates drugs and biologic products under the Federal Food, Drug and Cosmetic Act
(FDCA), its implementing regulations, and other laws including, in the case of biologics, the Public Health Service Act. Our
antibody product candidates are subject to regulation by the FDA as a biologic. Biologics require the submission of a
Biologics License Application (BLA) to the FDA and approval of the BLA by the FDA before marketing in the United
States. The process of obtaining regulatory approvals for commercial sale and distribution and the subsequent compliance
with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and
financial resources. Failure to comply with the applicable requirements at any time during the product development process,
approval process or after approval, may subject an applicant to administrative or judicial civil or criminal sanctions. These
sanctions could include the FDA’s refusal to approve pending applications, license suspension or revocation, withdrawal of
an approval, imposition of a clinical hold on clinical trials, warning letters, product recalls, product seizures, total or partial
suspension of production, or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or
civil and/or criminal penalties. The process required by the FDA before a biologic may be marketed in the United States
generally involves the following:
1.
2.
3.
4.
5.
6.
7.
completion of preclinical laboratory tests, animal studies, and formulation studies performed in accordance
with the FDA’s current Good Laboratory Practices (GLP) regulations;
submission to and acceptance by the FDA of an IND which must become effective before human clinical trials
in the United States may begin;
performance of adequate and well-controlled human clinical trials in accordance with the FDA’s current good
clinical practices (GCP) regulations to establish the safety and efficacy of the product candidate for its intended
use;
submission to and acceptance by the FDA of a BLA;
satisfactory completion of an FDA inspection (if the FDA deems it as a requirement) of the manufacturing
facility or facilities where the product is produced to assess compliance with the FDA’s cGMP regulations to
assure that the facilities, methods, and controls are adequate to preserve the product’s identity, strength, quality,
and purity;
potential audits by the FDA of the nonclinical and clinical trial sites that generated the data in support of the
BLA;
potential review of the BLA by an external Advisory Committee to the FDA, whose recommendations are not
binding on the FDA; and
8. FDA review and approval of the BLA prior to any commercial marketing or sale.
Before testing any compounds with potential therapeutic value in humans, the product candidate enters the
preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, stability, and formulation, as
well as animal studies to assess the potential toxicity and activity of the product candidate. Clinical trials involve the
administration of the product candidate to human patients under the supervision of qualified investigators, generally
physicians not employed by or under the clinical trial sponsor’s control. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria,
and the parameters to be used to monitor subject safety and effectiveness. The FDA or responsible Institutional Review
Board may place a trial on hold at any time related to perceived risks to patient safety.
19
Table of Contents
1. Phase 1. The product candidate is initially introduced into a limited population of healthy human subjects, or
in some cases, patients with the disease for which the drug candidate is intended, and tested for safety, dosage
tolerance, absorption, metabolism, distribution, and excretion. In the case of some products for some diseases,
or when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human
testing is often conducted in patients with the disease or condition for which the product candidate is intended
to gain an early indication of its effectiveness.
2. Phase 2. The product candidate is evaluated in a limited patient population (but larger than in Phase 1) to
identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for
specific targeted indications, and to assess dosage tolerance, optimal dosage, and dosing schedule.
3. Phase 3. Clinical trials are undertaken to further evaluate dosage and provide substantial evidence of clinical
efficacy and safety in an expanded patient population (such as several hundred to several thousand) at
geographically dispersed clinical trial sites. Phase 3 clinical trials are intended to establish the overall
risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, two adequate
and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA.
4. Post Approval. Clinical trials or other post-approval commitments may be conducted after initial marketing
approval. These studies are used to gain additional experience from the treatment of patients in the intended
therapeutic indication and may be required by the FDA as a condition of approval.
Concurrent with clinical trials, companies usually complete additional animal studies and must also develop
additional information about the chemistry and physical characteristics of the biologic and finalize a process for
manufacturing the product in commercial quantities in accordance with cGMP requirements.
U.S. Review and Approval Processes
The results of product development, preclinical studies and clinical trials, along with descriptions of the
manufacturing process, analytical tests, proposed labeling, and other relevant information are submitted to the FDA in the
form of a BLA requesting approval to market the product for one or more specified indications. The standard time for the
FDA to accept a BLA submission is two months.
If the FDA determines that the BLA is substantially complete, it will accept the BLA for review.
Once accepted, the FDA reviews the BLA to determine, among other things, whether the proposed product is safe
and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and
preserve the product’s identity, strength, quality, and purity, and it may inspect the manufacturing facilities to assure cGMP
compliance and clinical sites used during the clinical trials to assure cGMP compliance. The standard FDA review process is
10 months once a BLA is accepted for review, but it can take longer. During the review process, the FDA also will determine
whether a risk evaluation and mitigation strategy (REMS) is necessary to assure the safe use of the product. If the FDA
concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS prior to approval. A REMS can
substantially increase the costs of obtaining approval. In addition, under the Pediatric Research Equity Act, a BLA or
supplement to a BLA must contain data that are adequate to assess the safety and effectiveness of the product for the claimed
indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation
for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant
deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial
waivers from the pediatric data requirements.
The FDA will issue a complete response letter describing deficiencies in the BLA and recommend actions if the
agency decides not to approve the BLA. The applicant will have to address all of the deficiencies which could take
substantial time to address.
20
Table of Contents
If the product receives regulatory approval, the approval may be significantly limited to specific diseases and
dosages or the indications for use may otherwise be limited, and may require that certain contraindications, warnings, or
precautions be included in the product labeling. In addition, the FDA may require post marketing studies, sometimes referred
to as Phase 4 testing, which involves clinical trials designed to further assess drug safety and effectiveness and may require
testing and surveillance programs to monitor the safety of approved products that have been commercialized.
Post-Approval Requirements
Any biologic products for which we or our collaborators receive FDA approvals are subject to continuing regulation
by the FDA, including, among other things, cGMP compliance for product manufacture, record-keeping requirements,
reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product
sampling and distribution requirements, complying with certain electronic records and signature requirements, and
complying with FDA promotion and advertising requirements, which include, among others, restrictions on direct-to-
consumer advertising, promoting biologics for uses or in patient populations that are not described in the product’s approved
labeling (known as “off-label use”), industry-sponsored scientific and educational activities, and promotional activities
involving the internet. Failure to comply with these or other FDA requirements can subject a manufacturer to possible legal
or regulatory action, such as product reclass, warning letters, suspension of manufacturing, seizure of product, injunctive
action, mandated corrective advertising or communications with healthcare professionals, possible civil or criminal penalties,
or other negative consequences, including adverse publicity.
U.S. Patent Term Restoration and Marketing Exclusivity
Depending upon the timing, duration and specifics of the FDA approval of any of our biologic product candidates,
we may apply for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984,
commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration
term of up to five years for one patent per product as compensation for patent term lost during product development and the
FDA regulatory review process of that product. The U.S. Patent and Trademark Office, in consultation with the FDA,
reviews and approves the application for any patent term extension or restoration.
Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications
of other companies seeking to reference another company’s BLA. Specifically, the Biologics Price Competition and
Innovation Act established an abbreviated pathway for the approval of biosimilar and interchangeable biological products
generally not earlier than 12 years after the original BLA approval. The abbreviated regulatory pathway establishes legal
authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as
“interchangeable” based on their similarity to existing brand product.
U.S. Foreign Corrupt Practices Act
The U.S. Foreign Corrupt Practices Act, to which we are subject, prohibits corporations and individuals from
engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal
to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff
member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person
working in an official capacity.
21
Table of Contents
Pharmaceutical Coverage, Pricing and Reimbursement
The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest. We
expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the
increasing influence of managed care organizations and additional legislative proposals. Significant uncertainty exists and
will continue to exist as to the coverage and reimbursement status of any product candidate for which we obtain regulatory
approval. In the United States and markets in other countries, sales of any product for which we receive regulatory approval
for commercial sale will depend in part on the availability of coverage and adequate reimbursement from third-party payors.
Third-party payors include government payor programs at the federal and state levels, including Medicare and Medicaid,
managed care providers, private health insurers and other organizations. Third-party payors are increasingly challenging the
price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety
and efficacy. Formulary placement by third-party payors is very competitive and can lead to lower prices and may effectively
restrict patient access to our drugs. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals.
Our product candidates may not be considered medically necessary or cost-effective.
The U.S. government, state legislatures and foreign governments have shown significant interest in implementing
cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on
reimbursement and requirements for substitution of generic products for branded prescription drugs. In the United States,
there has been heightened government scrutiny over the manner in which manufacturers set prices for their marketed
products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, reduce the cost of products under Medicare, and reform government program reimbursement
methodologies for products. For example, at the federal level, on May 11, 2018, the president laid out his administration’s
“Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase
manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers
to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. In addition,
the administration’s budget proposal for fiscal year 2020 contains further price control measures that could be enacted during
the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to
negotiate the price of certain products under Medicare Part B, to allow some states to negotiate product prices under
Medicaid, and to eliminate cost sharing for generics for low-income patients. The Department of Health and Human Services
(HHS) has solicited feedback on some of these measures and has implemented others under its existing authority. For
example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B
drugs beginning January 1, 2020. This final rule codified CMS’s policy change that was effective January 1, 2019. Although
some of these and other measures may require additional authorization to become effective, Congress and the administration
have each indicated that it will continue to seek new legislation and/or administrative measures to control pharmaceutical
costs. In other countries, pricing and reimbursement schemes differ. In the European Community, governments influence the
price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems
that fund a large part of the cost of those products to consumers. The downward pressure on healthcare costs in general, and
particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry
of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure
on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations
for drug products will allow favorable reimbursement and pricing arrangements for any of our products.
22
Table of Contents
Healthcare Reform
In the United States and foreign jurisdictions, there have been and will continue to be a number of legislative and
regulatory proposals to change the healthcare system in ways that could affect our ability to sell our product candidates
profitably, once they are approved for sale. Among policy makers and payors in the United States and elsewhere, there is
significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs,
improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of
these efforts and has been significantly affected by major legislative initiatives.
For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act,
which, as amended by the Health Care and Education Reconciliation act of 2010 (Affordable Care Act) is a sweeping law
intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies
against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new
taxes and fees on the health industry and impose additional health policy reforms. In the years since its enactment, there have
been, and continue to be, significant developments in, and continued legislative activity around, attempts to repeal or repeal
and replace the Affordable Care Act. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable
Care Act is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax
Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the
District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to
determine whether the remaining provisions of the Affordable Care Act are invalid as well. It is unclear how this decision,
subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act. In
addition, other reform measures have been proposed and adopted since the Affordable Care Act was enacted.
Additional new laws may result in additional reductions in funding to Medicare and other healthcare programs and
other healthcare funding, which could have a material adverse effect on our customers and our financial operations. Further,
new laws may, among other things, increase drug rebates or discounts owed under federal health care programs, impose
additional reporting or compliance obligations, and/or otherwise put additional downward pressure on drug prices or increase
the burden of compliance on pharmaceutical manufacturers.
Other Healthcare Laws and Compliance Requirements
In the United States, the research, manufacturing, distribution, sale and promotion of drug products and medical
devices are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
the Centers for Medicare & Medicaid Services, other divisions of Health and Human Services (e.g., the Office of Inspector
General), the U.S. Department of Justice, state Attorneys General, and other state and local government agencies. For
example, sales, marketing and scientific/educational grant programs must comply with fraud and abuse laws such as the
federal Anti-Kickback Statute, as amended, the federal civil False Claims Act, as amended, and similar state laws. Pricing
and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget
Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made
available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and
requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair
competition laws.
23
Table of Contents
The federal Anti-Kickback Statute prohibits, among other things, any person, including a prescription drug
manufacturer (or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing
remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending
or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare
and Medicaid programs. The federal false claims laws, including the civil False Claims Act imposes liability on any person
or entity that, among other things, knowingly presents or causes to be presented, a false or fraudulent claim for payment by a
federal healthcare program. The qui tam provisions of the federal civil False Claims Act allow a private individual to bring
civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal
government, and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has
increased dramatically. In addition, various states have enacted anti-kickback statues and false claims laws analogous to the
federal civil False Claims Act. Also, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) created
several additional federal crimes, including healthcare fraud, and false statements relating to the delivery of or payments for
healthcare benefits, items or services. HIPAA, as amended the Health Information Technology for Economic and Clinical
Health Act (HITECH), and its implementing regulations also established uniform federal standards for certain “covered
entities” (certain healthcare providers, health plans and healthcare clearinghouses) and their “business associates”
(individuals and entities that create, receive, maintain or transmit individually identifiable health information for or on behalf
of a covered entity) governing the conduct of certain electronic healthcare transactions and protecting the security and
privacy of protected health information. In addition, we may be subject to health care professional payment transparency
laws and patient privacy and security regulation by the federal government and by the states and foreign jurisdictions in
which we conduct our business.
Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe
harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our
operations are found to be in violation of any of the federal and state laws described above or any other governmental
regulations that apply to us, we may be subject to penalties, including significant administrative, criminal and significant
civil monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare
programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-
marketing product approvals, private “qui tam” actions brought by individual whistleblowers in the name of the government
or refusal to allow us to enter into supply contracts, including government contracts, additional oversight and reporting
obligations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate
our business and our results of operations.
Europe / Rest of World Government Regulation
In addition to regulations in the United States, we, and our collaborators, will be subject to a variety of regulations
in other jurisdictions governing, among other things, clinical trials and any commercial sales, marketing and distribution of
our products, similar or more stringent than the U.S. laws.
Whether or not we, or our collaborators, obtain FDA approval for a product, we must obtain the requisite approvals
from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in
those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and
reimbursement vary from country to country. In addition, we and our collaborators may be subject to foreign laws and
regulations and other compliance requirements, including, without limitation, anti-kickback laws, false claims laws and other
fraud and abuse laws, as well as laws and regulations requiring transparency of pricing and marketing information and
governing the privacy and security of health information, such as the European Union’s Directive 95/46 on the Protection of
Individuals with regard to the Processing of Personal Data.
If we, or our collaborators, fail to comply with applicable foreign regulatory requirements, we may be subject to,
among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating
restrictions and criminal prosecution.
24
Table of Contents
Employees
As of December 31, 2019, we had 166 employees, all of whom were full-time, 45 of whom hold Ph.D. or M.D.
degrees, 135 of whom were engaged in research and development activities and 31 of whom were engaged in business
development, finance, information systems, facilities, human resources or administrative support. None of our employees are
represented by any collective bargaining unit. We believe that we maintain good relations with our employees.
Corporate Information
We were incorporated in California in August 1997 under the name Xencor. In September 2004, we reincorporated
in the state of Delaware under the name Xencor, Inc. Our principal offices are located at 111 West Lemon Avenue, Monrovia,
CA 91016, and our telephone number is (626) 305-5900. Our website address is www.xencor.com. Our website and the
information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in
and are not considered part of this Annual Report. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and amendments to reports filed or furnished pursuant to Section 13(a) and 15(d) of the
Securities Exchange Act of 1934, as amended, are available free of charge on the Investor Relations portion of our web site
at www.xencor.com as soon as reasonably practical after we electronically file such material with, or furnish it to, the
Securities and Exchange Commission (SEC).
Item 1A. Risk Factors.
Except for the historical information contained herein or incorporated by reference, this Annual Report and the
information incorporated by reference contains forward-looking statements that involve risks and uncertainties. These
statements include projections about our accounting and finances, plans and objectives for the future, future operating and
economic performance and other statements regarding future performance. These statements are not guarantees of future
performance or events. Our actual results may differ materially from those discussed here. Factors that could cause or
contribute to differences in our actual results include those discussed in the following section, as well as those discussed in
Part II, Item 7 entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and
elsewhere throughout this Annual Report and in any other documents incorporated by reference into this Annual Report. You
should consider carefully the following risk factors, together with all of the other information included or incorporated in
this Annual Report. Each of these risk factors, either alone or taken together, could adversely affect our business, operating
results and financial condition, as well as adversely affect the value of an investment in our common stock. There may be
additional risks that we do not presently know of or that we currently believe are immaterial which could also impair our
business and financial position.
Risks Relating to Our Business and to the Discovery, Development, Regulatory Approval of Our Product Candidates
and other Legal Compliance Matters
We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for
the foreseeable future.
We are a clinical-stage biopharmaceutical company. To date, we have financed our operations primarily through
equity and debt financings and our research and development licensing agreements and have incurred significant operating
losses since our inception in 1997. For the year ended December 31, 2019, we generated net income of $26.9 million and our
net loss for the year ended December 31, 2018 was $70.4 million. We have sustained losses on a regular basis expect for the
year ended December 31, 2016 when we earned a net income of $45.1 million. As of December 31, 2019, we had an
accumulated deficit of $296.4 million. We expect to incur additional losses in future years as we execute our plan to continue
our discovery, research and development activities, including the ongoing and planned clinical development of our antibody
product candidates, and incur the additional costs of operating as a public company. We are unable to predict the extent of
any future losses or when we will become profitable, if ever. Even if we do achieve profitability, we may not be able to
sustain or increase profitability on an ongoing basis which would adversely affect our business, prospects, financial condition
and results of operations.
25
Table of Contents
Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of
uncertainty. We have never generated any revenue from product sales and may never be profitable.
We have devoted substantially all of our financial resources and efforts to developing our proprietary XmAb
technology platform, identifying potential product candidates and conducting preclinical studies and clinical trials. We and
our partners are still in the early stages of developing our product candidates, and we have not completed development of any
products. Our revenue to date has been primarily revenue from the license of our proprietary XmAb technology platform for
the development of product candidates by others or revenue from our partners. Our ability to generate revenue and achieve
profitability depends in large part on our ability, alone or with partners, to achieve milestones and to successfully complete
the development of, obtain the necessary regulatory approvals for, and commercialize, product candidates. We do not
anticipate generating revenues from sales of products in the foreseeable future. Our ability to generate future revenues from
product sales depends heavily on our and our partners’ success in:
1.
2.
3.
4.
5.
6.
7.
8.
9.
completing clinical trials through all phases of clinical development of our current product candidates, and
advancing preclinical stage programs into clinical development;
seeking and obtaining marketing approvals for product candidates that successfully complete clinical trials;
obtaining satisfactory acceptance, formulary placement and coverage, and adequate reimbursement for our
approved products from third-party payors, including private health insurers, managed care providers and
governmental payor programs, including Medicare and Medicaid;
launching and commercializing product candidates for which we obtain marketing approval, with a partner or,
if launched independently, successfully establishing a sales force, marketing and distribution infrastructure;
identifying and developing new XmAb-engineered therapeutic antibody candidates;
establishing and maintaining supply and manufacturing relationships with third parties;
obtaining additional licensing and partnering opportunities, similar to our agreements with Genentech,
Novartis, Amgen, MorphoSys, Alexion, Gilead and Aimmune with leading pharmaceutical and biotechnology
companies;
achieving the milestones set forth in our agreements with our partners;
conducting further research into the function and application of antibody Fc domains in order to expand the
scope of our proprietary XmAb technology platform;
10. maintaining, protecting, expanding and enforcing our intellectual property; and
11. attracting, hiring and retaining qualified personnel.
26
Table of Contents
Because of the numerous risks and uncertainties associated with biologic product development, we are unable to
predict the timing or amount of increased expenses and when we will be able to achieve or maintain profitability, if ever. In
addition, our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration
(FDA), or foreign regulatory agencies, to perform studies and trials in addition to those that we currently anticipate, or if
there are any delays in our or our partners completing clinical trials or the development of any of our product candidates. If
one or more of the product candidates that we independently develop is approved for commercial sale, we anticipate
incurring significant costs associated with commercializing such product candidates. Even if we or our partners are able to
generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional
funding to continue operations, which may not be available to us on favorable terms, if at all. Even if we do achieve
profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and
remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business,
maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in
the value of our company could also cause you to lose all or part of your investment.
We will require additional financing and may be unable to raise sufficient capital, which could lead us to delay, reduce or
abandon research and development programs or commercialization.
As of December 31, 2019, we had $601.3 million in cash, cash equivalents and marketable securities. We expect our
expenses to increase in connection with our ongoing development activities, including the continued development of our
pipeline of bispecific drug candidates and other research activities. Identifying potential product candidates and conducting
preclinical testing and clinical trials are time-consuming, expensive and uncertain processes that take years to complete, and
we or our partners may never generate the necessary data or results required to obtain regulatory approval and achieve
product sales. In addition, our product candidates, if approved, may not achieve commercial success.
Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially
available for many years, if at all. If we obtain regulatory approval for any of our product candidates, we expect to incur
significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Accordingly, we
will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise
capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development
programs or any future commercialization efforts.
We believe our existing cash, cash equivalents and marketable securities, together with interest thereon and
expected milestones and royalty payments will be sufficient to fund our operations into 2024. However, changing
circumstances or inaccurate estimates by us may cause us to use capital significantly faster than we currently anticipate, and
we may need to spend more money than currently expected because of circumstances beyond our control. For example, our
current and our planned clinical trials may encounter technical, enrollment or other issues that could cause our development
costs to increase more than we expect. For example, in February 2019, we received notice from the FDA placing the
XmAb14045 study on partial clinical hold due to safety issues of cytokine release syndrome (CRS) and pulmonary toxicities,
which hold was lifted in April 2019. Under the Genentech Agreement, we will be sharing 45% of development costs
worldwide for XmAb24306 and other IL-15 programs, and under the Novartis Agreement, we are co-developing
XmAb14045 worldwide and sharing development costs. We do not have sufficient cash to complete the clinical development
of any of our product candidates and will require additional funding to complete the development activities required for
regulatory approval of our current product candidates or any other future product candidates that we develop independently.
Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will
require to complete research and development and commercialize our product candidates. Adequate additional financing may
not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market
conditions or strategic considerations; even if we believe we have sufficient funds for our current or future operating plans. If
we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our
research and development programs or any future commercialization efforts.
27
Table of Contents
The development and commercialization of biologic products is subject to extensive regulation, and we may not obtain
regulatory approvals for any of our product candidates.
The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion,
export, import, marketing and distribution and other possible activities relating to our current lead antibody product
candidates, as well as any other antibody product candidate that we may develop in the future, are subject to extensive
regulation in the United States as biologics. Biologics require the submission of a Biologics License Application (BLA) to
the FDA and we are not permitted to market any product candidate in the United States until we obtain approval from the
FDA of a BLA for that product. A BLA must be supported by extensive clinical and preclinical data, as well as extensive
information regarding chemistry, manufacturing and controls (CMC) sufficient to demonstrate the safety, purity, potency and
effectiveness of the applicable product candidate to the satisfaction of the FDA.
Regulatory approval of a BLA is not guaranteed, and the approval process is an expensive and uncertain process
that may take several years. The FDA and foreign regulatory entities also have substantial discretion in the approval process.
The number and types of preclinical studies and clinical trials that will be required for BLA approval varies depending on the
product candidate, the disease or the condition that the product candidate is designed to target and the regulations applicable
to any particular product candidate. Despite the time and expense associated with preclinical studies and clinical trials,
failure can occur at any stage, and we could encounter problems that require us to repeat or perform additional preclinical
studies or clinical trials or generate additional CMC data. The FDA and similar foreign authorities could delay, limit or deny
approval of a product candidate for many reasons, including because they:
1. may not deem our product candidate to be adequately safe and effective;
2. may not find the data from our preclinical studies and clinical trials or CMC data to be sufficient to support a
claim of safety and efficacy;
3. may not approve the manufacturing processes or facilities associated with our product candidate;
4. may conclude that we have not sufficiently demonstrated long-term stability of the formulation of the drug
product for which we are seeking marketing approval;
5. may change approval policies or adopt new regulations; or
6. may not accept a submission due to, among other reasons, the content or formatting of the submission.
Generally, public concern regarding the safety of drug and biologic products could delay or limit our ability to
obtain regulatory approval, result in the inclusion of unfavorable information in our labeling, or require us to undertake other
activities that may entail additional costs.
We have not submitted an application for approval or obtained FDA approval for any product. This lack of
experience may impede our ability to obtain FDA approval in a timely manner, if at all, for our product candidates.
To market any biologics outside of the United States, we and current or future collaborators must comply with
numerous and varying regulatory and compliance related requirements of other countries. Approval procedures vary among
countries and can involve additional product testing and additional administrative review periods, including obtaining
reimbursement and pricing approval in select markets. The time required to obtain approval in other countries might differ
from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks
associated with FDA approval as well as additional, presently unanticipated, risks. Regulatory approval in one country does
not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may
negatively impact the regulatory process in others, including the risk that our product candidates may not be approved for all
indications requested and that such approval may be subject to limitations on the indicated uses for which the drug may be
marketed. Certain countries have a very difficult reimbursement environment and we may not obtain reimbursement or
pricing approval, if required, in all countries where we expect to market a product, or we may obtain reimbursement approval
at a level that would make marketing a product in certain countries not viable.
28
Table of Contents
If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the
commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially
impaired which would adversely affect our business, prospects, financial condition and results of operations.
Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product
candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject
to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.
Any regulatory approvals that we or our partners receive for our product candidates may also be subject to
limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain
requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the
safety and efficacy of the product candidate. In addition, if the FDA or a comparable foreign regulatory authority approves
any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting,
storage, advertising, promotion, import, export and recordkeeping for the product will be subject to extensive and ongoing
regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports,
registration, as well as continued compliance with current good manufacturing practices (cGMPs), and current good clinical
practices (cGCPs), for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems
with a product, including adverse events of unanticipated severity or frequency, undesirable side effects caused by the
product, problems encountered by our third-party manufacturers or manufacturing processes, or failure to comply with
regulatory requirements, either before or after product approval, may result in, among other things:
1.
2.
3.
restrictions on the marketing or manufacturing of the product;
requirements to include additional warnings on the label;
requirements to create a medication guide outlining the risks to patients;
4. withdrawal of the product from the market;
5.
6.
7.
8.
voluntary or mandatory product recalls;
requirements to change the way the product is administered or for us to conduct additional clinical trials;
fines, warning letters or holds on clinical trials;
refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our
strategic partners, or suspension or revocation of product license approvals;
9.
product seizure or detention, or refusal to permit the import or export of products;
10. injunctions or the imposition of civil or criminal penalties; and
11. harm to our reputation.
Additionally, if any of our product candidates receives marketing approval, the FDA could require us to adopt a
REMS to ensure that the benefits of the therapy outweigh its risks, which may include, among other things, a medication
guide outlining the risks for distribution to patients and a communication plan to health care practitioners.
29
Table of Contents
Moreover, the FDA strictly regulates marketing, labeling, advertising and promotion of products. Drugs may be
promoted only for the approved indications and in accordance with the provisions of the approved label, although physicians,
in the practice of medicine, may prescribe approved drugs for unapproved indications. However, companies may share
truthful and not misleading information that is otherwise consistent with the labeling. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly
promoted off-label uses may be subject to significant liability.
Any of these events could prevent us from achieving or maintaining market acceptance of the product or the
particular product candidate at issue and could significantly harm our business, prospects, financial condition and results of
operations.
The FDA’s policies may change, and additional government regulations may be enacted that could prevent, limit or
delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow
or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able
to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve
or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.
If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory
approvals could be delayed or prevented.
We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and
enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory
authorities outside the United States. In addition, some of our competitors have ongoing clinical trials for product candidates
that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials
may instead enroll in clinical trials of our competitors’ product candidates.
Patient enrollment is affected by other factors including:
1.
2.
3.
4.
5.
6.
7.
the severity of the disease under investigation;
the patient eligibility criteria for the study in question;
the perceived risks and benefits of the product candidate under study;
our payments for conducting clinical trials;
the patient referral practices of physicians;
the ability to monitor patients adequately during and after treatment; and
the proximity and availability of clinical trial sites for prospective patients.
Our inability to enroll a sufficient number of patients for any of our clinical trials could result in significant delays
and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in
increased development costs for our product candidates and in delays to commercially launching our product candidates, if
approved, which would cause the value of our company to decline and limit our ability to obtain additional financing.
30
Table of Contents
The manufacture of biopharmaceutical products, including XmAb-engineered antibodies, is complex and manufacturers
often encounter difficulties in production. If we or any of our third-party manufacturers encounter any loss of our master
cell banks or if any of our third-party manufacturers encounter other difficulties, or otherwise fail to comply with their
contractual obligations, our ability to provide product candidates for clinical trials or our products to patients, once
approved, the development or commercialization of our product candidates could be delayed or stopped.
The manufacture of biopharmaceutical products is complex and requires significant expertise and capital
investment, including the development of advanced manufacturing techniques and process controls. We and our contract
manufacturers must comply with cGMP regulations and guidelines. Manufacturers of biopharmaceutical products often
encounter difficulties in production, particularly in scaling up and validating initial production and contamination. These
problems include difficulties with production costs and yields, quality control, including stability of the product, quality
assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state
and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in our products or in the
manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended
period of time to investigate and remedy the contamination.
All of our XmAb engineered antibodies are manufactured by starting with cells which are stored in a cell bank. We
have one master cell bank for each antibody manufactured in accordance with cGMP and multiple working cell banks and
believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we
could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks.
We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates
or products will not occur in the future. Additionally, our manufacturer may experience manufacturing difficulties due to
resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter
any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide any product
candidates to patients in clinical trials and products to patients, once approved, would be jeopardized. Any delay or
interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated
with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials
at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial
manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product
withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take
inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications,
undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties
faced at any level of our supply chain could materially adversely affect our business and delay or impede the development
and commercialization of any of our product candidates or products and could have a material adverse effect on our business,
prospects, financial condition and results of operations.
Clinical trials are expensive and take years to conduct and the outcome of such clinical trials is uncertain. Clinical trials
may fail to prove our product candidates are safe and effective. This could lead to delays, downsizing or termination of
clinical development plans for any our product candidates.
Each product candidate must receive regulatory approval and therefore must undergo rigorous and extensive
preclinical studies and clinical trials to demonstrate safety and efficacy in patients. Clinical trials at any stage in development
may fail to demonstrate the safety, efficacy or pharmacologic properties needed to be a viable product candidate in patients.
Early clinical trials may fail to demonstrate the safety and pharmacokinetic characteristics needed to invest in larger later
stage clinical studies. Later clinical studies that are larger may not demonstrate the desired safety and efficacy profile needed
to be of benefit to patients. Additionally, regulatory authorities may determine that the data provided is not sufficient to grant
marketing approval for our product candidates and may request additional data including additional clinical trials or reject
product approval.
31
Table of Contents
Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause
us to suspend or discontinue clinical trials, abandon product candidates, limit the commercial profile of an approved
label, or result in significant negative consequences following marketing approval, if any.
Conducting early clinical trials is complex and the outcomes are uncertain. Preclinical studies are performed to help
inform human clinical trials, but human and animal studies are not comparable. Expected or unexpected undesirable side
effects caused by our product candidates could result in the delay, suspension or termination of clinical trials by us, our
collaborators, the FDA or other regulatory authorities for a number of reasons. If we elect or are required to delay, suspend or
terminate any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates
will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or
eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of the product
candidate at issue. Any of these occurrences may harm our business, prospects, financial condition and results of operations
significantly.
We may not be successful in our efforts to use and expand our XmAb technology platform to build a pipeline of product
candidates and develop marketable products.
We are using our proprietary XmAb technology platform to develop engineered antibodies, with an initial focus on
four properties: immune inhibition, cytotoxicity, extended half-life and most recently, heterodimeric Fc domains enabling
molecules with dual target binding. This platform has led to our current pipeline of candidates as well as the other programs
that utilize our technology and that are being developed by our partners and licensees. While we believe our preclinical and
clinical data to date, together with our established partnerships, has validated our platform to a degree, we are at a very early
stage of development. Although the first drug candidate incorporating our Fc technology has been approved by the FDA,
other drug candidates that incorporate our Fc technologies or Fc candidates have not yet, and may never lead to, approved or
marketable therapeutic antibody products. Even if we are successful in continuing to build our pipeline, the potential product
candidates that we identify may not be suitable for clinical development, including as a result of their harmful side effects,
limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval
and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our
technological approach, we may not be able to obtain product or partnership revenues in future periods, which would
adversely affect our business, prospects, financial condition and results of operations.
We face significant competition from other biotechnology and pharmaceutical companies and our operating results will
suffer if we fail to compete effectively.
The biotechnology and pharmaceutical industries are intensely competitive. We have competitors both in the United
States and internationally, including major multinational pharmaceutical companies, biotechnology companies, universities
and other research institutions. Many of our competitors have substantially greater financial, technical and other resources,
such as larger research and development staff and experienced marketing and manufacturing organizations and well-
established sales forces. Competition may increase further as a result of advances in the commercial applicability of
technologies and greater availability of capital for investment in these industries. Our competitors may succeed in
developing, acquiring or licensing on an exclusive basis, drug products that are more effective or less costly than any product
candidate that we are currently developing or that we may develop.
Competition in autoimmune disease and cancer drug development is intense, with hundreds of compounds in
clinical trials by large multinational pharmaceutical companies. In addition, many currently marketed drugs are undergoing
clinical testing in new indications in order to expand their use to new patient populations. Other companies, including many
large international companies, are developing bispecific antibody technologies and checkpoint inhibitors. This includes
products in preclinical and clinical development. Some of these agents have received marketing approval, and companies
continue to conduct clinical trials to expand their currently approved indications. Alternative technologies, such as standard
chemotherapy, cellular therapies and cancer vaccines, may also compete with our products for patients to conduct clinical
trials and future potential market share.
32
Table of Contents
Our ability to compete successfully will depend largely on our ability to leverage our experience in drug discovery
and development to:
1.
2.
3.
4.
5.
discover and develop products that are superior to other products in the market;
attract qualified scientific, product development and commercial personnel;
obtain and maintain patent and/or other proprietary protection for our products and technologies;
obtain required regulatory approvals; and
successfully collaborate with pharmaceutical companies in the discovery, development and commercialization
of new products.
The availability and price of our competitors’ products could limit the demand, and the price we are able to charge,
for any of our product candidates, if approved. We will not achieve our business plan if acceptance is inhibited by price
competition or the reluctance of physicians to switch from existing drug products to our products, or if physicians switch to
other new drug products or choose to reserve our products for use in limited circumstances.
Established biopharmaceutical companies may invest heavily to accelerate discovery and development of products
that could make our product candidates less competitive. In addition, any new product that competes with an approved
product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price
competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection,
receiving FDA approval or discovering, developing and commercializing medicines before we do, which would have a
material adverse impact on our business. We will not be able to successfully commercialize our product candidates without
establishing sales and marketing capabilities internally or through collaborators.
Our current and future relationships with healthcare professionals, principal investigators, consultants, customers and
third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback,
fraud and abuse, false claims, physician payment transparency, health information privacy and security and other
healthcare laws and regulations, which could expose us to penalties.
Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role
in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and
future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may
expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-
Kickback Statute and the federal civil False Claims Act, that may constrain the business or financial arrangements and
relationships through which we sell, market and distribute any product candidates for which we obtain marketing approval.
In addition, we may be subject to physician payment transparency laws and patient privacy and security regulation by the
federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable federal, state
and foreign healthcare laws that may affect our ability to operate include the following:
● the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or
reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation
of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and
state healthcare programs such as Medicare and Medicaid;
33
Table of Contents
● federal civil and criminal false claims laws, including, without limitation, the federal civil False Claims Act
which can be enforced through civil whistleblower or qui tam actions, which prohibit individuals or entities for,
among other things, knowingly presenting, or causing to be presented, to the federal government, including
federal health care programs, such as, the Medicare and Medicaid programs, claims for payment that are false
or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the
federal government;
● the civil monetary penalties statute, which imposes penalties against any person or entity who, among other
things, is determined to have presented or caused to be presented a claim to a federal health program that the
person knows or should know is for an item or service that was not provided as claimed or is false or
fraudulent;
● the Health Insurance Portability and Accountability Act of 1996 (HIPAA) which created additional federal civil
and criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to
defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or
promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit
program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing
from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and
knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making
any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or
services relating to healthcare matters;
● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH),
and their respective implementing regulations, which impose obligations on “covered entities,” including
certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective “business
associates” that create, receive, maintain or transmit individually identifiable health information for or on
behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually
identifiable health information;
● the Physician Payments Sunshine Act, created under Section 6002 of the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the
“Affordable Care Act”), imposed annual reporting requirements for certain manufacturers of drugs, devices,
biologics and medical supplies for certain payments and “transfers of value” provided to physicians, as defined
by such law, and teaching hospitals, as well as ownership and investment interests held by physicians and their
immediate family members. Failure to submit timely, accurately and completely the required information for
all payments, transfers of value and ownership or investment interests may result in significant civil monetary
penalties; and
● analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or
marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to
comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws
and regulations, or that otherwise restrict payments that may be made to healthcare providers; state and foreign
laws that require manufacturers to report information related to payments and other transfers of value to
physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of
information related to drug pricing; state and local laws that require the registration of pharmaceutical sales
representatives; and state and foreign laws governing the privacy and security of health information in certain
circumstances, many of which differ from each other in significant ways and often are not preempted by
HIPAA, thus complicating compliance efforts.
34
Table of Contents
Further, the Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback
Statute and the healthcare fraud statute. A person or entity no longer needs to have actual knowledge of these statutes or
specific intent to violate them in order to have committed a violation. In addition, the Affordable Care Act provided that the
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.
Efforts to ensure that our future business arrangements with third parties will comply with applicable healthcare
laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our
business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and
abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including,
without limitation, damages, fines, imprisonment, disgorgement, exclusion from participation in government healthcare
programs, such as Medicare and Medicaid, additional reporting requirements and/or oversight if we become subject to a
corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the
curtailment or restructuring of our operations, as well as reputational harm, which could significantly harm our business.
Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and
commercialize our product candidates and affect the prices we may obtain.
Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting
changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding
access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by major legislative initiatives. In March 2010, President Obama signed into law the Affordable Care
Act, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending,
enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance
industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Affordable
Care Act established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded
prescription drugs and biologic agents, addressed a new methodology by which rebates owed by manufacturers under the
Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased
the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the
Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care
organizations, and provided incentives to programs that increase the federal government’s comparative effectiveness
research.
In addition, the Affordable Care Act implemented payment system reforms including a national pilot program on
payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency
of certain healthcare services through bundled payment models. There remain judicial and Congressional challenges to
certain aspects of the Affordable Care Act, as well as recent efforts by the administration to repeal or replace certain aspects
of the Affordable Care Act. Since January 2017, the president has signed two Executive Orders and other directives designed
to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the
requirements for health insurance mandated by the Affordable Care Act. Concurrently, Congress has considered legislation
that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive
repeal legislation, two bills affecting the implementation of certain taxes under the Affordable Care Act have been signed
into law. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017 (TCJA), includes a provision
which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act
on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as
the “individual mandate”.
35
Table of Contents
In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the Affordable
Care Act’s mandated fees “Cadillac” tax on high cost employer-sponsored health coverage, and medical device tax and,
effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018 (BBA) among other
things, amended the Affordable Care Act, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-
sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap
in most Medicare drug plans, commonly referred to as the “donut hole”. In December 2018, the Centers for Medicare &
Medicaid Services (CMS) published a new final rule permitting further collections and payments to and from certain
Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment
program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk
adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional
in its entirety because the “individual mandate” was repealed by Congress as part of the TCJA. Additionally, on December
18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was
unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the
Affordable Care Act are invalid as well. It is unclear how this decision, future decisions, subsequent appeals, and other
efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business.
In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted.
On August 2, 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the
Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select
Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the
legislation’s automatic reduction to several government programs. This includes reductions to Medicare payments to
providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislation, including the
BBA, will remain in effect through 2029 unless additional Congressional action is taken. On January 2, 2013, President
Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments
to several providers, including hospitals, imaging centers and cancer treatment centers and increased the statute of limitations
period for the government to recover overpayments to providers from three to five years.
Further, there has been heightened governmental scrutiny recently over the manner in which manufacturers set
prices for their marketed products, which have resulted in several Congressional inquiries and proposed and enacted federal
and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, reduce the cost of products under Medicare, and reform government
program reimbursement methodologies for products. At the federal level, the administration’s budget proposal for fiscal year
2020 contains further price control measures that could be enacted during the 2019 budget process or in other future
legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain products under
Medicare Part B, to allow some states to negotiate product prices under Medicaid, and to eliminate cost sharing for generics
for low-income patients. Additionally, the administration released a “Blueprint” to lower drug prices and reduce out of
pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power
of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out
of pocket costs of drug products paid by consumers. HHS solicited feedback on some of these measures and has
implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare
Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS’
policy change that was effective January 1, 2019. While some of these and other proposed measures may require additional
authorization to become effective, Congress and the administration have each indicated that it will continue to seek new
legislative and/or administrative measures to control pharmaceutical costs. At the state level, legislatures have increasingly
passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit
the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced
demand for our products or additional pricing pressure.
36
Table of Contents
We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage
criteria and lower reimbursement, and in additional downward pressure on the price that may be charged for any of our
product candidates, if approved.
Even if we are able to commercialize any product candidates, our product candidates may be subject to unfavorable
pricing regulations, third-party coverage and reimbursement policies or healthcare reform initiatives.
Our ability to commercialize any product candidates successfully will depend, in part, on the extent to which
coverage and adequate reimbursement for our product candidates will be available from government payor programs at the
federal and state levels, including Medicare and Medicaid, private health insurers, managed care plans and other third-party
payors. Government authorities and other third-party payors, such as private health insurers and health maintenance
organizations, decide which medical products they will pay for and establish reimbursement levels. Increasingly, third-party
payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for products. Coverage and reimbursement may not be available for any product that we commercialize and,
even if these are available, the level of reimbursement may not be satisfactory. Inadequate reimbursement levels may
adversely affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining
and maintaining adequate reimbursement for our drugs may be difficult. We may be required to conduct expensive
pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement compared to other therapies.
If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not
be able to successfully commercialize any product candidates for which marketing approval is obtained.
In addition, net prices for products may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of products from
countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy
requirement for coverage and reimbursement for drug products exists among third-party payors in the United States.
Therefore, coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination
process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use
of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied
consistently or obtained at all. Further, there may be significant delays in obtaining coverage and reimbursement for newly
approved products, and coverage may be more limited than the indications for which the product is approved by the FDA or
similar regulatory authorities outside the United States. Moreover, eligibility for coverage and reimbursement does not imply
that a product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture,
sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to
cover our costs and may not be made permanent. Our inability to promptly obtain coverage and adequate reimbursement
rates from both government-funded and private payors for any approved products that we develop could significantly harm
our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.
The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs and biological
products vary widely from country to country. Current and future legislation may significantly change the approval
requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require
approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains
subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing
approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the
product, possibly for lengthy time periods, and negatively impact the revenues able to be generated from the sale of the
product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product
candidates, even if our product candidates obtain marketing approval.
37
Table of Contents
There can be no assurance that our product candidates, if they are approved for sale in the United States or in other
countries, will be considered medically reasonable and necessary for a specific indication, that they will be considered cost-
effective by third-party payors, that coverage or an adequate level of reimbursement will be available, or that third-party
payors’ reimbursement policies will not adversely affect our ability to sell our product candidates profitably if they are
approved for sale.
Our business could be negatively impacted by cyber security threats and other disruptions, including the theft of our
intellectual property, and could compromise our information and expose us to liability, which would cause our business
and reputation to suffer.
We are increasingly dependent on information technology systems and infrastructure, including mobile
technologies, to operate our business. In the ordinary course of our business, we use our data centers and our networks to
store and access confidential and proprietary business information. The information includes, among other things, our
intellectual property and proprietary information, the confidential information of our collaborators and licensees and the
personally identifiable information of our employees, and the individually identified health information of patients
participating in our clinical trials. It is important to our operations and business strategy that this electronic information
remains secure and is perceived to be secure. The size and complexity of our information technology systems, and those of
our partners and third-party vendors with whom we contract together with the volume of data we retain, make such systems
potentially vulnerable to breakdown, malicious intrusion, security breaches and other cyber-security attacks.
Information security risks have significantly increased in recent years in part due to the proliferation of new
technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties,
including foreign state actors. We face various cyber security threats, including cyber security attacks to our information
technology infrastructure and attempts by others to gain access to our proprietary or sensitive information. A security breach
or privacy violation that leads to disclosure or modification of or prevents access to personally identifiable information or
other protected information could harm our reputation, compel us to comply with federal and/or state breach notification
laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database
contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased
costs or loss of revenue. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could
result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
Moreover, a security breach that exposes our confidential intellectual property could compromise our patent portfolio.
Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to
remedy. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial
measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory
penalties because of lost or misappropriated information. In addition, these breaches and other inappropriate access can be
difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the
prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could
lead to the loss of confidential information, trade secrets or other intellectual property. As cyber threats continue to evolve,
we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to
investigate and remediate any information security vulnerabilities.
The procedures and controls we use to monitor these threats and mitigate our exposure may not be sufficient to
prevent cyber security incidents. The result of these incidents could have a material adverse effect on our business, financial
condition and results of operations including disrupted operations, lost opportunities, misstated financial data, liability for
stolen assets or information, increased costs arising from the implementation of additional security protective measures,
litigation and reputational damage. Any remedial costs or other liabilities related to cyber security incidents may not be fully
insured or indemnified by other means.
38
Table of Contents
Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or
inhibit our ability to collect and process data globally, and the failure to comply with such requirements could have a
material adverse effect on our business, financial condition or results of operations.
The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information
worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. For example, the EU’s General
Data Protection Regulation (GDPR), imposes strict obligations on the processing of personal data, including personal health
data, and the free movement of such data. The GDPR applies to any company established in the EU as well as any company
outside the EU that processes personal data in connection with the offering of goods or services to individuals in the EU or
the monitoring of their behavior.
As such, the GDPR will apply to us in connection with any clinical trials we conduct in the EU. The GDPR enhances
data protection obligations for processors and controllers of personal data, including, for example, obligations relating to:
processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data
processing activities; responding to data subject requests; taking certain measures when engaging third-party processors;
notifying data subjects and regulators of data breaches; implementing safeguards to protect the security and confidentiality of
personal data; and transferring personal data to countries outside the EU, including the U.S. The GDPR imposes substantial
fines for breaches of data protection requirements, which can be up to four percent of global revenue or 20 million euros,
whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection
requirements. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of
sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our
business practices or lead to government enforcement actions, private litigation or significant penalties against us and could
have a material adverse effect on our business, financial condition or results of operations.
Additionally, California recently enacted legislation that has been dubbed the first “GDPR-like” law in the U.S.
Known as the California Consumer Privacy Act (CCPA), it creates new individual privacy rights for consumers (as that word
is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of
consumers or households. The CCPA, which went into effect on January 1, 2020, requires covered companies to provide new
disclosures to California consumers, and provides such consumers new ways to opt-out of certain sales of personal
information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is
expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some
observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the
U.S., which could increase our potential liability and adversely affect our business.
Risks Relating to Our Dependence on Third Parties
Our existing partnerships are important to our business, and future partnerships may also be important to us. If we are
unable to maintain any of these partnerships, or if these partnerships are not successful, our business could be adversely
affected.
Because developing biologics products, conducting clinical trials, obtaining regulatory approval, establishing
manufacturing capabilities and marketing approved products are expensive, we have entered into partnerships, and may seek
to enter into additional partnerships, with companies that have more resources and experience than us, and we may become
dependent upon the establishment and successful implementation of partnership agreements.
Our partnership and license agreements include those we have announced with Genentech, Novartis, Amgen,
MorphoSys, Alexion and others. These partnerships and license agreements also have provided us with important funding for
our development programs, and we expect to receive additional funding under these partnerships in the future. Our existing
partnerships, and any future partnerships we enter into, may pose a number of risks, including the following:
1.
collaborators have significant discretion in determining the efforts and resources that they will apply to these
partnerships. In December 2018, Novartis notified us of its decision to return the rights to plamotamab to us
under the terms of the Novartis Agreement;
39
Table of Contents
2.
3.
4.
5.
6.
7.
8.
9.
our Novartis Agreement requires us to co-develop worldwide with Novartis our lead bispecific antibody
candidate, XmAb14045, and share development costs. Such an arrangement may require us to incur substantial
costs in excess of our available resources;
our Genentech Agreement requires that we fund 45% of worldwide development costs of XmAb24306 and
other IL-15 candidates. Such an arrangement may require us to incur substantial costs in excess of available
resources;
collaborators may not perform their obligations as expected;
collaborators may not pursue development and commercialization of any product candidates that achieve
regulatory approval or may elect not to continue or renew development or commercialization programs based
on clinical trial results, changes in the collaborators’ strategic focus or available funding, or external factors,
such as an acquisition, that divert resources or create competing priorities;
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical
trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a
product candidate for clinical testing;
collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our products or product candidates if the collaborators believe that competitive products are
more likely to be successfully developed or can be commercialized under terms that are more economically
attractive than ours, which may cause collaborators to cease to devote resources to the commercialization of
our product candidates;
a collaborator with marketing and distribution rights to one or more of our product candidates that achieve
regulatory approval may not commit sufficient resources to the marketing and distribution of such product or
products;
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or termination of the research, development or
commercialization of product candidates, might lead to additional responsibilities for us with respect to product
candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;
10. while we have generally retained the right to maintain and defend our intellectual property under our
agreements with collaborators, certain collaborators may not properly maintain or defend certain of our
intellectual property rights or may use our proprietary information in such a way as to invite litigation that
could jeopardize or invalidate our intellectual property or proprietary information;
11. collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation
and potential liability;
12. collaborators may learn about our technology and use this knowledge to compete with us in the future;
13. results of collaborators’ preclinical or clinical studies could produce results that harm or impair other products
using our XmAb technology platform;
14. there may be conflicts between different collaborators that could negatively affect those partnerships and
potentially others; and
15. the number and type of our partnerships could adversely affect our attractiveness to future collaborators or
acquirers.
40
Table of Contents
If our partnerships and license agreements do not result in the successful development and commercialization of
products or if one of our collaborators terminates its agreement with us, we may not receive any future research and
development funding or milestone or royalty payments under the arrangement. If we do not receive the funding we expect
under these arrangements, our continued development of our product candidates could be delayed, and we may need
additional resources to develop additional product candidates. All of the risks described in these risk factors relating to
product development, regulatory approval and commercialization described in this Annual Report also apply to the activities
of our collaborators and there can be no assurance that our partnerships and license agreements will produce positive results
or successful products on a timely basis or at all.
Our partnership agreements generally grant our collaborators exclusive rights under certain of our intellectual
property and may therefore preclude us from entering into partnerships with others relating to the same or similar
compounds, indications or diseases. In addition, partnership agreements may place restrictions or additional obligations on
our ability to license additional compounds in different indications, diseases or geographical locations. If we fail to comply
with or breach any provision of a partnership agreement, a collaborator may have the right to terminate, in whole or in part,
such agreement or to seek damages. Many of our collaborators also have the right to terminate the partnership agreement for
convenience. If a partnership agreement is terminated, in whole or in part, we may be unable to continue the development
and commercialization of the applicable product candidates, and even if we are able to do so, such efforts may be delayed
and result in additional costs.
There is no assurance that a collaborator who is acquired by a third party would not attempt to change certain
contract provisions that could negatively affect our partnership. The acquiring company may also not accept the terms or
assignment of our contracts and may seek to terminate the agreements. Any one of our partners could breach covenants,
restrictions and/or sub-license agreement provisions leading us into disputes and potential breaches of our agreements with
other partners.
We may in the future determine to partner with additional pharmaceutical and biotechnology companies for
development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate
collaborators. Our ability to reach a definitive agreement for a partnership will depend, among other things, upon our
assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed partnership and the
proposed collaborator’s evaluation of a number of factors. If we elect to fund and undertake development or
commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be
available to us on acceptable terms or at all. If we fail to enter into partnerships and do not have sufficient funds or expertise
to undertake the necessary development and commercialization activities, we may not be able to further develop our product
candidates or bring them to market or continue to develop our product platform and our business, prospects, financial
condition and results of operations may be materially and adversely affected.
We rely upon third-party contractors and service providers for the execution of most aspects of our development
programs. Failure of these collaborators to provide services of a suitable quality and within acceptable timeframes may
cause the delay or failure of our development programs.
We outsource certain functions, tests and services to contract research organizations (CROs), medical institutions
and collaborators as well as outsourcing manufacturing to collaborators and/or contract manufacturers, and we rely on third
parties for quality assurance, clinical monitoring, clinical data management and regulatory expertise. We also have engaged,
and may in the future engage, a CRO to run all aspects of a clinical trial on our behalf. There is no assurance that such
individuals or organizations will be able to provide the functions, tests, biologic supply or services as agreed upon or in a
quality fashion and we could suffer significant delays in the development of our products or processes.
41
Table of Contents
In some cases, there may be only one or few providers of such services, including clinical data management or
manufacturing services. In addition, the cost of such services could be significantly increased over time. We rely on third
parties and collaborators as mentioned above to enroll qualified patients and conduct, supervise and monitor our clinical
trials. Our reliance on these third parties and collaborators for clinical development activities reduces our control over these
activities. Our reliance on these parties, however, does not relieve us of our regulatory responsibilities, including ensuring
that our clinical trials are conducted in accordance with GCP regulations and the investigational plan and protocols contained
in the regulatory agency applications. In addition, these third parties may not complete activities on schedule or may not
manufacture under GMP conditions. Preclinical or clinical studies may not be performed or completed in accordance with
Good Laboratory Practices (GLP) regulatory requirements or our trial design. If these third parties or collaborators do not
successfully carry out their contractual duties or meet expected deadlines, obtaining regulatory approval for manufacturing
and commercialization of our product candidates may be delayed or prevented. We rely substantially on third-party data
managers for our clinical trial data. There is no assurance that these third parties will not make errors in the design,
management or retention of our data or data systems. There is no assurance these third parties will pass FDA or regulatory
audits, which could delay or prohibit regulatory approval.
We rely on third parties to manufacture supplies of our preclinical and clinical product candidates. The development of
such candidates could be stopped or delayed if any such third party fails to provide us with sufficient quantities of product
or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance.
We do not currently have nor do we plan to acquire the infrastructure or capability internally to manufacture our
clinical drug supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture
any clinical candidates on a clinical scale. Instead, we rely on our third-party manufacturing partners to manufacture our
clinical drug supply. Any of our contract manufacturers may not perform as agreed, may be unable to comply with cGMP
requirements and with FDA, state and foreign regulatory requirements or may terminate their respective agreements with us.
In addition, manufacturers are subject to ongoing periodic unannounced inspection by the FDA and other
governmental authorities to ensure strict compliance with government regulations. We do not control the manufacturing
processes of our third-party manufacturing partners, which include, among other things, quality control, quality assurance
and the maintenance of records and documentation. If we were to experience an unexpected loss of supply, we could
experience delays in our planned clinical trials as our third-party manufacturing partner would need to manufacture
additional clinical drug supply and would need sufficient lead time to schedule a manufacturing slot. While there are other
potential suppliers of clinical supplies of our biologics, the long transition periods necessary to switch manufacturers for any
of our clinical drug supply would significantly delay our clinical trials and the commercialization of such products, if
approved.
We intend to rely on third parties to manufacture commercial supplies of our product candidate. If we are unable to enter
into commercial supply agreements with third-party suppliers or if any such third-party supplier fails to provide us with
sufficient quantities or fails to comply with regulatory requirements, commercialization of such products could be delayed
or stopped.
We do not currently have nor do we plan to acquire the infrastructure or capability internally to manufacture our
products on a commercial scale. Although we have entered into agreements for the manufacture of clinical supplies of our
clinical drug supplies, we have not entered into a commercial supply agreement with any manufacturer for large commercial
scale drug supply. We might be unable to identify manufacturers for late stage clinical trials or commercial supply on
acceptable terms or at all. A change to the manufacturing process for any of our product candidates would cause us to incur
significant costs and to devote significant efforts to implement such a change. Additionally, the late-stage clinical
development and commercialization of any product candidates by us or our collaborators may be delayed as a result, which
would materially and adversely affect our business.
42
Table of Contents
If our third-party manufacturers cannot successfully manufacture material that conforms to our specifications and
the applicable regulatory authorities’ strict regulatory requirements, or pass regulatory inspection, they will not be able to
secure or maintain regulatory approval for the manufacturing facilities. In addition, we have no control over the ability of any
third-party manufacturer to maintain adequate quality control, quality assurance and qualified personnel. The facilities used
by our third-party manufacturers to manufacture clinical drug supply for our product candidates and any other potential
product candidates that we may develop in the future must be approved by the applicable regulatory authorities, including the
FDA, pursuant to inspections that will be conducted after we submit our BLA to the FDA. In addition, manufacturers are
subject to ongoing periodic unannounced inspection by the FDA and other governmental authorities to ensure strict
compliance with government regulations. If the FDA or any other applicable regulatory authorities do not approve these
facilities for the manufacture of our products or if they withdraw any such approval in the future, or if our suppliers or third-
party manufacturer decide they no longer want to supply our biologics or manufacture our products, we may need to find
alternative manufacturing facilities, which would significantly impact our ability to market our products and our business,
prospects, financial condition and results of operations may be materially and adversely affected.
Risks Relating to Our Intellectual Property
If we are unable to obtain, maintain and enforce intellectual property protection covering our products, others may be
able to make, use or sell products substantially the same as ours, which could adversely affect our ability to compete in the
market.
Our commercial success depends, in part, on our ability to obtain, maintain and enforce patents, trade secrets,
trademarks and other intellectual property rights and to operate without having third parties infringe, misappropriate or
circumvent the rights that we own or license. The value of many of our partnered licensing arrangements is based on the
underlying intellectual property and related patents. If we are unable to obtain, maintain and enforce intellectual property
protection covering our products or underlying technologies, others may be able to make, use or sell products that are
substantially the same as ours without incurring the sizeable development and licensing costs that we have incurred, which
would adversely affect our ability to compete in the market. As of December 31, 2019, we held over 1,000 issued patents and
pending patent applications. We file patent applications in the United States, Canada, Japan, Europe and other major markets
either directly or via the Patent Cooperation Treaty. Our ability to stop third parties from making, using, selling, offering to
sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable
patents or trade secrets that cover these activities. However, the patent positions of biopharmaceutical companies, including
ours, can be highly uncertain and involve complex legal and factual questions for which important legal principles remain
unresolved. No consistent policy regarding the breadth of claims allowed in patents in these fields has emerged to date in the
United States. The U.S. patent laws have recently changed, there have been changes regarding how patent laws are
interpreted, and the U.S. Patent and Trademark Office (the PTO) has also implemented changes to the patent system. Some
of these changes are currently being litigated, and we cannot accurately determine the outcome of any such proceedings or
predict future changes in the interpretation of patent laws or changes to patent laws which might be enacted into law. Those
changes may materially affect our patents, our ability to obtain patents or the patents and applications of our collaborators
and licensors. The patent situation in the biopharmaceutical industry outside the United States is even more uncertain.
Therefore, there is no assurance that our pending patent applications will result in the issuance of patents or that we will
develop additional proprietary products which are patentable. Moreover, patents issued or to be issued to us may not provide
us with any competitive advantage. Our patent position is subject to numerous additional risks, including the following:
1. we may fail to seek patent protection for inventions that are important to our success;
2.
our pending patent applications may not result in issued patents;
3. we cannot be certain that we are the first to invent the inventions covered by pending patent applications or that
we were the first to file such applications and, if we are not, we may be subject to priority disputes;
4. we may be required to disclaim part or all of the term of certain patents or all of the term of certain patent
applications;
43
Table of Contents
5. we may file patent applications but have claims restricted or we may not be able to supply sufficient data to
support our claims and, as a result, may not obtain the original claims desired or we may receive restricted
claims. Alternatively, it is possible that we may not receive any patent protection from an application;
6. we could inadvertently abandon a patent or patent application, resulting in the loss of protection of certain
intellectual property rights in a certain country. We, our collaborators or our patent counsel may take action
resulting in a patent or patent application becoming abandoned which may not be able to be reinstated or if
reinstated, may suffer patent term adjustments;
7.
8.
9.
the claims of our issued patents or patent applications when issued may not cover our product candidates;
no assurance can be given that our patents would be declared by a court to be valid or enforceable or that a
competitor’s technology or product would be found by a court to infringe our patents. Our patents or patent
applications may be challenged by third parties in patent litigation or in proceedings before the PTO or its
foreign counterparts, and may ultimately be declared invalid or unenforceable, or narrowed in scope;
there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim.
There also may be prior art of which we are aware, but which we do not believe affects the validity or
enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of
a claim;
10. third parties may develop products which have the same or similar effect as our products without infringing our
patents. Such third parties may also intentionally circumvent our patents by means of alternate designs or
processes or file applications or be granted patents that would block or hurt our efforts;
11.
there may be dominating patents relevant to our product candidates of which we are not aware;
12. our patent counsel, lawyers or advisors may have given us, or may in the future give us incorrect advice or
counsel. Opinions from such patent counsel or lawyers may not be correct or may be based on incomplete
facts;
13. obtaining regulatory approval for biopharmaceutical products is a lengthy and complex process, and as a result,
any patents covering our product candidates may expire before, or shortly after such product candidates are
approved and commercialized;
14. the patent and patent enforcement laws of some foreign jurisdictions do not protect intellectual property rights
to the same extent as laws in the United States, and many companies have encountered significant difficulties
in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties or we are
otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our
business prospects could be substantially harmed; and
15. we may not develop additional proprietary technologies that are patentable.
Any of these factors could hurt our ability to gain full patent protection for our products. Registered trademarks and
trademark applications in the United States and other countries are subject to similar risks as described above for patents and
patent applications, in addition to the risks described below.
44
Table of Contents
Many of our product development partnership agreements are complex and may call for licensing or cross-licensing
of potentially blocking patents, know-how or intellectual property. Due to the potential overlap of data, know-how and
intellectual property rights there can be no assurance that one of our collaborators will not dispute our right to use, license or
distribute data, know-how or other intellectual property rights, and this may potentially lead to disputes, liability or
termination of a program. There are no assurances that our actions or the actions of our collaborators would not lead to
disputes or cause us to default with other collaborators. For example, we may become involved in disputes with our
collaborators relating to the ownership of intellectual property developed in the course of the partnership. We also cannot be
certain that a collaborator will not challenge the validity or enforceability of the patents we license.
We cannot be certain that any country’s patent and/or trademark office will not implement new rules which could
seriously affect how we draft, file, prosecute and/or maintain patents, trademarks and patent and trademark applications. We
cannot be certain that increasing costs for drafting, filing, prosecuting and maintaining patents, trademarks and patent and
trademark applications will not restrict our ability to file for patent protection. For example, we may elect not to seek patent
protection in certain jurisdictions or for certain inventions in order to save costs. We may be forced to abandon or return the
rights to specific patents due to a lack of financial resources.
We currently rely, and may in the future rely, on certain intellectual property rights licensed from third parties to
protect our technology and certain product candidates. We have licensed and sublicensed certain intellectual property relating
to our Xtend technology from a third party. We have also sublicensed certain intellectual property rights related to our
bispecific technology from a third party and, we have licensed certain intellectual property rights from a third party related to
our XmAb18087 product candidate. We also license certain rights to the underlying cell lines for all our product candidates
from third parties. Under these licenses, we have no right to control patent prosecution of the intellectual property or to
enforce the patents, and as such the licensed rights may not be adequately maintained by the licensors. The termination of
these or other licenses could also prevent us from commercializing product candidates covered by the licensed intellectual
property.
Furthermore, the research resulting in the in-licensed patents was developed in the course of research funded by the
U.S. government. As a result, the U.S. government may have certain rights (“march-in rights”) to intellectual property
embodied in our Xtend products. Government rights in certain inventions developed under a government-funded program
include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose.
Circumstances that trigger march-in rights include, for example, failure to take, within a reasonable time, effective steps to
achieve practical application of the invention in a field of use, failure to satisfy the health and safety needs of the public and
failure to meet requirements of public use specified by federal regulations. Federal law requires any licensor of an invention
that was partially funded by the federal government to obtain a covenant from any exclusive licensee to manufacture
products using the invention substantially in the United States. The U.S. government also has the right to use and disclose,
without limitation, scientific data relating to licensed technology that was developed in whole or in part at government
expense. The government funding agency can elect to exercise these march-in rights on their own initiative or at the request
of a third party. It is also possible that we might knowingly or unknowingly in-license additional technology that is subject to
U.S. government march-in rights.
We intend to file applications for trademark registrations in connection with our product candidates in various
jurisdictions, including the United States. No assurance can be given that any of our trademark applications will be registered
in the United States or elsewhere, or that the use of any registered or unregistered trademarks will confer a competitive
advantage in the marketplace. Furthermore, even if we are successful in our trademark registrations, the FDA and regulatory
authorities in other countries have their own process for drug nomenclature and their own views concerning appropriate
proprietary names. No assurance can be given that the FDA or any other regulatory authority will approve of any of our
trademarks or will not request reconsideration of one of our trademarks at some time in the future. The loss, abandonment, or
cancellation of any of our trademarks or trademark applications could negatively affect the success of the product candidates
to which they relate.
45
Table of Contents
If we are not able to prevent disclosure of our trade secrets and other proprietary information, the value of our
technology and products could be significantly diminished.
We rely on trade secret protection to protect our interests in proprietary know-how and in processes for which
patents are difficult to obtain or enforce. We may not be able to protect our trade secrets adequately. We have a policy of
requiring our consultants, advisors and collaborators to enter into confidentiality agreements and our employees to enter into
invention, non-disclosure and non-compete agreements. However, no assurance can be given that we have entered into
appropriate agreements with all parties that have had access to our trade secrets, know-how or other proprietary information.
There is also no assurance that such agreements will provide for a meaningful protection of our trade secrets, know-how or
other proprietary information in the event of any unauthorized use or disclosure of information. Furthermore, we cannot
provide assurance that any of our employees, consultants, contract personnel, or collaborators, either accidentally or through
willful misconduct, will not cause serious damage to our programs and/or our strategy, for example by disclosing important
trade secrets, know-how or proprietary information to our competitors. It is also possible that our trade secrets, know-how or
other proprietary information could be obtained by third parties as a result of breaches of our physical or electronic security
systems. Any disclosure of confidential data into the public domain or to third parties could allow our competitors to learn
our trade secrets and use the information in competition against us. In addition, others may independently discover our trade
secrets and proprietary information. Any action to enforce our rights is likely to be time consuming and expensive, and may
ultimately be unsuccessful, or may result in a remedy that is not commercially valuable. These risks are accentuated in
foreign countries where laws or law enforcement practices may not protect proprietary rights as fully as in the United States
or Europe. Any unauthorized disclosure of our trade secrets or proprietary information could harm our competitive position.
We may be required to reduce the scope of our intellectual property due to third-party intellectual property claims.
Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours.
Any such patent application may have priority over our patent applications, which could further require us to obtain rights to
issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours
that claims priority to an application filed prior to March 16, 2013, we may have to participate in an interference proceeding
declared by the PTO to determine priority of invention in the United States. The costs of these proceedings could be
substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently
arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect
to such inventions. In addition, changes enacted on March 15, 2013 to the U.S. patent laws under the America Invents Act
resulted in the United States changing from a “first to invent” country to a “first to file” country. As a result, we may lose the
ability to obtain a patent if a third-party files with the PTO first and could become involved in proceedings before the PTO to
resolve disputes related to inventorship. We may also become involved in similar proceedings in other jurisdictions.
Furthermore, recent changes in U.S. patent law under the America Invents Act allows for post-issuance challenges
to U.S. patents, including ex parte reexaminations, inter parte reviews and post-grant oppositions. There is significant
uncertainty as to how the new laws will be applied and if our U.S. patents are challenged using such procedures, we may not
prevail, possibly resulting in altered or diminished claim scope or loss of patent rights altogether. Similarly, some countries,
notably members of the European Union, also have post grant opposition proceedings that can result in changes in scope
and/or cancellation of patent claims.
46
Table of Contents
Our products could infringe patents and other property rights of others, which may result in costly litigation and, if we
are not successful, could cause us to pay substantial damages or limit our ability to commercialize our products, which
could have a material adverse effect on our business.
Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture,
market and sell our product candidates and use our proprietary technologies without infringing the patents and other
proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and
pharmaceutical industries. For example, we are aware of an issued U.S. patent owned by Genentech that may relate to and
claim components of certain of our candidates and partnered products, including Ultomiris, XmAb20717, XmAb22841,
XmAb23104, and XmAb24306 or their manufacture. We believe that this patent will expire in the United States in 2020.
Furthermore, we are aware of issued patents owned by Merus B.V. (Merus) that may relate to and claim components of our
bispecific antibody product candidates and partnered bispecific product candidates, including XmAb14045, plamotamab,
XmAb18087, XmAb20717, XmAb23104 and XmAb22841, and will putatively expire in 2033. We are additionally aware of
several patents and pending applications directed to the use of IL-15 fused with Fc domains, and in some cases in
combination with targeting domains, that might be relevant to XmAb24306, with putative expirations ranging from 2025 to
later than 2032. It is possible that these terms could be extended, for example, as a result of patent term restoration to
compensate for regulatory delays. While we believe that our current development of these candidates currently falls into the
“safe harbor” of non-infringement under 35 U.S.C. §271€(1), this protection terminates upon commercialization. In addition,
there can be no assurance that our interpretation of this statutory exemption would be upheld. We believe there exists
reasonable arguments of invalidity for the Genentech patent, the Merus patents and the IL-15 patents; however, we cannot
assure that if challenged in litigation for infringement of these patents that we would prevail. In order to successfully
challenge the validity of any issued U.S. patent, we would need to overcome a presumption of validity. This burden is a high
one requiring us to present clear and convincing evidence as to the invalidity of such claims. There is no assurance that a
court would find these claims to be invalid or not infringed.
In addition, as the biopharmaceutical industry expands and more patents are issued, the risk increases that there may
be patents issued to third parties that relate to our products and technology of which we are not aware or that we must
challenge to continue our operations as currently contemplated. Our products may infringe or may be alleged to infringe
these patents. Because some patent applications in the United States may be maintained in secrecy until the patents are
issued, because patent applications in the United States and many foreign jurisdictions are typically not published until
eighteen months after filing and because publications in the scientific literature often lag behind actual discoveries, we
cannot be certain that others have not filed patents that may cover our technologies, our product candidates or their use.
Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a
manner that could cover our technologies, our products or the use of our products. We may become party to, or threatened
with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and
technology. Third parties may assert infringement claims against us based on existing patents or patents that may be granted
in the future.
If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not
infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this.
Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and
convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these
proceedings, we may incur substantial costs and divert management’s time and attention in pursuing these proceedings,
which could have a material adverse effect on us.
Any such claims are likely to be expensive to defend, and some of our competitors may be able to sustain the costs
of complex patent litigation more effectively than we can because they have substantially greater resources.
47
Table of Contents
If we are found to infringe a third party’s intellectual property rights, we could be required to obtain a license from
such third party to continue developing and marketing our products and technology. We may also elect to enter into such a
license in order to settle litigation or in order to resolve disputes prior to litigation. However, we may not be able to obtain
any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-
exclusive, thereby giving our competitors access to the same technologies licensed to us and could require us to make
substantial royalty payments. We could also be forced, including by court order, to cease commercializing the infringing
technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys’
fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing
our product candidates or force us to cease some of our business operations, which could materially harm our business.
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar
negative impact on our business.
Our intellectual property may be infringed upon by a third party.
Third parties may infringe one or more of our issued patents or trademarks. We cannot predict if, when or where a
third party may infringe one or more of our issued patents or trademarks. To counter infringement, we may be required to file
infringement claims, which can be expensive and time consuming. There is no assurance that we would be successful in a
court of law in proving that a third party is infringing one or more of our issued patents or trademarks. Any claims we assert
against perceived infringers could also provoke these parties to assert counterclaims against us, alleging that we infringe their
intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or
unenforceable, in whole or in part, construe the patent’s claims narrowly and/or refuse to stop the other party from using the
technology at issue on the grounds that our patents do not cover the technology in question, any of which may adversely
affect our business. Even if we are successful in proving in a court of law that a third party is infringing one or more of our
issued patents or trademarks there can be no assurance that we would be successful in halting their infringing activities, for
example, through a permanent injunction, or that we would be fully or even partially financially compensated for any harm
to our business. We may be forced to enter into a license or other agreement with the infringing third party at terms less
profitable or otherwise commercially acceptable to us than if the license or agreement were negotiated under conditions
between those of a willing licensee and a willing licensor. We may not become aware of a third-party infringer within legal
timeframes for compensation or at all, thereby possibly losing the ability to be compensated for any harm to our business.
Such a third party may be operating in a foreign country where the infringer is difficult to locate and/or the intellectual
property laws may be more difficult to enforce. Some third-party infringers may be able to sustain the costs of complex
infringement litigation more effectively than we can because they have substantially greater resources. Any inability to stop
third-party infringement could result in loss in market share of some of our products or even lead to a delay, reduction and/or
inhibition of the development, manufacture or sale of certain products by us. There is no assurance that a product produced
and sold by a third-party infringer would meet our or other regulatory standards or would be safe for use. Such third-party
infringer products could irreparably harm the reputation of our products thereby resulting in substantial loss in market share
and profits.
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or
disclosed confidential information of third parties.
We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We
may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise
used or disclosed confidential information of our employees’ former employers or other third parties. We may also be subject
to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary
to defend against these claims. There is no guarantee of success in defending these claims, and if we do not prevail, we could
be required to pay substantial damages and could lose rights to important intellectual property. Even if we are successful,
litigation could result in substantial cost and be a distraction to our management and other employees.
48
Table of Contents
Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business
We are subject to competition for our skilled personnel and may experience challenges in identifying and retaining key
personnel that could impair our ability to conduct and grow our operations effectively.
Our planned growth and future success depend on our ability to retain our executive officers and to attract, retain
and motivate qualified personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not
be able to successfully implement our business strategy. Although we have not experienced problems attracting and retaining
highly qualified personnel in the recent past, our industry has experienced a high rate of turnover of management personnel
in recent years. Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon
our ability to attract and retain highly qualified management, scientific and medical personnel. We are highly dependent on
our current management team, whose services are critical to the successful implementation of our product candidate
development and regulatory strategies. In order to induce valuable employees to continue their employment with us, we have
provided stock options that vest over time. The value to employees of stock options that vest over time is significantly
affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more
lucrative offers from other companies.
Despite our efforts to retain valuable employees, members of our management team may terminate their
employment with us at any time, with or without notice. Further, we do not maintain “key person” insurance for any of our
executives or other employees. The loss of the services of any of our executive officers and our inability to find suitable
replacements could harm our business, financial condition, prospects and ability to achieve the successful development or
commercialization of our product candidates. Our success also depends on our ability to continue to attract, retain and
motivate highly skilled scientific and medical personnel at all levels.
In 2016 we began to increase the number of our employees and expand the scope of our operations with a goal of
advancing multiple clinical candidates into development. The increase in employees, especially in clinical development,
places a significant strain on our management, operations and financial resources, and we may have difficulty managing this
future potential growth. As we continue to grow our operations and advance our clinical programs into later stages of
development, it will require us to recruit and retain employees with additional knowledge and skill sets and no assurance can
be provided that we will be able to attract employees with the necessary skill set to assist in our growth. Many of the other
biotech and pharmaceutical companies and academic institutions that we compete against for qualified personnel have
greater financial and other resources, different risk profiles and a longer history in the industry than we do. We also may
employ consultants or part-time and contract employees. There can be no assurance that these individuals are retainable.
While we have been able to attract and retain skilled and experienced personnel and consultants in the past, no assurance can
be given that we will be able to do so in the future.
We may become subject to the risk of product liability claims.
We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face
an even greater risk if we or our partners commercialize any products. Human therapeutic products involve the risk of
product liability claims and associated adverse publicity. Currently, the principal risks we face relate to patients in our
clinical trials, who may suffer unintended consequences. Claims might be made by patients, healthcare providers or
pharmaceutical companies or others. For example, we may be sued if any product we develop allegedly causes injury or is
found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims
may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product,
negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If
we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to
limit commercialization of our product candidates, if approved. Even successful defense would require significant financial
and management resources. Regardless of the merits or eventual outcome, liability claims may result in:
1.
2.
decreased demand for our products due to negative public perception;
injury to our reputation;
49
Table of Contents
3. withdrawal of clinical trial participants or difficulties in recruiting new trial participants;
4.
5.
6.
7.
8.
9.
initiation of investigations by regulators;
costs to defend or settle the related litigation;
a diversion of management’s time and resources;
substantial monetary awards to trial participants or patients;
product recalls, withdrawals or labeling, marketing or promotional restrictions;
loss of revenues from product sales; and
10. the inability to commercialize any of our product candidates, if approved.
We may not have or be able to obtain or maintain sufficient and affordable insurance coverage to cover product
liability claims, and without sufficient coverage any claim brought against us could have a materially adverse effect on our
business, financial condition or results of operations. We run clinical trials through investigators that could be negligent
through no fault of our own and which could affect patients, cause potential liability claims against us and result in delayed
or stopped clinical trials. We are required by contractual obligations to indemnify collaborators, partners, third-party
contractors, clinical investigators and institutions. These indemnifications could result in a material impact due to product
liability claims against us and/or these groups. We currently carry at least $10.0 million in product liability insurance, which
we believe is appropriate for our current clinical trials. Although we maintain such insurance, any claim that may be brought
against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our
insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and
we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by
a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we
may not have, or be able to obtain, sufficient capital to pay such amounts. We may also need to expand our insurance
coverage as our business grows or if any of our product candidates is commercialized. We may not be able to maintain or
increase insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.
Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements and insider trading.
We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include
intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with
manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and
regulations, or to report financial information or data accurately or disclose unauthorized activities to us. In particular, sales,
marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to
prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or
prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and
other business arrangements. Employee misconduct could also involve the improper use of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a
Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or
losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in
compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of
significant civil, criminal, and administrative sanctions, and our reputation.
50
Table of Contents
In addition, during the course of our operations our directors, executives, and employees may have access to
material, nonpublic information regarding our business, our results of operations, or potential transactions we are
considering. We may not be able to prevent a director, executive, or employee from trading in our common stock on the basis
of, or while having access to, material, nonpublic information. If a director, executive, or employee was to be investigated or
an action was to be brought against a director, executive, or employee for insider trading, it could have a negative impact on
our reputation and our stock price. Such a claim, with or without merit, could also result in substantial expenditures of time
and money, and divert attention of our management team from other tasks important to the success of our business.
We may be vulnerable to disruption, damage and financial obligation as a result of system failures.
Despite the implementation of security measures, any of the internal computer systems belonging to us, our
collaborators or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access,
natural disasters, terrorism, war and telecommunication and electrical failure. Any system failure, accident or security breach
that causes interruptions in our own, in collaborators’ or in third-party service vendors’ operations could result in a material
disruption of our drug discovery and development programs. For example, the loss of clinical trial data from completed or
future clinical trials could result in delays in our or our partners’ regulatory approval efforts and significantly increase our
costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss or
damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur
liability as a result, our drug discovery programs and competitive position may be adversely affected and the further
development of our product candidates may be delayed. Furthermore, we may incur additional costs to remedy the damages
caused by these disruptions or security breaches.
Our business involves the controlled use of hazardous materials and as such we are subject to environmental and
occupational safety laws. Continued compliance with these laws may incur substantial costs and failure to maintain
compliance could result in liability for damages that may exceed our resources.
Our research, manufacturing and development processes, and those of our third-party contractors and partners,
involve the controlled use of hazardous materials. We and our manufacturers are subject to federal, state and local laws and
regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products. Our
operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our
operations also produce hazardous waste products. The risk of accidental contamination or injury from these materials cannot
be completely eliminated. In the event of such an accident, we could be held liable for any damages that result, and any such
liability could exceed our resources. We are not insured against this type of liability. We may be required to incur significant
costs to comply with environmental laws and regulations in the future, and our operations, business or assets may be
materially adversely affected by current or future environmental laws or regulations or any liability thereunder.
Risks Related to Ownership of Our Common Stock
The market price of our common stock is likely to be highly volatile, and you could lose all or part of your investment.
Prior to our initial public offering (IPO), there was no public market for our common stock. The trading price of our
common stock is likely to be volatile. Since our IPO, the trading price of our common stock has ranged from a low of
approximately $5.75 to a high of approximately $48.38. Our stock price could be subject to wide fluctuations in response to a
variety of factors, including the following:
1.
2.
3.
adverse results or delays in clinical trials by us or our partners;
inability to obtain additional funding;
any delay in submitting a BLA for any of our product candidates or by our partner’s candidates and any
adverse development or perceived adverse development with respect to the FDA’s review of that BLA;
51
Table of Contents
4.
5.
6.
7.
8.
9.
delays or cancellations of clinical programs by any of our partners, particularly those in later stages of
development;
failure to successfully develop and commercialize our product candidates;
changes in laws or regulations applicable to our products;
inability to obtain adequate product supply for our product candidates, or the inability to do so at acceptable
prices;
adverse regulatory decisions;
changes in the structure of healthcare payment systems;
10. introduction of new products or technologies by our competitors;
11. failure to meet or exceed product development or financial projections we provide to the public;
12. the perception of the pharmaceutical and biotechnology industry by the public, legislatures, regulators and the
investment community;
13. announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us
or our competitors;
14. disputes or other developments relating to proprietary rights, including patents, litigation matters and our
ability to obtain patent protection for our technologies;
15. additions or departures of key scientific or management personnel;
16. significant lawsuits, including patent or stockholder litigation;
17. changes in the market valuations of similar companies;
18. sales of our common stock by us or our stockholders in the future; and
19. trading volume of our common stock.
In addition, the stock market in general, and the Nasdaq Global Market and biotechnology companies in particular,
have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating
performance of these companies. Broad market and industry factors may negatively affect the market price of our common
stock, regardless of our actual operating performance.
In the past, securities class action litigation has often been brought against a company following a decline in the
market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced
significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion
of management’s attention and resources, which could harm our business.
52
Table of Contents
Our principal stockholders, directors and management own a significant percentage of our stock and will be able to exert
significant control over matters subject to stockholder approval.
Based on information available to us as of December 31, 2019 our executive officers, directors, 5% stockholders
and their affiliates beneficially owned, as a group, approximately 70.15% of our voting stock. Further John S. Stafford III, a
former director of our company, beneficially owns approximately 11.36% of our voting stock and his family members
beneficially own approximately an additional 3.11% of our voting stock.
Therefore, our officers, directors and 5% stockholders and their affiliates, including Mr. Stafford, will have the
ability to influence us through this ownership position and so long as they continue to beneficially own a significant amount
of our outstanding voting stock. These stockholders may be able to determine all matters requiring stockholder approval and
this concentration of ownership may deprive other stockholders from realizing the true value of our common stock. For
example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational
documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage
unsolicited acquisition proposals, offers for our common stock or other transactions or arrangements that you may believe are
in your best interest as one of our stockholders.
Raising additional funds through debt or equity financing may be dilutive or restrict our operations and raising funds
through licensing may require us to relinquish rights to our technology or product candidates.
To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of
those securities could result in substantial dilution for our current stockholders and the terms may include liquidation or other
preferences that adversely affect the rights of our current stockholders. Existing stockholders may not agree with our
financing plans or the terms of such financings. Moreover, the incurrence of debt financing could result in a substantial
portion of our operating cash flow being dedicated to the payment of principal and interest on such indebtedness and could
impose restrictions on our operations. Debt financing and preferred equity financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. In addition, if we raise additional funds through product development
partnerships and licensing arrangements, it may be necessary to relinquish potentially valuable rights to our products or
proprietary technologies or grant licenses on terms that are not favorable to us. If we are unable to obtain additional funding
on required timelines, we may be required to (1) seek collaborators for one or more of our product candidates at an earlier
stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; (2) relinquish
or license on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or
commercialize ourselves; or (3) significantly curtail one or more of our research or development programs or cease
operations altogether. Additional funding may not be available to us on acceptable terms, or at all.
The clinical development stage of our operations may make it difficult for you to evaluate the success of our business to
date and to assess our future viability.
Our operations to date have been limited to organizing and staffing our company, business planning, raising capital,
developing our proprietary XmAb technology platform, identifying potential product candidates, and conducting preclinical
studies and clinical trials. We have conducted, or are currently conducting, early phase clinical trials for several product
candidates, but have not completed any late stage clinical trials for these or any other product candidate. We have not yet
demonstrated our ability to successfully complete any pivotal clinical trials, obtain regulatory approvals, manufacture a
commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities
necessary for successful product commercialization. Consequently, any predictions you make about our future success or
viability may not be as accurate as they could be if we were further advanced in development of our product candidates.
In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and
unknown factors. We will need to transition at some point from a company with a research and development focus to a
company capable of supporting commercial activities. We may not be successful in such a transition.
53
Table of Contents
We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter
and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the
results of any quarterly or annual periods as indications of future operating performance.
If our internal control over financial reporting is not effective, we may not be able to accurately report our financial
results or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported
financial information and may lead to a decline in our stock price.
Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely
manner. If we fail to adequately staff our accounting and finance function to address the additional demands that will be
placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act of 2002, or fail to maintain
adequate internal control over financial reporting, it could prevent our management from concluding our internal control over
financial reporting is effective and impair our ability to prevent material misstatements in our financial statements, which
could cause our business to suffer.
As a large accelerated filer, we are subject to additional internal control requirements of the Sarbanes-Oxley Act of
2002.
Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could
cause our stock price to fall.
If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the
public market, the trading price of our common stock could decline. In addition, a substantial number of shares of common
stock are subject to outstanding options that are or will become eligible for sale in the public market to the extent permitted
by the provisions of various vesting schedules. If these additional shares of common stock are sold, or if it is perceived that
they will be sold, in the public market, the trading price of our common stock could decline.
Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity
incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our
stock price to fall.
We expect that significant additional capital will be needed in the future to continue our planned operations. To the
extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may
sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we
determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one
transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our
existing stockholders, and new investors could gain rights superior to our existing stockholders.
Pursuant to our 2013 equity incentive plan (2013 plan), subject to board approval, our management is authorized to
grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares
available for future grant under the 2013 plan will automatically increase each year until 2023 by 4% of all shares of our
capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our Board of Directors to take
action to reduce the size of the increase in any given year. As of December 31, 2019, we had options to purchase 7,174,319
shares outstanding under our equity compensation plans. In addition, we are also authorized to grant equity awards, including
stock options, to our employees, directors and consultants, covering up to 11,277,816 shares of our common stock, pursuant
to our equity compensation plans. We plan to register the number of shares available for issuance or subject to outstanding
awards under our equity compensation plans. If our Board of Directors elects to increase the number of shares available for
future grant by the maximum amount each year, our stockholders may experience additional dilution, which could cause our
stock price to fall.
54
Table of Contents
Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect
on our business, cash flow, financial condition or results of operations.
New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which
could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules,
regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the TCJA enacted
many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities
with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation.
In addition, it is uncertain if and to what extent various states will conform to the TCJA or any newly enacted federal tax
legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of
foreign earnings, and the deductibility of expenses under the TCJA or future reform legislation could have a material impact
on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax
expense.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
Our net operating loss (NOL) carryforwards generated in tax years ending on or prior to December 31, 2017, are only
permitted to be carried forward for 20 years under applicable U.S. tax law. Under the TCJA, our federal NOLs generated in
tax years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs
generated in tax years beginning after December 31, 2017, is limited. It is uncertain if and to what extent various states will
conform to the TCJA. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and
corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a
greater than 50% change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-
change NOL carryforwards and other pre-change U.S. tax attributes (such as research tax credits) to offset its post-change
income or taxes may be limited. Upon analysis, we believe that we triggered an “ownership change” as a result of the sale of
stock in connection with our IPO in December 2013 and our net operating loss and tax credit carryforwards have been
limited as a result. It is also possible that we have in the past undergone, and in the future may undergo, additional ownership
changes besides our IPO that could result in additional limitations on our net operating loss and tax credit carryforwards.
As a result, our pre-2018 NOL carryforwards may expire prior to being used, and our NOL carryforwards generated in
2018 and thereafter will be subject to a percentage limitation. Similar provisions of state tax law may also apply to limit our
use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is
suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, if we earn net
taxable income, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could
potentially result in increased future tax liability to us and adversely affect our future cash flows.
We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain
future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any
cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their
stock.
Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law,
could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would
benefit our stockholders or remove our current management.
Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage
an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our
stockholders to replace or remove our current management. These provisions include:
55
Table of Contents
● authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of
which may be issued without stockholder approval;
● prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a
meeting of our stockholders;
● eliminating the ability of stockholders to call a special meeting of stockholders; and
● establishing advance notice requirements for nominations for election to the board of directors or for proposing
matters that can be acted upon at stockholder meetings.
These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
management by making it more difficult for stockholders to replace members of our Board of Directors, which is responsible
for appointing the members of our management. In addition, we are subject to Section 203 of the Delaware General
Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business
combinations with an interested stockholder for a period of three years following the date on which the stockholder became
an interested stockholder, unless such transactions are approved by our Board of Directors. This provision could have the
effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. Further,
other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us. Any
provision of our certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring change in
control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and
could also affect the price that some investors are willing to pay for our common stock.
Requirements associated with being a public reporting company will continue to increase our costs significantly, as well
as divert significant company resources and management attention.
We have been subject to the reporting requirements of the Exchange Act and the other rules and regulations of the
Securities and Exchange Commission (SEC) since December 2013. Effective for the year-ended December 31, 2016, we
became a large accelerated filer and are subject to additional internal control and SEC reporting obligations. Compliance
with the various reporting and other requirements applicable to public reporting companies requires considerable time,
attention of management, and financial resources.
Further, the listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance
requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and
voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel need to devote a
substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements,
rules and regulations increase our legal and financial compliance costs and also make some activities more time-consuming
and costly. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure
associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to
serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance,
including directors’ and officers’ insurance, on acceptable terms.
In addition, being a public company could make it more difficult or more costly for us to obtain certain types of
insurance, including directors’ and officers’ liability insurance, and we may be forced to accept reduced policy limits and
coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also
make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or
as executive officers.
Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations
as a public company on a timely basis, or at all.
56
Table of Contents
Item 1B. Unresolved Staff Comments.
None.
Item 2. Properties.
Our principal laboratory and administrative facilities are located in Monrovia, California, which is located in the
greater Los Angeles region. We currently lease 48,000 square feet of laboratory and office space in Monrovia, California.
The original lease was for 24,000 square feet under a lease that expires June 2020. In July 2017, we entered into an amended
lease for an additional 24,000 square feet of space in the same building. The amended lease includes a 64-month term for the
additional 24,000 square feet with an option to renew for an additional five years at then market rates. The lease terms for the
original space were not amended. We are currently negotiating a new lease for the original 24,000 square feet space of our
Monrovia office space. In June 2017, we entered into a lease for 23,500 of office space in San Diego. The lease term has a
61-month term beginning from August 2017 and includes an option to renew for an additional five years. We believe that our
existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available to
meet future needs on commercially reasonable terms.
Item 3. Legal Proceedings.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
PART II
Securities
Market Information
Our common stock began trading on The Nasdaq Global Market on December 3, 2013 under the symbol “XNCR.”
Prior to such time, there was no public market for our common stock. On February 14, 2020, the closing price for our
common stock as reported on the Nasdaq Global Market was $36.49.
Holders of Record
As of February 14, 2020, we had 56,943,858 shares of common stock outstanding held by approximately 193
stockholders of record. The actual number of stockholders is greater than this number of record holders, and includes
stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This
number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
Dividend Policy
We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available
funds and any future earnings to support our operations and finance the growth and development of our business. We do not
intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our
dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our
results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors
our board of directors may deem relevant.
57
Table of Contents
Securities Authorized for Issuance Under Equity Compensation Plans
Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this
Annual Report.
Performance Graph
The following graph shows a comparison from December 31, 2014 through December 31, 2019 of the cumulative
total return for our common stock, the Nasdaq Biotechnology Index (NBI) and the Nasdaq Composite Index (CCMP). The
graph assumes an initial investment of $100 on December 31, 2013 and assumes reinvestment of the full amount of all
dividends, if any. The comparisons in the graph are not intended to forecast or be indicative of possible future performance of
our common stock.
The performance graph shall not be deemed to be incorporated by reference by means of any general statement incorporating by
reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Exchange Act, except to the extent
that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.
Recent Sales of Unregistered Securities
There were no sales of unregistered securities during the year ended December 31, 2019.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
58
Table of Contents
Item 6. Selected Financial Data.
The selected financial data set forth below as of December 31, 2019, and 2018, and for the years ended December 31, 2019,
2018, and 2017, are derived from our audited financial statements included elsewhere in this Annual Report. This information should be
read in conjunction with those financial statements and notes thereto and with “Management’s Discussion and Analysis of Financial
Condition and Results of Operations.” The selected financial data set forth below as of December 31, 2016 and 2015 are derived from our
audited financial statements that are contained in reports previously filed with the SEC, not included herein. Periods prior to 2018 have
been revised to reflect the adoption of Accounting Standards Codification Topic 606 (ASC 606) related to changes in standards for revenue
recognition. (Amounts are in thousands, except share and per share amounts).
Statement of Operations:
Revenues
Operating expenses:
Research and development
General and administrative
Total operating expenses
Income (loss) from operations
Other income (expenses)
Interest income, net
Other income (expense)
Total other income, net
Net income (loss) before tax
Income tax expense (benefit)
Net income (loss) attributable to common
stockholders
Other comprehensive income (loss)
Net unrealized gain (loss) on
marketable securities, net of tax
Comprehensive income (loss)
Net income (loss) per share attributed to
common stockholders (1):
Basic
Diluted
Weighted average shares of common
stock used in computed net income (loss)
attributable to common stockholders:
Basic
Diluted
2019
2018
Year Ended
December 31,
2017
2016
2015
$
156,700
$
40,603
$
46,150
$
109,020 $
26,602
118,590
24,286
142,876
13,824
13,619
(256)
13,363
27,187
312
97,501
22,472
119,973
(79,370)
9,086
(125)
8,961
(70,409)
—
71,772
17,501
89,273
(43,123)
4,181
(7)
4,174
(38,949)
(463)
51,872
13,108
64,980
44,040
2,070
6
2,076
46,116
991
34,140
11,960
46,100
(19,498)
1,827
(1,081)
746
(18,752)
—
$
26,875
$
(70,409) $
(38,486) $
45,125 $
(18,752)
2,132
29,007
$
$
$
0.48
0.46
$
$
$
837
(69,572) $
(367)
(38,853) $
(925)
44,200 $
(516)
(19,268)
(1.31) $
(1.31) $
(0.82) $
(0.82) $
1.09 $
1.07 $
(0.48)
(0.48)
56,531,439
58,467,880
53,942,116
53,942,116
46,817,756
46,817,756
41,267,329
42,388,867
39,015,131
39,015,131
(1) See Note 1 to our Annual Financial Statements appearing elsewhere in this document for a description of the method used to
calculate basic and diluted income (loss) per common share.
59
Table of Contents
2019
2018
As of December 31,
(in thousands)
2017
2016
2015
Balance Sheet Data:
Cash, cash equivalents and marketable
securities
Working capital
Patents, licenses, and other intangible assets, net
Total assets
Deferred revenue
Total stockholders’ equity
$ 601,308
491,847
14,421
670,250
47,131
$ 593,201
$ 530,469
261,874
11,969
576,732
40,079
$ 521,681
$ 363,328 $ 403,476
50,720
10,362
429,263
80,168
$ 316,464 $ 337,933
158,229
11,148
390,202
60,118
$ 193,321
54,883
9,971
208,210
32,650
$ 164,911
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis together with “Item 6. Selected Financial Data” and our financial
statements and related notes included elsewhere in this Annual Report. The following discussion contains forward-looking statements that
involve risks and uncertainties. Our actual results could differ materially from those expressed or implied in any forward-looking
statements as a result of various factors, including those set forth under the caption “Item 1A. Risk Factors.”
Overview
We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal
antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. We are
developing a suite of clinical-stage drug candidates, ourselves and with our partners, from our proprietary XmAb®
technology platforms that are designed to treat cancer and autoimmune diseases. In contrast to conventional approaches to
antibody design, which focus on the segment of antibodies that interact with target antigens, our protein engineering efforts
and the XmAb technologies are focused on the parts of the antibody that interacts with multiple segments of the immune
system and controls antibody structure. This segment, referred to as the Fc domain, is constant and interchangeable among
antibodies. Our engineered Fc domains, the XmAb technology, can be readily substituted for natural Fc domains.
We believe our XmAb technologies enhance antibody performance by, for example, increasing immune inhibitory
activity, improving cytotoxicity, extending circulating half-life, or stabilizing novel antibody and other protein structures,
while maintaining 99.5% identity in structure and sequence to natural antibodies. By designing antibodies and other protein
molecules with improved function, we believe that our XmAb-engineered proteins offer innovative approaches to treating
disease and potential clinical advantages over other treatments.
Our protein engineering capabilities allow us to continually explore new functionality in the Fc region, which
provides us with opportunities to:
● Identify new technology platforms;
● Identify new drug candidates for internal development; and
● Provide collaboration and licensing opportunities with partners for access to our technologies, to our drug
candidates, or a combination of both.
The most recent expansion of our platform is the XmAb bispecific Fc domains, which enable the rapid design and
simplified development of antibodies and other protein structures that can bind two or more different targets simultaneously.
60
Table of Contents
XmAb® Technologies
A distinguishing feature of our XmAb technologies is our modular approach to protein engineering. This provides
us with flexibility to seek out new applications of the bispecific Fc domain, allows us to design drug candidates with distinct
and novel mechanisms-of-action, and also allows for different variable target combinations. This approach is illustrated
through our expansion of our bispecific Fc platform and the novel candidates that we have designed.
CD3 candidates: the initial bispecific antibody candidates we designed were created with our engineered
heterodimer Fc domain, or bispecific Fc domain, and are dual-antigen targeting molecules, containing an anti-tumor
associated antigen binding domain and a second binding domain targeted to CD3, an activating receptor on T-cells. The goal
of the “CD3 bispecific” is to recruit or activate T cells against tumor cells expressing the antigen target. We are currently
conducting Phase 1 studies for three CD3 bispecific antibody candidates: XmAb14045, plamotamab (XmAb13676), and
XmAb18087.
TME activator candidates: we expanded the functionality of our bispecific Fc platform with a suite of tumor
microenvironment (TME) activators that have been designed to promote tumor-selective T-cell activation by targeting
multiple checkpoints or co-stimulating receptors. These TME activator candidates use our bispecific Fc domain and
incorporate our Xtend technology for longer half-life. We are currently conducting Phase 1 studies for three TME activator
candidates: XmAb20717, XmAb22841, and XmAb23104.
Cytokine candidates: the most recent expansion of our bispecific Fc platform is our novel cytokine candidates.
These cytokines are built on our bispecific Fc domain and have potency tuned to improve therapeutic index. These
candidates also incorporate our Xtend technology for longer half-life. Our first cytokine candidate is XmAb24306, an IL-
15/IL-15Ra cytokine complex built with our bispecific Fc domain, which we believe is a promising candidate for oncology
combination therapies. In 2020, our partner Genentech plans to initiate a Phase 1 clinical study of XmAb24306. Our second
cytokine candidate is XmAb27564, an IL-2 Fc fusion protein with our bispecific Fc domain, which is currently in
investigational new drug (IND)-enabling studies.
We continue to invest in our protein engineering efforts to identify additional novel technologies and drug
candidates.
Other XmAb Fc Technologies
Our business, research, and clinical efforts are in developing and advancing our bispecific Fc technology and
pipeline of drug candidates in oncology and autoimmune diseases. We have also designed additional Fc technologies and
XmAb drug candidates that we have partnered with other companies, and we will continue to seek additional partnering and
licensing opportunities for these technologies and candidates. Our Fc domains and technologies include:
1.
Immune Inhibitor Fc Domain – selective immune inhibition and rapid target clearance, targeting the
receptor FcγRIIb;
2. Cytotoxic Fc Domain – increased cytotoxicity, targeting the receptors FcγRIIIa on natural killer (NK) cells
and FcγRIIa on other immune system cells; and
3. Xtend™ Fc Domain – extended antibody half-life, targeting the receptor FcRn on endothelial cells.
Wholly Owned and Co-Developed Drug Candidates
There are currently ten drug candidates that have been engineered with our bispecific Fc domain in clinical
development: five candidates are wholly owned and are being evaluated by us in Phase 1 studies, two candidates are being
co-developed with our partners, and three candidates are being advanced into clinical studies by our partners. Eight of the
candidates are currently advancing in Phase 1 studies, and two have IND applications that have been allowed by the FDA
and which are expected to initiate clinical studies in 2020.
61
Table of Contents
Wholly owned and co-developed drug candidates in clinical development include:
XmAb14045 is a bispecific antibody that targets CD123, an antigen on acute myeloid leukemia (AML) cells and
leukemic stem cells, and CD3, an activating receptor on T cells. It is being developed in collaboration with our partner
Novartis Institutes for BioMedical Research, Inc. (Novartis) and is being evaluated in a Phase 1 study. In September 2016,
we dosed the first patient in an open-label, multiple-dose, dose escalation study to assess the safety, tolerability, and
preliminary anti-tumor activity of XmAb14045 in patients with relapsed or refractory AML and other CD123-expressing
hematologic malignancies. We presented initial data from the study in December 2018 at the American Society of
Hematology (ASH) Annual Meeting. The data presented indicated multiple complete remissions had been achieved with
weekly dosing of XmAb14045 in this heavily pretreated patient population.
In February 2019, we received notice from the FDA placing the XmAb14045 study on partial clinical hold due to
safety issues of cytokine release syndrome and pulmonary toxicities. In April 2019, the FDA lifted the partial clinical hold
following discussion and agreement on amendments to the study protocol, including guidance on the monitoring and clinical
management of cytokine release syndrome. In July 2019, we resumed enrolling patients in the study based on the amended
protocol. In 2020, pending agreement with our partner, Novartis, we plan to initiate additional clinical studies evaluating
XmAb14045.
Plamotamab (XmAb13676) is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3 for the
treatment of B-cell malignancies. In February 2017, we dosed the first patient in an open-label, Phase 1, multiple-dose, dose
escalation study to assess the safety, tolerability, and preliminary anti-tumor activity of plamotamab in patients with B-cell
malignancies. This program was also partnered with Novartis as part of our Novartis collaboration. In December 2018, as
part of a strategic pipeline reprioritization, Novartis notified us of its decision to return its rights to develop and
commercialize plamotamab, which became effective June 21, 2019.
At the ASH Annual Meeting in December 2019, we presented preliminary safety and anti-tumor activity of
plamotamab in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
As of November 8, 2019, the data cut-off for analysis, 53 patients were treated with plamotamab monotherapy with 45 NHL
patients and 8 CLL patients. Plamotamab was generally well tolerated with safety events mild or moderate in severity.
Cytokine release syndrome (CRS) was reported in 53% (28 of 53) patients with most CRS occurring with the first dosing of
the drug. Plamotamab demonstrated clinical activity in DLBCL at doses of 80 mcg/kg and higher (the top dose through the
cut-off date was 170 mcg/kg) in a dose-dependent manner. In DLBCL, the objective response rate (ORR) was 7/18 (38.0%),
and the complete response rate (CRR) was 5/18 (27.8%).
We continue to enroll patients in the ongoing dose-escalation study, and we are planning to initiate additional studies
for plamotamab.
XmAb18087 is a bispecific antibody that targets somatostatin receptor 2, or SSTR2, a target on neuroendocrine
tumors (NET) and gastrointestinal stromal tumors (GIST), and CD3. In February 2018, we dosed the first patient in an open-
label, Phase 1, dose-escalation study to assess the safety, tolerability, and preliminary anti-tumor activity of XmAb18087 in
patients with NET or GIST. XmAb18087 is our first CD3 bispecific antibody to be evaluated in solid tumors. We expect to
provide initial data from this study in 2020.
XmAb20717 is a bispecific antibody that targets PD-1 and CTLA-4, two immune checkpoint receptors, to
selectively activate the tumor microenvironment, and is being developed in broad oncology indications including patients
with solid tumors. In July 2018, we dosed the first patient in an open-label Phase 1 dose-escalation study to assess the safety,
tolerability, and preliminary anti-tumor activity of XmAb20717 in patients with selected solid tumors. We expect to provide
initial data from this study in 2020.
XmAb22841 is a bispecific antibody that targets CTLA-4 and LAG-3, also an immune checkpoint receptor, and is
being developed in multiple oncology indications. We are advancing XmAb22841 in combination with an anti-PD-1 drug to
create a triple checkpoint blockade. In May 2019, we dosed the first patient in in an open-label, Phase 1, dose-escalation
study to assess the safety, tolerability, and preliminary anti-tumor activity of XmAb22841 in patients with selected solid
tumors.
62
Table of Contents
XmAb23104 is a bispecific antibody that targets PD-1 and ICOS, an immune co-stimulatory receptor, and is being
developed in multiple oncology indications. In May 2019, we dosed the first patient in a an open-label, Phase 1, dose-
escalation study to assess the safety, tolerability, and preliminary anti-tumor activity of XmAb23104 in patients with selected
solid tumors.
XmAb24306, our initial cytokine candidate, is an IL15/IL15-receptor alpha complex fused to our bispecific Fc
domain (IL15/IL15Ra-Fc) and incorporates our Xtend technology for extended half-life. We believe a broad combination
development strategy will be critical to realize the potential of IL-15 cytokines like XmAb24306. In February 2019, we
entered into a research and license agreement with Genentech to develop and commercialize novel IL-15 cytokine
therapeutics, whereby the companies will co-develop XmAb24306 and other potential IL-15 programs. In 2020, Genentech
plans to dose the first patient in an open-label, Phase 1 dose-escalation study of XmAb24306.
Obexelimab (XmAb5871) uses our XmAb Immune Inhibitor Fc Domain and targets CD19 with its variable domain,
which is designed to inhibit the function of B cells, an important component of the immune system. We believe that
obexelimab has the potential to address a key unmet need in autoimmune diseases due to its combination of potent reversible
B-cell inhibition without B-cell depletion, enabling the immune system to resume natural function once treatment is no
longer needed. We have completed Phase 2 clinical trials for obexelimab in three autoimmune disease areas: Systemic Lupus
Erythematosus (SLE), IgG4-Related Disease (IgG4-RD), and Rheumatoid Arthritis (RA). We have also completed a Phase 1
bioequivalence trial using a subcutaneous (SC) formulation, and we expect that further clinical studies of obexelimab could
be conducted with the SC formulation. We believe that the clinical trials that we have conducted with obexelimab show the
potential of this molecule in treating B-cell mediated autoimmune indications. We are looking to continue developing
obexelimab in additional late-stage clinical trials with a partner that has the resources and infrastructure to maximize the
potential of this compound.
Collaborations
An important part of our business strategy is to leverage the value of our Fc technologies and drug candidates with
partnerships and collaborations. Our goal in such partnerships is to a retain a major economic interest in drug candidates that
we develop or, are developed with our XmAb technologies, in the form of retention of U.S. commercial rights, profit-sharing
interest, co-development opportunities, upfront payments, milestones, and royalties on approved drug candidates. We seek to
partner with companies that can provide infrastructure for late stage development, have a track record of developing and
commercializing oncology drug candidates, or have a pipeline of development and commercial compounds for potential
combination with our bispecific compounds. The plug-and-play nature of our technologies allows us to license access to our
bispecific Fc platform to partners with limited effort or resources on our part.
We primarily enter into three types of collaborations to broaden the use of our technology or to advance the
development of our drug candidates. We have co-development collaborations with Genentech for XmAb24306 and with
Novartis for XmAb14045, in which we share development activities and costs in order to bring significant resources to
develop the program. We have product candidate license agreements with MorphoSys for tafasitamab and with Aimmune
Therapeutics for XmAb7195, in which they conduct all future development and commercialization and we receive license
fees, milestone payments and royalties on sales. We also have several XmAb technology license agreements with a variety of
partners that monetize limited access to one or more of our Fc technologies in return for license fees, milestones and
royalties.
63
Table of Contents
A summary of our key collaboration and partnerships include:
Aimmune
In February 2020, we entered into a License, Development and Commercialization Agreement (the Aimmune
Agreement) with Aimmune Therapeutics, Inc. (Aimmune), in which we granted them an exclusive worldwide license to
XmAb7195, which was renamed AIMab7195. Under the Aimmune Agreement, Aimmune will be responsible for all further
development and commercialization activities for XmAb7195. We will receive an upfront payment of $10.0 million which
includes $5.0 million in cash proceeds and shares of Aimmune common stock with an aggregate value of $5.0 million, and
we are eligible to receive up to $385.0 million in milestones, which include $22.0 million in development milestones, $53.0
million in regulatory milestones and $310.0 million in sales milestones, and tiered royalties on net sales of approved products
from high-single to mid-teen percent range.
Gilead
In January 2020, we entered into a Technology License Agreement (the Gilead Agreement) with Gilead Sciences,
Inc. (Gilead), in which we provided an exclusive license to our Cytotoxic Fc and Xtend Fc technologies for an initial
identified antibody and options for up to three additional compounds directed to the same molecular target. Xencor retains
the right to grant licenses for other antibodies directed to the target. These additional antibodies selected by Gilead are
subject to our approval. Gilead is responsible for all development and commercialization activities for all target candidates.
We received an upfront payment of $6.0 million and are eligible to receive up to $67.0 million in milestones, which include
$10.0 million in development milestones, $27.0 million in regulatory milestones and $30.0 million in sales milestones for
each antibody selected. In addition, we are eligible to receive royalties in the low-single digit percentage range on net sales of
approved products.
Gilead has advanced the initial compound, GS-9722 into Phase 1 clinical studies.
Vir Biotechnology
In August 2019, we entered into a Patent License Agreement with Vir Biotechnology (VirBio), in which we
provided a non-exclusive license to our Xtend technology for up to two targets. We received an upfront payment, and we are
eligible to receive total milestones of $155.25 million, including $5.25 million of development milestones, $30.0 million of
regulatory milestones and $120.0 million of sales milestones and royalties on the net sales of approved products in the low
single digits.
VirBio has advanced a program using Xtend technology into a Phase 1 clinical study.
Astellas
In March 2019, we entered into a Research and License Agreement (Astellas Agreement) with Astellas Pharma Inc.
(Astellas) pursuant to which the Company and Astellas will conduct a discovery program to characterize compounds and
products for development and commercialization. Under the Astellas Agreement, Astellas was granted a worldwide
exclusive license, with the right to sublicense products in the field created by the research activities.
Pursuant to the Astellas Agreement, we are applying our bispecific Fc technology to an antigen pair provided by
Astellas to generate bispecific antibody candidates and are conducting limited testing and characterization of the bispecific
antibody candidates and will return the candidates to Astellas for development and commercialization. The activities are
being conducted under a research plan agreed to by both parties. Astellas will assume full responsibility for development and
commercialization of the antibody candidate. Pursuant to the Astellas Agreement, we received an upfront payment of $15.0
million, and we are eligible to receive up to $240.0 million in milestones which include $32.5 million in development
milestones, $57.5 million in regulatory milestones and $150.0 million in sales milestones and royalties on net sales that range
from the high-single to low-double digit percentages.
64
Table of Contents
During 2019, we completed delivery of bispecific drug candidates to Astellas and are conducting testing and
characterization of the candidates.
Genentech
In February 2019, we entered into a research and license agreement with Genentech to develop and commercialize
novel IL-15 cytokine therapeutics that use our bispecific Fc technology, including XmAb24306, a Collaboration Product. We
are jointly collaborating on the worldwide development of XmAb24306 and potentially other IL-15 cytokine therapeutics,
each a Collaboration Product, with Genentech maintaining worldwide commercialization rights, subject to us having a co-
promotion option in the U.S. We retain the right to perform clinical studies of Collaboration Products in combination with
other therapeutic agents at our sole expense, subject to certain restrictions. Genentech received a worldwide exclusive license
to XmAb24306 and other Collaboration Products.
The key aspects of the agreement include: receipt of an upfront payment of $120.0 million and eligibility to receive
up to $160.0 million in clinical milestone payments for XmAb24306 and up to $180.0 million in clinical milestones for each
new Collaboration Product; eligibility to receive a 45% share of net profits from sales of XmAb24306 and other
Collaboration Products, while also sharing in the net losses at the same percentage rate; sharing in 45% of development and
commercialization costs of XmAb24306, while Genentech will pay for commercial launch costs; and, conducting a two-year
joint research program to discover additional targeted IL-15 programs, including ones targeted to specific immune cells, and
we are eligible for clinical milestone payments for each new Collaboration Product developed under a research plan.
Genentech plans to dose the first patient in a Phase 1 study with XmAb24306 in 2020.
Novartis
In June 2016, we entered into a Collaboration and License Agreement (the Novartis Agreement) with Novartis to
develop and commercialize bispecific and other Fc engineered antibody drug candidates. We granted Novartis certain
exclusive rights to research, develop and commercialize XmAb14045 and plamotamab, our two lead bispecific clinical
candidates.
In December 2018, Novartis returned all their rights to plamotamab to us. In November 2019, we and Novartis
amended the Novartis Agreement and Novartis paid us $1.4 million in settlement of its remaining projected cost-sharing
obligations due for the plamotamab program.
We and Novartis are co-developing XmAb14045 worldwide and sharing development costs equally. We are eligible
to receive up to $325.0 million in milestone payments in connection with the development of XmAb14045, including $90.0
million in development milestones, $110.0 million in regulatory milestones, and $125.0 million in sales milestones, and low-
double digit royalties on sales of approved products in all territories outside the United States (ex-U.S. rights). We retained
the commercialization rights to all XmAb14045 candidates in the U.S.
We will also apply our bispecific technology to up to four target pair antibodies selected by Novartis, subject to
approval by us. Novartis is responsible for development and commercialization of each global discovery product candidate.
In December 2019, Novartis dosed the first patient in a Phase 1 study of an undisclosed bispecific antibody candidate that
was a target pair antibody, and we received a $10.0 million milestone.
65
Table of Contents
Amgen
In September 2015, we entered into a research and license agreement (the Amgen Agreement) with Amgen Inc.
(Amgen) to develop and commercialize products using our bispecific technology. Under the Amgen Agreement, we licensed
the rights to our internally developed, preclinical CD38 x CD3 bispecific antibody candidate, now AMG 424, to Amgen and
also agreed to apply our bispecific technology to five previously identified Amgen antibodies. We have received $60.5
million in upfront and milestone payments and are eligible to receive up to an additional $600.0 million in milestone
payments and royalties on approved products. Amgen is responsible for all development of the bispecific antibody
candidates under the Amgen Agreement. Current programs in development from the Amgen collaboration include:
● AMG 424, a bispecific antibody that targets CD38 and CD3 and is in clinical development for multiple
myeloma. The program is currently in a Phase 1 clinical study, and we are eligible to receive up to $345.0
million in additional milestones payments and royalties from high-single to low-double digit percentage
range on the sale of approved products from this program, and
● AMG 509, a bispecific antibody that targets STEAP1 and CD3 and is being developed for patients with
prostate cancer. Amgen has received FDA allowance for its IND submission and plans to initiate a Phase 1
study for this candidate in 2020. We received a $5.0 million milestone related to allowance of the IND, and
we are eligible to receive up to $255.0 million in additional milestone payments and tiered royalties in the
mid-to-high-single digit percentage range on the sale of approved products.
Alexion
In 2013 we licensed Alexion Pharmaceuticals, Inc. (Alexion) the right to access our Xtend Fc domain, which
Alexion used to develop Ultomiris, an improved version of Alexion’s commercialized Soliris product. The Xtend technology
has increased the half-life of Ultomiris by over three fold compared to Soliris and extended the dosing schedule to bimonthly
for Ultomiris compared to biweekly for Soliris.
In December 2018, Alexion received U.S. marketing approval for Ultomiris for the treatment of adult patients with
PNH. During 2019, Alexion received marketing approval in Europe and Japan for Ultomiris for the treatment of adult
patients with PNH and also marketing approval in the U.S. for the treatment of adult patients with atypical hemolytic uremic
syndrome (aHUS). During 2019, we received $8.0 million in milestone payments and recorded royalty revenue of $5.0
million from this partnership. We are eligible to receive an additional $30.0 million in sales milestones and a continued low-
single digit percent royalty on the sale of approved products.
MorphoSys
In June 2010, we entered into a collaboration and license agreement (the MorphoSys Agreement) with MorphoSys
AG (MorphoSys) to license the worldwide rights to tafasitamab (formerly MOR208 and XmAb5574). Tafasitamab is an anti-
CD19 antibody drug candidate initially developed by us, and it incorporates our XmAb Cytotoxic Fc domain.
MorphoSys submitted a BLA to the FDA in December 2019 for treating patients with DLBCL.
We are eligible to receive an additional $37.5 million in regulatory milestones related to DLBCL. We are also
eligible to receive up to $98 million in additional milestones for development of tafasitamab in additional oncology
indications and up to $50.0 million in sales milestones across all indications. If licensed products are commercialized, we are
entitled to receive tiered royalties in the high-single digit to low-double digit percent range.
The term of this agreement will continue until all of MorphoSys’ royalty payment obligations have expired unless
terminated earlier.
66
Table of Contents
Human Capital Management
Our ability to develop XmAb technologies, advance our programs into late-stage development, position our
programs for commercialization and identify successful business partnerships is dependent on attracting and retaining
experienced leadership. In 2019, we identified certain gaps in the skillsets and experience provided by our senior
management and appointed executives into the newly created positions of vice president, regulatory affairs and quality
assurance; vice president, business development; and vice president, general counsel and corporate secretary.
Additionally, our former senior vice president and chief medical officer, retired effective at the end of October 2019.
In December 2019, we appointed Allen Yang, M.D., Ph.D., who had been serving as the acting chief medical officer of Jazz
Pharmaceuticals, as our senior vice president and chief medical officer. In this role, Dr. Yang is responsible for leading
development strategy and overseeing clinical operations for our portfolio of bispecific antibody and cytokine candidates.
Financial Operations Overview
Revenues
Our revenues to date have been generated primarily from our collaboration agreements and our technology licensing
agreements. Revenue recognized from our collaboration agreements includes non-refundable upfront payments and
milestone payments while revenue from our technology licensing agreements includes upfront payments, annual
maintenance fees, option payments to obtain commercial licenses and milestone payments. Since our inception through
December 31, 2019, we have generated $422.9 million in revenues under the various product development partnership and
technology license arrangements. Several of our product development partnership and technology license agreements provide
us the opportunity to earn future milestone payments, royalties on product sales and option exercise payments.
Summary of Collaboration and Licensing Revenue by Partner
The following is a comparison of collaboration and licensing revenue for the years ended December 31, 2019, 2018
and 2017 (in millions):
Amgen
Alexion
Astellas
CSL
Genentech
MorphoSys
Novartis
Other
Total
Year Ended
December 31,
2018
2017
2019
$
5.0 $
0.6
$
13.0
14.0
—
113.9
—
10.0
0.8
156.7
$
20.0
—
—
—
—
20.0
—
40.6
$
$
67
10.0
—
—
3.5
—
12.5
20.1
0.1
46.2
Table of Contents
Research and Development Expenses
Research and development expenses consist primarily of salaries, benefits, stock-based compensation and related
personnel costs, supplies, facility costs and preclinical testing costs, clinical trial costs and fees paid to external service
providers. External service providers include contract research organizations (CRO) and contract manufacturing
organizations (CMO) to conduct clinical trials, manufacturing and process development, IND-enabling toxicology testing
and formulation of clinical drug supplies. We expense research and development expenses as incurred. We account for
nonrefundable advance payments for goods and services that will be used in future research and development activities as
expense when the service has been performed or when the goods have been received. We estimate contract manufacturing,
preclinical study and clinical trial expenses based on the services performed pursuant to the contracts with manufacturing,
research institutions and clinical research organizations that manufacture and conduct and manage preclinical studies and
clinical trials on our behalf based on the actual time and expenses incurred by them. We accrue expenses related to clinical
trials based on the level of patient enrollment and activity according to the related agreement. We monitor patient enrollment
levels and related activity to the extent reasonably possible and adjust estimates accordingly. Our estimates of clinical trial
expense have fluctuated on a period-to-period basis due to changes in the stage of the clinical trials and patient enrollment
levels. We expect to experience a continuing pattern of fluctuations in clinical trial expenses as current clinical trials are
completed and as we initiate additional and later stage clinical trials. To date, we have not experienced significant differences
between our periodic estimates of clinical trial expense and the actual costs incurred. We expect changes in future clinical
trial expenses to be driven by changes in service provider costs and changes in clinical stage and patient enrollment. We have
incurred a total of $584.7 million in research and development expenses from inception through December 31, 2019.
We expect that our future research and development expenses may increase overspending levels in recent years if
we are successful in advancing our current clinical-stage drug candidates or any of our preclinical programs into later stages
of clinical development. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory
approval is costly and time-consuming. We or our partners may never succeed in achieving marketing approval for any of
our product candidates. Numerous factors may affect the probability of success for each product candidate, including
preclinical data, clinical data, competition, manufacturing capability, approval by regulatory authorities and commercial
viability.
Our research and development operations are conducted such that design, management and evaluation of results of
all of our research and development is performed internally, while the execution of certain phases of our research and
development programs, such as toxicology studies in accordance with Good Laboratory Practices (GLP), and manufacturing
in accordance with current Good Manufacturing Practices (cGMP), is accomplished using CROs and CMOs. We account for
research and development costs on a program-by-program basis except in the early stages of research and discovery, when
costs are often devoted to identifying preclinical candidates and improving our discovery platform and technologies, which
are not necessarily allocable to a specific development program. We assign costs for such activities to distinct projects for
preclinical pipeline development and new technologies. We allocate research management, overhead, commonly used
laboratory supplies and equipment, and facility costs based on the number of full-time research personnel allocated to each
program.
68
Table of Contents
The following is a comparison of research and development expenses for the years ended December 31, 2019, 2018
and 2017 (in millions):
Product programs:
Obexelimab (XmAb5871) programs
XmAb7195 program
Bispecific programs:
CD3*
Tumor microenvironment (TME) activators
Cytokines*
Subtotal Bispecific programs
Other, research and early stage programs
Total research and development expenses
2019
17.5
0.3
37.2
28.2
22.0
87.4
13.4
118.6
$
$
Year Ended
December 31,
2018
2017
$
$
23.0
0.8
23.1
33.1
7.7
63.9
9.8
97.5
$
$
20.3
3.4
21.3
20.7
—
42.0
6.1
71.8
*Includes net payments to, and reimbursements from our partners pursuant to agreements that include cost-sharing arrangements.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related benefits, including stock-based
compensation related to our executive, finance, business development, and support functions. Other general and
administrative expenses include intellectual property costs, facility costs, and professional fees for auditing, tax and legal
services.
Other Income, Net
For the years ended December 31, 2019, 2018 and 2017, other income, net consists primarily of interest income
from our investments during the years.
Critical Accounting Policies, Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our
financial statements, which have been prepared in accordance with accounting principles generally accepted in the United
States (GAAP). The preparation of our financial statements in conformity with GAAP requires our management to make
estimates and assumptions that affect the amounts and disclosures reported in the financial statements and accompanying
notes. Actual results could differ materially from those estimates. Our management believes judgment is involved in
determining revenue recognition, the fair value-based measurement of stock-based compensation, the fair value estimate of
marketable securities, the capitalization and recoverability of intellectual property costs, valuation of deferred tax assets and
accruals. Our management evaluates estimates and assumptions as facts and circumstances dictate. As future events and their
effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those
differences could be material to the financial statements. If our assumptions change, we may need to revise our estimates, or
take other corrective actions, either of which may also have a material adverse effect on our statements of operations,
liquidity and financial condition.
While our significant accounting policies are described in more detail in Note 1 to our financial statements included
elsewhere in this Annual Report, we believe the following accounting policies to be critical to the judgments and estimates
used in the preparation of our financial statements.
69
Table of Contents
Revenue Recognition
We have, to date, earned revenue from research and development collaborations, which may include research and
development services, licenses of our internally developed technologies, licenses of our internally developed drug
candidates, or combinations of these.
The terms of our license and research and development and collaboration agreements generally include non-
refundable upfront payments, research funding, co-development reimbursements, license fees and, milestone and other
contingent payments to us for the achievement of defined collaboration objectives and certain clinical, regulatory and sales-
based events, as well as royalties on sales of any commercialized products.
The terms of our licensing agreements include non-refundable upfront fees, annual licensing fees, and contractual
payment obligations for the achievement of pre-defined preclinical, clinical, regulatory and sales-based events by our
partners. The licensing agreements also include royalties on sales of any commercialized products by our partners.
Effective January 1, 2018, we adopted ASC 606. Subsequent to the adoption, we recognize revenue through the
five-step process in accordance with ASC 606 Revenue Recognition when control of the promised goods or services is
transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those
goods or services.
We used the full retrospective method and as a result we revised our comparative financial statements for the prior
period as if ASC 606 had been in effect for that period.
The most significant changes to revenue recognition under ASC 606 relate to the timing of revenue recognized for
arrangements that include licensing of our technologies. Under ASC 606 revenue related to licensing of access to our
technologies is recognized at inception of the agreement, generally the effective date of the agreement. For licensing
arrangements in effect at the date ASC 606 was implemented, the effect of ASC 606 was to shift revenue to earlier periods.
The other significant change under ASC 606 relates to the timing of collaboration revenue when we complete our
performance obligations for delivery of a drug candidate to its collaboration partners after applying its technologies. For
certain collaborations, the effect of ASC 606 is to accelerate revenue recognition to earlier periods. Approximately $6.25
million of collaboration revenue recognized in 2017 and 2018 under historical accounting guidance was recognized in 2016
under ASC 606. An additional $20.5 million of collaboration revenue that would be recognized in 2018 was recognized in
2017.
Capitalized Intellectual Property Costs
We capitalize and amortize third-party intellectual property costs such as amounts paid to outside patent counsel for
filing, prosecuting and obtaining patents for our internally developed technologies and product candidates, to the extent such
patents are deemed to have probable future economic benefit. We also capitalize amounts paid to third parties for licenses
that we acquire for intellectual property or for research and development purposes. The net capitalized patents, licenses and
other intangible assets as of December 31, 2019 and 2018 was $14.4 million and $12.0 million, respectively. We believe that
these costs should be capitalized as the intellectual property portfolio is the underlying property right to our technologies and
product candidates and supports the upfront payments, licensing fees, and milestone payments made by our collaboration
partners for licensing our technologies and product candidates.
We begin amortization of capitalized patent costs during the period that we obtain a patent relating to the capitalized
cost over the shorter of the patent life or the estimated economic useful life. Capitalized licensing costs are amortized
beginning in the period that access to the license or technology is available and is amortized over the shorter of the license
term or the estimated economic useful life of the licensed asset. Such amortization is recorded as general and administrative
expenses.
70
Table of Contents
On a regular basis we review the capitalized intellectual property portfolio and determine if there have been changes
in the scientific or patent landscape that leads us to decide to abandon an in-process patent application or abandon a
previously issued patent. While we confer with outside patent counsel, the decision to continue prosecuting certain patent
claims or abandon other claims are made by us based on our judgment and existing knowledge of our technology, current
U.S. and foreign patent authority rulings and expected rulings, and scientific advances and patent filings by competitors
operating in our technology or drug development field. We record an expense for the write-off of capitalized intangible assets
in the period that the decision to abandon a claim or license is made. We also review the carrying value of capitalized
licensing costs on a regular basis to determine if there have been any changes to the useful life or estimated amortization
period over which the costs should be amortized. We recorded a charge for abandoned intangible assets of $0.2 million, $0.2
million and $0.4 million for the years ended December 31, 2019, 2018 and 2017, respectively. Such charges are reflected as
general and administrative expenses.
We determine if there has been an impairment of our intangible assets which include the capitalized patent and
licensing costs whenever events such as recurring operating losses or changes in circumstances indicate that the carrying
amount of the assets may not be recoverable.
Accrued Research and Development Expenses
As part of the process of preparing our financial statements, we are required to estimate our accrued research and
development expenses. This process involves reviewing contracts and purchase orders, reviewing the terms of our license
agreements, communicating with our applicable personnel to identify services that have been performed on our behalf, and
estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced
or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services
performed. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances
known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make
adjustments if necessary. Examples of estimated accrued research and development expenses include fees to:
● CROs and other service providers in connection with clinical studies;
● contract manufacturers in connection with the production of and testing of clinical trial materials; and
● vendors in connection with preclinical development activities.
We base our expenses related to clinical studies on our estimates of the services received and efforts expended
pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical
studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and
may result in uneven payment flows and expense recognition. Payments under some of these contracts depend on factors
such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing these costs, we
estimate the time period over which services will be performed for which we have not been invoiced and the level of effort to
be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate,
we adjust the accrual accordingly. Our understanding of the status and timing of services performed relative to the actual
status and timing of services performed may vary and may result in our reporting changes in estimates in any particular
period.
71
Table of Contents
Income Taxes
Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis
of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the
differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as
income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary,
by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.
Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-
likely-than not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized
is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Our policy is to
record interest and penalties related to uncertain tax positions as a component of income tax expense. We have concluded
that there are no material uncertain tax positions and have not recorded an income tax expense or liability for uncertain tax
positions as of December 31, 2019.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (TCJA) was enacted into law, which beginning in 2018,
made several changes to U.S. corporate income tax provisions. We have identified changes in the TCJA which will have a
material effect on our tax provision and future tax obligations. The TCJA reduced the U.S. corporate rate from a maximum
rate of 35% to 21% effective January 1, 2018. The effect of this change was to reduce the potential future tax benefits from
our deferred tax assets by $19.6 million that we had as of December 31, 2017. The TCJA also changed the potential benefit
of net operating losses incurred after January 1, 2018. The new law limits the amount of net operating losses incurred post
January 1, 2018 that can be used to offset taxable income to 80% of the taxable income generated in any one year, however,
these net operating losses do not expire.
The other material change in our tax provision from the TCJA is elimination of the U.S. corporate alternative
minimum tax (AMT) system and allowance for a tax refund for AMT credit carryovers as of December 31, 2017, which do
not expire. We recorded an income tax receivable related to AMT credit carryovers of $0.8 million and $1.6 million as of
December 31, 2019 and December 31, 2018, respectively.
We recorded net deferred tax assets of $77.4 million as of December 31, 2019, which was fully offset by a valuation
allowance due to uncertainties surrounding our ability to realize these tax benefits. The deferred tax assets are primarily
comprised of deferred revenue, federal and state tax net operating loss (NOL) carryforwards and research and development
tax credit carryforwards. As of December 31, 2019, we had cumulative net operating loss carryforwards for federal income
tax purposes of approximately $144.7 million; $68.0 million of such losses were incurred prior to December 31, 2017 and
$76.7 million were incurred in the year December 31, 2018. We also had available tax credit carryforwards of $19.7 million
for federal tax purposes. We had cumulative state tax loss carryforwards at December 31, 2019 of $92.8 million, and
available state tax credit carryforwards of approximately $11.0 million, which can be carried forward to offset future taxable
income, if any.
Our federal net operating loss carryforwards incurred prior to January 1, 2018, expire starting in 2026, state net
operating loss carryforwards expire starting in 2031, and federal tax credit carryforwards begin to expire starting in 2019.
Approximately $0.4 million of federal tax credits will expire if unused from 2019 through 2024. Upon analysis, we believe
that our net operating losses and tax credits were subject to an annual limitation due to the ownership change provisions by
the Internal Revenue Code under Section 382 and similar state provisions. As a result of the limitations under Section 382,
our federal and state tax operating loss and tax credit carryforwards have been limited.
We recorded an income tax expense of $0.3 million related to state AMT for the year ended December 31, 2019. No
income tax expense or benefit was recorded for the year ended December 31, 2018. We recorded an income tax benefit of
$0.5 million, related to federal and state AMTs, for the year ended December 31, 2017.
72
Table of Contents
Valuation of Stock-Based Compensation
We record the fair value of stock options and shares issued under our Employee Stock Purchase Plan (ESPP) to
employees as of the grant date as compensation expense over the service period, which is generally the vesting period. For
non-employees, we also record the fair value of stock options as of the grant date as compensation expense over the service
period. We then periodically re-measure the awards to reflect the current fair value at each reporting period until the non-
employee completes the performance obligation or the date on which a performance commitment is reached. Expense is
recognized over the related service period.
We calculate the fair value of stock-based compensation awards using the Black-Scholes option-pricing model. The
Black-Scholes option-pricing model requires the use of subjective assumptions, including volatility of our common stock, the
expected term of our stock options, the risk free interest rate for a period that approximates the expected term of our stock
options and the fair value of the underlying common stock on the date of grant.
Common Stock Options Fair Value
We recognize stock-based compensation expense in accordance with the provisions of ASC Topic 718,
Compensation—Stock Compensation. The use of a Black-Scholes model requires us to apply judgment and make
assumptions and estimates that include the following:
● Expected Volatility—Volatility is a measure of the amount by which a financial variable such as a share price
has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.
● Expected Dividend Yield—We have never declared or paid dividends and have no plans to do so in the
foreseeable future.
● Risk-Free Interest Rate—This is the U.S. Treasury rate for the week of each option grant during the year,
having a term that most closely resembles the expected life of the option.
● Expected Term—This is the period of time that the options granted are expected to remain unexercised. Options
granted have a maximum term of ten years and we have estimated the expected life of the option term to be
between six and eight years. We use a simplified method to calculate the average expected term for employee
awards.
Results of Operations
Comparison of the Years Ended December 31, 2019 and 2018
The following table summarizes our results of operations for the years ended December 31, 2019 and 2018 (in
millions):
73
Table of Contents
Revenues:
Research collaboration
Milestone
Licensing
Royalties
Total revenues
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income, net
Income tax expense
Net income (loss)
Revenues
Year ended
December 31,
2018
2019
Change
$
$
16.3
23.2
112.2
5.0
156.7
118.6
24.3
142.9
13.4
0.3
26.9
$
$
20.1
20.5
—
—
40.6
97.5
22.5
120.0
9.0
—
(70.4)
$
$
(3.8)
2.7
112.2
5.0
116.1
21.1
1.8
22.9
4.4
0.3
97.3
Research collaboration revenues in 2019 represent revenue recognized under our Genentech and Astellas
agreements while the research collaboration revenues in 2018 represent revenue recognized under our Novartis Agreement.
Milestone payments increased by $2.7 million in 2019 over 2018 amounts primarily due to receiving contractual
milestones in 2019 from Amgen, Alexion and Novartis compared to contractual milestones received primarily from Alexion
in 2018.
Licensing revenues in 2019 primarily consist of revenues recognized from our Genentech agreement.
Royalty revenues for 2019 represent royalty revenue recognized from our Alexion agreement.
Research and Development Expenses
The following table summarizes our research and development expenses for the years ended December 31, 2019
and 2018 (in millions):
Product programs:
Obexelimab (XmAb5871) programs
XmAb7195 program
Bispecific programs:
CD3*
Tumor microenvironment (TME) activators
Cytokines*
Subtotal Bispecific programs
Other, research and early stage programs
Total research and development expense
Year Ended
December 31,
2018
Change
$
$
23.0
0.8
23.1
33.1
7.7
63.9
9.8
97.5
$
$
(5.5)
(0.5)
14.1
(4.9)
14.3
23.5
3.6
21.1
2019
17.5
0.3
37.2
28.2
22.0
87.4
13.4
118.6
$
$
*Includes net reimbursements from our partners pursuant to agreements that include cost-sharing arrangements.
74
Table of Contents
Research and development expenses increased by $21.1 million in 2019 over 2018 amounts as we continue to
expand our pipeline of bispecific antibody and cytokine candidates. Increased spending on our bispecific CD3 and our
cytokine programs offset reduced spending on our TME activator candidates during the year.
General and Administrative Expenses
General and administrative expenses increased by $1.8 million in 2019 over 2018 amounts primarily due to an
increase in facility costs, staffing and intellectual property costs.
Other Income, Net
Other income, net increased by $4.4 million in 2019 over 2018 amounts reflecting additional interest income earned
on our investments in marketable securities, which is due to higher investment balances as a result of our upfront proceeds
received from our Genentech and Astellas agreements in March 2019.
Comparison of the Years Ended December 31, 2018 and 2017
The following table summarizes our results of operations for the year ended December 31, 2018 and 2017 (in
millions):
Revenues:
Research collaboration
Milestone
Licensing
Total revenues
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income, net
Income tax benefit
Net loss
Revenues
2018
20.1
20.5
—
40.6
97.5
22.5
120.0
9.0
—
(70.4)
$
$
$
$
Year Ended
December 31,
2017
Change
20.1
26.0
0.1
46.2
71.8
17.5
89.3
4.2
(0.5)
(38.4)
$
$
—
(5.5)
(0.1)
(5.6)
25.7
5.0
30.7
4.8
0.5
(32.0)
Research collaboration revenue in 2018 and 2017 represents revenue recognized under our Novartis Agreement.
Milestone and contingent payments decreased by $5.5 million in 2018 over 2017 amounts primarily due to
receiving contractual milestones in 2017 from Amgen, CSL and MorphoSys, compared to contractual milestones received
from Alexion in 2018.
75
Table of Contents
Research and Development Expenses
The following table summarizes our research and development expenses for the years ended December 31, 2018
and 2017 (in millions):
Product programs:
Obexelimab (XmAb5871) programs
XmAb7195 program
Bispecific programs:
CD3*
Tumor microenvironment (TME) activators
Cytokines*
Subtotal Bispecific programs
Other, research and early stage programs
Total research and development expense
Year Ended
December 31,
2017
2018
Change
$
$
23.0
0.8
23.1
33.1
7.7
63.9
9.8
97.5
$
$
20.3
3.4
21.3
20.7
—
42.0
6.1
71.8
$
$
2.7
(2.6)
1.8
12.4
7.7
21.9
3.7
25.7
*Includes net payments from our partners pursuant to agreements that include cost-sharing arrangements.
Research and development expenses increased by $25.7 million in 2018 over 2017 amounts as we continue to
expand our pipeline of bispecific antibody and cytokine candidates. The primary increases in research and development
spending were on our bispecific TME activator and cytokine programs. Increased spending on our obexelimab program and
early discovery research programs was partially offset by reduced spending on the XmAb7195 program.
General and Administrative Expenses
General and administrative expenses increased by $5.0 million in 2018 over 2017 amounts primarily due to an
increase in facility costs, staffing and stock-based compensation costs.
Other Income, Net
Other income, net increased by $4.8 million in 2018 over 2017 amounts, reflecting additional interest income
earned on our investments in marketable securities, which is higher due to increased investment balances as a result of our
follow-on public offering in March 2018.
Liquidity and Capital Resources
Since our inception, our operations have been primarily financed through proceeds from public offering, private
sales of our equity, convertible notes and payments received under our collaboration and development partnerships and
licensing arrangements. We have devoted our resources to funding research and development programs, including discovery
research, preclinical and clinical development activities.
We have incurred substantial operating losses since our inception, and we expect to continue to incur operating
losses into the foreseeable future as we advance the ongoing development of our bispecific Fc domain pipeline of product
candidates, evaluate opportunities for the potential clinical development of our other preclinical programs, and continue our
research efforts.
In March 2019, we received a total of $135.0 million in upfront payment in connection with our Genentech and
Astellas collaboration agreements.
76
Table of Contents
In March 2018, we completed the sale of 8,395,000 shares of common stock which included shares that we issued
pursuant the underwriters’ exercise of their over-allotment option pursuant to a follow-on public offering. We received net
proceeds of $245.5 million, after deducting underwriters’ discounts and offering expenses.
On September 19, 2016, we entered into an Equity Distribution Agreement (the Distribution Agreement) with Piper
Jaffray & Co (Piper Jaffray) pursuant to which we could sell from time to time, at our option, up to an aggregate of $40
million of common stock through Piper Jaffray as sales agent. The issuance and sale of these shares by Xencor under the
Distribution Agreement were pursuant to our shelf registration statement on Form S-3 (File No.333-213700) declared
effective by the SEC on October 5, 2016. We did not sell any shares under the Distribution Agreement, and the Distribution
Agreement expired in October 2019.
At December 31, 2019, we had $601.3 million of cash, cash equivalents and marketable debt securities compared to
$530.5 million at December 31, 2018. We expect to continue to receive additional payments from our collaborators for
research and development services rendered, additional milestone, contingent payments, opt-in and royalty payments. In
early 2020, we received a $6.0 million upfront payment related to our collaborations with Gilead and will receive an
additional $5.0 million in upfront payments and $5.0 million in Aimmune stock related to our Aimmune collaboration. Our
ability to receive milestone payments and contingent payments from our partners is dependent upon either our ability or our
partners’ abilities to achieve certain levels of research and development activities and is therefore uncertain at this time.
Funding Requirements
We have not generated any revenue from product sales and do not expect to do so until we obtain regulatory
approval and commercialize one or more of our product candidates. As we are currently in the early clinical stages of
development, it will be some time before we expect to achieve this, and it is uncertain that we ever will. We expect that our
operating expenses will continue to increase in connection with ongoing as well as additional planned clinical and preclinical
development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for
additional collaboration and licensing opportunities.
Although it is difficult to predict our funding requirements, based upon our current operating plan, we believe that
our existing cash, cash equivalents and marketable securities, together with interest thereon and expected milestone and
royalty payments will be sufficient to fund our operations into 2024. We have based these estimates on assumptions that may
prove to be wrong, and we could use our capital resources sooner than we currently expect.
Cash Flows
The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods
presented below (in thousands):
Net cash provided by (used in):
Operating activities
Investing activities
Financing activities
Net increase in cash and cash equivalents
Operating Activities
Year Ended December 31,
2018
2019
2017
$
$
64,374
(50,970)
10,662
24,066
$
$
(79,756)
(164,767)
254,241
9,718
$
$
(33,597)
31,864
3,733
2,000
Net cash provided by operating activities for the year ended December 31, 2019 reflects upfront and milestone
payments received in excess of operating expenses, while net cash used in operations for the years ended December 31, 2018
and December 31, 2017 reflects operating expenses in excess of milestone payments primarily for advancing our pipeline of
bispecific antibody candidates during such years.
77
Table of Contents
Investing Activities
Investing activities consist primarily of proceeds from maturities of marketable securities offset by purchases of
marketable securities available-for-sale, acquisition of intangible assets and purchases of property and equipment. In 2019,
we purchased $39.9 million of marketable securities, net of $456.9 million of proceeds from sales and maturities. In 2018,
we purchased $155.7 million in marketable securities, net of $222.1 million of proceeds from sale and maturities and in 2017
we received $39.2 million in marketable securities, net of $76.5 million of purchases. We acquired $3.7 million, $1.9 million
and $2.0 million of intangible assets in the years ended December 31, 2019, 2018 and 2017, respectively. We purchased $7.4
million, $7.2 million and $5.3 million of capital equipment for the years ended December 31, 2019, 2018 and 2017
respectively. The increase in capital expenditure in 2019 and 2018 compared to 2017 is primarily due to leasehold
improvements purchased our laboratory facilities.
Financing Activities
Net cash provided by financing activities during the year ended December 31, 2019 consists primarily of cash from
stock option exercises and the sales of shares under the ESPP.
Net cash provided by financing activities during the year ended December 31, 2018 consists primarily of net
proceeds from our March 2018 follow-on public offering and cash from stock option exercises and the sale of shares under
the ESPP.
Net cash provided by financing activities during the year ended December 31, 2017 consists primarily of cash from
stock option exercises and the sale of shares under the ESPP.
Contractual Obligations and Commitments
The following table summarizes our contractual obligations at December 31, 2019 (in thousands):
Operating lease obligation relating to facilities (1)
Total
5,790 $
$
Payments due by period
Less
than
1 year
1 - 3
Years
3 - 5
Years
2,404 $ 3,386 $
— $
More
than
5 years
—
(1) Consists of operating leases on our corporate headquarters in Monrovia, CA encompassing two floors of 24,000 square feet each that
expire in June 2020 and September 2022, respectively, and on our San Diego, CA offices encompassing 24,000 square feet that
expires in August 2022.
We are obligated to make future payments to third parties under in-license agreements, including sublicense fees,
royalties, and payments that become due and payable on the achievement of certain development and commercialization
milestones. We have also entered into agreements with third party vendors which will require us to make future payments
upon the delivery of goods and services in future periods.
In February 2015, we entered into a license agreement with BIO-TECHNE Corporation (BIO-TECHNE) for a non-
exclusive license to certain antibody technology including monoclonal antibodies which recognize human somatostatin
receptor 2 (SSTR2). The variable domain of this antibody is incorporated in our XmAb18087 drug candidate. Under this
license agreement, we may be required to make $3.8 million in additional contingent payments which include $800,000 of
clinical milestones and $3.0 million of regulatory milestones, in addition to royalties upon commercial sales of products of
less than 1%. We made an upfront payment of $200,000 in connection with this license and made a Phase 1 milestone
payment of $100,000 in 2018. We have not made any additional milestone payments under this arrangement.
78
Table of Contents
In January 2019, we entered into a second agreement with BIO-TECHNE which agreement is effective February
2018 for a non-exclusive license to certain recombinant monoclonal antibody reactive with human programmed death
protein, PD-1 antibody. We expect to use this protein in certain of our oncology drug candidates. Under this license
agreement, we may be required to make $22.0 million in additional contingent payments which include $1.5 million of
clinical milestones, $4.5 million of regulatory milestones and milestones on the achievement of certain sales of $16.0
million, in addition to royalties upon commercial sales of products of 1%. We made an upfront payment in connection with
this license in 2019 and have not made any additional payments under this license agreement.
In November 2015, we entered into a worldwide exclusive commercial license agreement with Selexis SA to
develop and commercialize products produced from the Selexis cell line that was manufactured in connection with our
XmAb14045 drug candidate. We made an upfront payment of 50,000 Swiss Francs (CHF) in connection with the license and
may be required to make CHF 1.7 million in additional contingent obligations which include CHF 500,000 in development
milestones, CHF 400,000 in regulatory milestones and CHF 800,000 in sales milestones, in addition to royalties upon
commercial sales of products of less than 1%. During 2016, we made a CHF 100,000 milestone payment in connection with
an IND submission. There were no additional milestone payments made under this license agreement.
In February 2016, we entered into a worldwide exclusive commercial license agreement with Selexis SA to develop
and commercialize products produced from the Selexis cell line that was manufactured in connection with our plamotamab
drug candidate. In connection with the license we may be required to make CHF 1.7 million in additional contingent
obligations which include CHF 500,000 in development milestones, CHF 400,000 in regulatory milestones and CHF 800,000
in sales milestones, in addition to royalties upon commercial sales of products of less than 1%. During 2016, we made a CHF
100,000 milestone payment in connection with an IND submission. There were no additional milestone payments made
under this license agreement.
In December 2017, we entered into worldwide exclusive commercial license agreements with Selexis to develop
and commercialize products produced from the Selexis cell line that was manufactured for each of our bispecific antibody
and cytokine drug candidates: XmAb18087, XmAb20717, XmAb22841, XmAb23104, XmAb24306 and XmAb27564. The
terms for each agreement are identical and for each licensed cell line we may be required to make up to CHF 1.4 million in
total development, regulatory and sales milestones which include CHF 425,000 in development milestones, CHF 340,000 in
regulatory milestones and CHF 680,000 in sales milestones. In addition, we may be obligated to pay royalties upon
commercial sales of approved products of less than 1%. In 2017, we made a CHF 85,000 milestone payment in connection
with an IND submission. In 2018, we made three milestone payments of CHF 85,000 each in connection with three separate
IND submissions. In 2019, we made a milestone payment of CHF 75,000 in connection with an IND submission.
In December 2015, we entered into a Cell Line Sale Agreement with Catalent Pharma Solutions LLC for a
worldwide license to develop and commercialize products produced from the Catalent cell line that was manufactured in
connection with our obexelimab drug candidate. Under the terms of the agreement, we may be obligated to make contingent
payments upon transfer of the obexelimab manufacturing process to a third party. These contingent payments total $2.75
million and include $500,000 in development milestones and $2.25 million in regulatory milestones in addition to royalties
on net sales of obexelimab approved products with such royalties less than 1%. In 2017, we transferred the manufacturing
process for obexelimab to a third-party manufacturer. We did not make any milestone payments under this agreement in 2019
or 2018.
79
Table of Contents
In December 2011, we entered into a Cell Line Sale Agreement with Catalent Pharma Solutions LLC for a
worldwide license to develop and commercialize products produced from the Catalent cell line that was manufactured in
connection with the XmAb7195 drug candidate. This agreement was subsequently amended in April 2015. Under the terms
of the agreement, we may be obligated to make contingent payments upon transfer of the XmAb7195 manufacturing process
to a third party. These contingent payments total $2.75 million and include $0.5 million in development milestones and $2.25
million in regulatory milestones in addition to royalties on net sales of XmAb7195 approved products with such royalties less
than 1%. We did not make any milestone payments under this Agreement in 2019 and 2018. In February 2020, we
sublicensed our rights under the Cell Line Agreement to Aimmune in connection with our license to XmAb7195. Under the
sublicensing agreement, Aimmune will assume all responsibilities and obligations under the Cell Line Agreement.
In December 2012, we entered into a Cross-License Agreement with MedImmune, LLC (MedImmune) for a non-
exclusive license to certain MedImmune patents related to half-life technology. Under the terms of the agreement, we may be
obligated to make contingent payments in connection with the use of our Xtend™ technology, including use by us in our
development candidates and also for use by our licensees. These contingent payments total $250,000 per program and
include $150,000 in clinical milestones and $100,000 in regulatory milestones. In addition, we may be obligated to make
contingent payments for tiered sales milestones on the sale of approved products from $20,000 per year to $1.0 million per
year. Our obligations to make payments under this agreement expire in December 2021. We made milestone payments under
this agreement of $75,000, $125,000 and $75,000 for 2017, 2018 and 2019, respectively.
As the amount and timing of sublicense fees and the achievement and timing of these milestones are not probable
and estimable, such commitments have not been included on our balance sheet or in the contractual obligations and
commitment tables above.
Off-Balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements.
New Accounting Pronouncements
See Note 1 - Recent Accounting Pronouncements in the accompanying financial statements for information
regarding recent accounting pronouncements.
80
Table of Contents
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level
of U.S. interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments,
an immediate 10.0% change in interest rates would not have a material effect on the fair market value of our portfolio.
Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of
a sudden change in market interest rates on our investment portfolio.
We do not believe that our cash, cash equivalents and marketable securities have significant risk of default or
illiquidity. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot
provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In
addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess
of federally insured limits.
Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation
has had a material effect on our results of operations during the periods presented.
Item 8. Financial Statements and Supplementary Data
Xencor, Inc.
Financial Statements
Audited Financial Statements for the Years Ended December 31, 2019, 2018 and 2017:
Report of Independent Registered Public Accounting Firm
Balance Sheets
Statements of Comprehensive Income (Loss)
Statements of Stockholders’ Equity
Statements of Cash Flows
Notes to Financial Statements
82
85
86
87
88
89
81
Table of Contents
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of
Xencor, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Xencor, Inc. (the Company) as of December 31, 2019 and 2018, the
related statements of comprehensive income (loss), stockholders’ equity and cash flows for each of the three years in the
period ended December 31, 2019, and the related notes to the financial statements. In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the
results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity
with accounting principles generally accepted in the United States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in
Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission in 2013, and our report, dated February 24, 2020, expressed an unqualified opinion on the effectiveness of the
Company’s internal control over financial reporting.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion
on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and
are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether
due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the
overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that
was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that
are material to the financial statements; and (2) involved our especially challenging, subjective or complex judgments. The
communication of the critical audit matter does not alter in any way our opinion on the financial statements taken as a whole,
and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or
on the accounts or disclosures to which it relates.
Revenue Recognition—Collaboration and Licensing Agreements
As discussed in Note 10 to the financial statements, the Company entered into collaboration and licensing agreements during
the year ended December 31, 2019. These contracts contain multiple performance obligations. For each performance
obligation identified, the Company recognizes revenue upon transfer of control of promised intellectual property and
technology licenses, or upon delivery of research and development services to its collaboration and licensing partners in an
amount that reflects the consideration the Company expects to receive in exchange for those licenses or services.
Management applies significant judgment in determining the revenue recognition for these collaboration and licensing
contracts, including the identification of and accounting for all performance obligations and the calculation of the standalone
selling price (SSP) for each identified performance obligation. Management’s identification of the performance obligations
requires significant judgment, including whether the performance
82
Table of Contents
obligations are distinct and capable of being distinct, which requires management to evaluate whether the customer can
benefit from the good or service on its own, or together with other resources readily available to the customer. The
Company’s estimate of SSP for each performance obligation within these customer contracts requires management to
consider many factors, including external market data, as well as an estimate of future profitability.
We identified the Company’s revenue recognition related to the collaboration and licensing agreements as a critical audit
matter because auditing the identification and accounting for performance obligations, and the calculation of the SSP for
each performance obligation, required significant audit effort and a high degree of auditor judgment and subjectivity to
perform our audit procedures and evaluate the audit evidence obtained.
Our audit procedures related to the Company’s collaboration and licensing contracts included the following, among others:
● We obtained and read the collaboration and licensing agreements and evaluated the completeness of the
performance obligations identified by management, and performed an evaluation of whether these performance
obligations were distinct and capable of being distinct.
● We obtained an understanding of the relevant controls related to the collaboration and licensing contracts and tested
such controls for design and operating effectiveness, including management review controls related to identifying
distinct performance obligations and when transfer of control is satisfied, and determining the SSP over each of the
identified performance obligations.
● We tested management’s process used to estimate the SSP by evaluating the models, including testing the accuracy
and completeness of data used, and reasonableness of assumptions applied by management.
● As each contract has multiple performance obligations, we also tested the allocation of the transaction price to each
performance obligation based upon the SSP.
We have served as the Company’s auditor since 2015.
/s/ RSM US LLP
Los Angeles, California
February 24, 2020
83
Table of Contents
Report of Independent Registered Public Accounting Firm
Regarding Internal Control Over Financial Reporting
To the Stockholders and the Board of Directors of
Xencor, Inc.
Opinion on Internal Control Over Financial Reporting
We have audited Xencor, Inc.’s (the Company) internal control over financial reporting as of December 31, 2019, based on
criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission in 2013. In our opinion, the Company maintained, in all material respects, effective internal control
over financial reporting as of December 31, 2019, based on criteria established in Internal Control—Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the balance sheets of the Company as of December 31, 2019 and 2018, the related statements of comprehensive
income (loss), stockholders’ equity and cash flows for each of the years in the period ended December 31, 2019, of the
Company and our report, dated February 24, 2020, expressed an unqualified opinion.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting in the accompanying Management’s Report on
Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over
financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be
independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in
all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the
risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control
based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the
circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
accounting principles generally accepted in the United States of America (U.S. GAAP). A company’s internal control over
financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S.
GAAP, and that receipts and expenditures of the company are being made only in accordance with authorizations of
management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial
statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ RSM US LLP
Los Angeles, California
February 24, 2020
84
Table of Contents
Xencor, Inc.
Balance Sheets
(in thousands, except share and per share data)
December 31,
2019
2018
Assets
Current assets
Cash and cash equivalents
Marketable securities
Accounts receivable
Income tax receivable
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Patents, licenses, and other intangible assets, net
Marketable securities - long term
Income tax receivable
Right of use asset
Other assets
Total assets
Liabilities and stockholders’ equity
Current liabilities
Accounts payable
Accrued expenses
Deferred rent
Lease liabilities
Deferred revenue
Total current liabilities
Deferred rent, net of current portion
Lease liabilities, net of current portion
Deferred revenue, net of current portion
Total liabilities
Commitments and contingencies (see note 9)
Stockholders’ equity
$
50,312
479,470
21,574
502
6,547
558,405
15,805
14,421
71,526
402
9,380
311
$ 670,250
$
10,189
8,995
—
2,169
45,205
66,558
—
8,565
1,926
77,049
$
26,246
268,115
10,187
804
10,375
315,727
11,813
11,969
236,108
804
—
311
$ 576,732
$
3,797
9,662
315
—
40,079
53,853
1,198
—
—
55,051
Preferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and
outstanding shares at December 31, 2019 and 2018
Common stock, $0.01 par value: 200,000,000 authorized shares; 56,902,301 issued and
outstanding shares at December 31, 2019 and 56,279,542 issued and outstanding at
December 31, 2018
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
—
—
569
887,873
1,161
(296,402)
593,201
$ 670,250
563
845,366
(971)
(323,277)
521,681
$ 576,732
See accompanying notes to the financial statements.
85
Table of Contents
Xencor, Inc.
Statements of Comprehensive Income (Loss)
(in thousands, except share and per share data)
Revenue
Collaborations, licenses, milestones and royalties
Operating expenses
Research and development
General and administrative
Total operating expenses
Income (loss) from operations
Other income (expense)
Interest income, net
Other income (expense)
Total other income, net
Income (loss) before income tax
Income tax expense (benefit)
Net income (loss)
Other comprehensive income (loss)
Net unrealized gain (loss) on marketable securities available-for-sale
Comprehensive income (loss)
Net income (loss) per share attributable to common stockholders:
Basic
Diluted
Weighted average shares used to compute net income (loss) per share
attributable to common stockholders:
Basic
Diluted
Year ended December 31,
2018
2017
2019
$
156,700
$
40,603
$
46,150
118,590
24,286
142,876
13,824
13,619
(256)
13,363
27,187
312
26,875
2,132
29,007
0.48
0.46
$
$
$
97,501
22,472
119,973
(79,370)
9,086
(125)
8,961
(70,409)
—
(70,409)
837
(69,572)
(1.31)
(1.31)
$
$
$
71,772
17,501
89,273
(43,123)
4,181
(7)
4,174
(38,949)
(463)
(38,486)
(367)
(38,853)
(0.82)
(0.82)
$
$
$
56,531,439
58,467,880
53,942,116
53,942,116
46,817,756
46,817,756
See accompanying notes to the financial statements.
86
Table of Contents
Xencor, Inc.
Statements of Stockholders’ Equity
(in thousands, except share data)
Stockholders’ Equity
Balance, December 31, 2016
Issuance of common stock upon exercise of
stock awards
Issuance of common stock under the Employee
Stock Purchase Plan
Comprehensive loss
Stock-based compensation
Balance, December 31, 2017
Sale of common stock, net of issuance cost
Issuance of common stock upon exercise of
stock awards
Issuance of common stock under the Employee
Stock Purchase Plan
Comprehensive income (loss)
Stock-based compensation
Balance, December 31, 2018
Issuance of common stock upon exercise of
stock awards
Issuance of common stock under the Employee
Stock Purchase Plan
Issuance of restricted stock units
Comprehensive income
Stock-based compensation
Balance, December 31, 2019
Common Stock
Shares
46,567,978
Amount
466
Additional
Paid
in-Capital
553,290
Accumulated
Other
Comprehensive Accumulated
Loss
(1,441)
Deficit
(214,382)
Total
Stockholders’
Equity
337,933
363,603
4
2,793
—
—
2,797
70,907
—
—
47,002,488
8,395,000
—
—
—
470
84
936
—
13,651
570,670
245,420
824,731
8
7,609
57,323
—
—
56,279,542
543,887
67,561
11,311
—
—
56,902,301
1
—
—
563
5
1
—
—
—
1,119
—
20,548
845,366
9,264
1,392
—
—
31,851
$
569 $ 887,873 $
—
(367)
—
(1,808)
—
—
—
837
—
(971)
—
—
—
(38,486)
—
(252,868)
—
936
(38,853)
13,651
316,464
245,504
—
7,617
—
(70,409)
—
(323,277)
—
—
1,120
(69,572)
20,548
521,681
9,269
1,393
2,132
—
1,161 $
26,875
—
(296,402) $
29,007
31,851
593,201
See accompanying notes to the financial statements.
87
Table of Contents
Xencor, Inc.
Statements of Cash Flows
(in thousands)
Cash flows from operating activities
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in)
operating activities:
Depreciation and amortization
Amortization of premium on marketable securities
Stock-based compensation
Abandonment of capitalized intangible assets
Loss on disposal of assets
Loss on sale of marketable securities available-for-sale
Changes in operating assets and liabilities:
Accounts receivable
Interest receivable
Prepaid expenses and other current assets
Income tax receivable
Other assets
Accounts payable
Accrued expenses
Deferred rent
Income tax payable
Lease liabilities and ROU assets
Deferred revenue
Net cash provided by (used in) operating activities
Cash flows from investing activities
Proceeds from sale and maturities of marketable securities available-for-sale
Proceeds from sale of property and equipment
Purchase of marketable securities
Purchase of intangible assets
Purchase of property and equipment
Proceeds from repayment of (investment in) loan receivable
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from issuance of common stock upon exercise of stock awards
Proceeds from issuance of common stock from Employee Stock Purchase
Plan
Proceeds from issuance of common stock
Common stock issuance costs
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Supplemental disclosures of cash flow information
Cash paid for:
Interest
Taxes
Supplemental Schedule of Noncash Investing Activities
Net unrealized gain (loss) on marketable securities available-for-sale
$
$
$
$
Year ended December 31,
2018
2019
2017
$
26,875
$
(70,409)
$
(38,486)
4,298
(4,321)
31,851
221
8
—
(11,321)
(387)
3,828
704
—
6,392
(667)
(1,513)
—
1,354
7,052
64,374
456,923
—
(496,855)
(3,685)
(7,353)
—
(50,970)
9,269
1,393
—
—
10,662
24,066
26,246
50,312
11
400
2,132
3,251
(394)
20,548
239
102
74
(9,045)
(535)
(4,769)
(84)
(46)
(3,072)
4,182
398
(157)
—
(20,039)
(79,756)
2,030
2,845
13,651
396
83
—
7,474
(307)
(2,705)
(1,524)
(161)
2,989
(1,212)
589
91
—
(19,350)
(33,597)
222,125
9
(377,840)
(1,935)
(7,212)
86
(164,767)
115,757
—
(76,529)
(1,967)
(5,311)
(86)
31,864
7,617
2,797
1,120
260,245
(14,741)
254,241
9,718
16,528
26,246
16
233
837
$
$
$
$
936
—
—
3,733
2,000
14,528
16,528
13
969
(367)
$
$
$
$
See accompanying notes to the financial statements.
88
Table of Contents
1. Summary of Significant Accounting Policies
Description of Business
Xencor, Inc. (we, us, our, or the Company) was incorporated in California in 1997 and reincorporated in Delaware
in September 2004. We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered
monoclonal antibody and proteins to treat severe and life-threatening diseases with unmet medical needs. We use our
proprietary XmAb technology platform to create next-generation antibody product candidates designed to treat cancer and
autoimmune diseases. We focus on the portion of the antibody that interacts with multiple segments of the immune system,
referred to as the Fc domain, which is constant and interchangeable among antibodies. Our engineered Fc domains, the
XmAb technology, are applied to our pipeline of antibody and protein-based drug candidates to increase immune inhibition,
improve cytotoxicity, extend half-life and most recently to create bispecific antibodies and cytokines.
Our operations are based in Monrovia, California and San Diego, California.
Basis of Presentation
The Company’s financial statements as of December 31, 2019, 2018, and 2017 and for the years then ended have
been prepared in accordance with accounting principles generally accepted in the United States (U.S.).
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United
States of America requires management to make estimates and assumptions that affect the amounts reported in the financial
statements and accompanying notes. Significant estimates include useful lives of long-lived assets, the periods over which
certain revenues and expenses will be recognized including collaboration revenue recognized from non-refundable upfront
licensing payments, the amount of non-cash compensation costs related to share-based payments to employees and non-
employees and the period over which these costs are expensed.
Recent Accounting Pronouncements
Pronouncements adopted in 2019
Effective January 1, 2019, the Company adopted Accounting Standards Codification Topic 842 (ASC 842), Leases,
which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for leases with terms greater than 12
months and also requires disclosures about the amount, timing and uncertainty of cash flows arising from such leases. The
Company adopted ASC 842 using the optional transition method provided under ASU 2018-11, which did not require
adjustments to comparative periods nor require modified disclosures in those comparative periods. Under this method, the
Company adjusted its financial statements for the cumulative effect of the adoption of ASC 842 at the beginning of January
1, 2019.
At inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on
the unique facts and circumstances. For leases with a term of one year or longer where the Company is the lessee, ROU
assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation
to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement
date based on the present value of lease payments over the lease term. The interest rate implicit with such leases is typically
not readily determined. The Company has determined the appropriate incremental borrowing rate by reference to an estimate
of the current market borrowing rate for a collateralized asset over a similar term as the lease term.
89
Table of Contents
The new standard impacts our reporting on the leases on our facilities in Monrovia and San Diego. Under ASC 842,
tenant allowances under such operating leases are no longer tracked separately as a deferred rent liability; instead, it is
integrated as part of the ROU asset. As a result, we recorded an adjustment to the beginning balance for deferred rent liability
and adopted the use of ROU asset and lease liability. We recorded lease liabilities of $12.7 million and ROU assets of $11.4
million for lease agreements in effect as of January 1, 2019.
Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Compensation (Topic
718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include
share-based payments issued to nonemployees for goods and services. The standard requires a modified retrospective
transition approach, with a cumulative adjustment to retained earnings as of adoption date, for all liability-classified awards
that have not been settled as of the adoption date and equity-classified nonemployee awards for which a measurement date
has not been established. The adoption of this standard did not have any impact on the Company’s financial statements.
Pronouncements not yet effective
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement
of Credit Losses on Financial Instruments, which amends the guidance on reporting credit losses for assets held at amortized
cost basis and available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded
through an allowance for credit losses rather than as a direct write-down to the security. Credit losses on available-for-sale
securities, that are determined to be impaired, will be required when the amortized cost is below the fair market value. The
amendment is effective for fiscal years beginning after December 15, 2019 including interim periods within those fiscal
years. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial
Instruments – Credit Losses, which clarifies that receivables arising from operating leases are not within the scope of Topic
326. We will apply the standard’s provision as a cumulative effect adjustment to retained earnings as of the beginning of the
first effective reporting period. We do not expect the adoption to have a material impact on our results of operations or
financial position.
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework
– Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosures for transfers between
Level 1 and Level 2 of the fair value hierarchy, modifies the Level 3 disclosure requirements for non-public entities and
requires additional disclosure for Level 3 fair value hierarchy. The amendment is effective for fiscal years beginning after
December 15, 2019. The Company does not anticipate that the standard will have a significant impact on its financial
statements.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal Use Software
(Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a
Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that
is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use
software (and hosting arrangements that include an internal-use software license). The accounting for the service element of
a hosting arrangement that is a service contract is not affected by the amendment. The amendment is effective for annual
periods, including interim periods within those annual periods, beginning after December 15, 2019. The Company does not
anticipate that the standard will have a significant impact on its financial statements.
In October 2018, the FASB issued ASU No. 2018-17, Consolidation (Topic 810): Targeted Improvements to Related
Party Guidance for Variable Interest Entities, which amends the guidance for determining whether a decision-making fee is a
variable interest. The amendments require organizations to consider indirect interests held through related parties under
common control on a proportional basis rather than as the equivalent of a direct interest in its entirety (as currently required).
The amendments are effective for fiscal years beginning after December 15, 2019 and interim periods within those years.
The Company does not anticipate that the standard will have a significant impact on tis financial statements.
90
Table of Contents
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the
Interaction Between Topic 808 and Topic 606, which provides guidance on how to assess whether certain transactions
between collaborative arrangement participants should be accounted for within the revenue recognition standard. The
standard is effective for fiscal years beginning after December 15, 2019 and interim periods within those years. The
Company does not anticipate that the standard will have a significant impact on its financial statements.
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for
Income Taxes, which is effective for fiscal years beginning and after December 15, 2020, and interim periods within those
fiscal years. The standard removes specific exceptions to the general principles in Topic 740 and simplifies the accounting
for income taxes. The Company does not anticipate that the standard will have a significant impact on its financial
statements.
Revenue Recognition
We have, to date, earned revenue from research and development collaborations, which may include research and
development services, licenses of our internally developed technologies, licenses of our internally developed drug
candidates, or combinations of these.
The terms of our license and research and development and collaboration agreements generally include non-
refundable upfront payments, research funding, co-development reimbursements, license fees and, milestone and other
contingent payments to us for the achievement of defined collaboration objectives and certain clinical, regulatory and sales-
based events, as well as royalties on sales of any commercialized products.
The terms of our licensing agreements include non-refundable upfront fees, annual licensing fees, and contractual
payment obligations for the achievement of pre-defined preclinical, clinical, regulatory and sales-based events by our
partners. The licensing agreements also include royalties on sales of any commercialized products by our partners.
We recognize revenue through the five-step process in accordance with ASC 606 Revenue Recognition when
control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we
expect to be entitled to in exchange for those goods or services.
Deferred Revenue
Deferred revenue arises from payments received in advance of the culmination of the earnings process. We have
classified deferred revenue for which we stand ready to perform within the next 12 months as a current liability. We
recognize deferred revenue as revenue in future periods when the applicable revenue recognition criteria have been met. The
total amounts reported as deferred revenue were $47.1 million and $40.1 million at December 31, 2019 and 2018,
respectively.
Research and Development Expenses
Research and development expenses include costs we incur for our own and for our collaborators’ research and
development activities. Research and development costs are expensed as incurred. These costs consist primarily of salaries
and benefits, including associated stock-based compensation, laboratory supplies, facility costs, and applicable overhead
expenses of personnel directly involved in the research and development of new technology and products, as well as fees
paid to other entities that conduct certain research development activities on our behalf. We estimate preclinical study and
clinical trial expenses based on the services performed pursuant to the contracts with research institutions and clinical
research organizations that conduct and manage preclinical studies and clinical trials on our behalf based on the actual time
and expenses incurred by them. Further, we accrue expenses related to clinical trials based on the level of patient enrollment
and activity according to the related agreement. We monitor patient enrollment levels and related activity to the extent
reasonably possible and adjust estimates accordingly.
91
Table of Contents
We capitalize acquired research and development technology licenses and third-party contract rights and amortize
the costs over the shorter of the license term or the expected useful life. We review the license arrangements and the
amortization period on a regular basis and adjust the carrying value or the amortization period of the licensed rights if there is
evidence of a change in the carrying value or useful life of the asset.
Cash and Cash Equivalents
We consider cash equivalents to be only those investments which are highly liquid, readily convertible to cash and
which mature within three months from the date of purchase.
Marketable Securities
The Company has an investment policy that includes guidelines on acceptable investment securities, minimum
credit quality, maturity parameters and concentration and diversification. The Company invests its excess cash primarily in
marketable debt securities issued by investment grade institutions.
The Company considers its marketable debt securities to be “available-for-sale”, as defined by authoritative
guidance issued by the FASB. These assets are carried at fair value and the unrealized gains and losses are included in
accumulated other comprehensive income (loss). Accrued interest on marketable debt securities is included in marketable
securities. Accrued interest was $2.7 million and $2.3 million at December 31, 2019 and 2018, respectively. If a decline in
the value of a marketable security in the Company’s investment portfolio is deemed to be other-than-temporary, the
Company writes down the security to its current fair value and recognizes a loss as a charge against income. The Company
reviews its portfolio of marketable debt securities, using both quantitative and qualitative factors, to determine if declines in
fair value below cost are other-than-temporary.
Concentrations of Risk
Cash, cash equivalents and marketable debt securities are financial instruments that potentially subject the Company
to concentrations of risk. We invest our cash in corporate debt securities and U.S. sponsored agencies with strong credit
ratings. We have established guidelines relative to diversification and maturities that are designed to help ensure safety and
liquidity. These guidelines are periodically reviewed to take advantage of trends in yields and interest rates.
Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally
insured limits. We have never experienced any losses related to these balances. Amounts on deposit in excess of federally
insured limits at December 31, 2019 and 2018 approximated $50.0 million and $26.0 million, respectively.
We have payables with two service providers that represent 48% of our total payables and four service providers
that represented 49% of our total payables at December 31, 2019 and 2018, respectively. We rely on three critical suppliers
for the manufacture of our drug product for use in our clinical trials. While we believe that there are alternative vendors
available, a change in manufacturing vendors could cause a delay in the availability of drug product and result in a delay of
conducting and completing our clinical trials. No other vendor accounted for more than 10% of total payables at
December 31, 2019 or 2018.
Fair Value of Financial Instruments
Our financial instruments primarily consist of cash and cash equivalents, marketable debt securities, accounts
receivable, accounts payable and accrued expenses. Marketable debt securities and cash equivalents are carried at fair value.
The fair value of the other financial instruments closely approximate their fair value due to their short maturities.
92
Table of Contents
The Company accounts for recurring and non-recurring fair value measurements in accordance with FASB
Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair
value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosure
about fair value measurements. The ASC 820 hierarchy ranks the quality of reliable inputs, or assumptions, used in the
determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the
following three categories:
Level 1—Fair Value is determined by using unadjusted quoted prices that are available in active markets for
identical assets or liabilities.
Level 2—Fair Value is determined by using inputs other than Level 1 quoted prices that are directly or
indirectly observable. Inputs can include quoted prices for similar assets or liabilities in active
markets or quoted prices for identical assets or liabilities in markets that are not active. Related
inputs can also include those used in valuation or other pricing models, such as interest rates and
yield curves that can be corroborated by observable market data.
Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use
of these inputs involves significant and subjective judgments to be made by the reporting entity –
e.g. determining an appropriate discount factor for illiquidity associated with a given security.
The Company measures the fair value of financial assets using the highest level of inputs that are reasonably
available as of the measurement date. The assets recorded at fair value are classified within the hierarchy as follows for the
periods reported (in thousands):
Money Market Funds in Cash and Cash Equivalents
Corporate Securities
Government Securities
Money Market Funds in Cash and Cash Equivalents
Corporate Securities
Government Securities
Property and Equipment
December 31, 2019
Total
Fair Value
Level 1
Level 2
$
$
$
$
32,009
281,751
269,245
583,005
$
$
32,009
—
—
32,009
December 31, 2018
Total
Fair Value
Level 1
18,270
104,967
399,256
522,493
$
$
18,270
—
—
18,270
$
$
$
$
—
281,751
269,245
550,996
Level 2
—
104,967
399,256
504,223
Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated
useful lives of the assets. Expenditures for repairs and maintenance are charged to expense as incurred while renewals and
improvements are capitalized. Useful lives by asset category are as follows:
Computers, software and equipment
Furniture and fixtures
Leasehold improvements
3 - 5 years
5 - 7 years
5 - 7 years or remaining
lease term, whichever is less
93
Table of Contents
Patents, Licenses, and Other Intangible Assets
The cost of acquiring licenses is capitalized and amortized on the straight-line basis over the shorter of the term of
the license or its estimated economic life, ranging from five to 25 years. Third-party costs incurred for acquiring patents are
capitalized. Capitalized costs are accumulated until the earlier of the period that a patent is issued, or we abandon the patent
claims. Cumulative capitalized patent costs are amortized on a straight-line basis from the date of issuance over the shorter of
the patent term or the estimated useful economic life of the patent, ranging from 13 to 20 years. Our senior management,
with advice from outside patent counsel, assesses three primary criteria to determine if a patent will be capitalized initially:
i) technical feasibility, ii) magnitude and scope of new technical function covered by the patent compared to the company’s
existing technology and patent portfolio, particularly assessing the value added to our product candidates or licensing
business, and iii) legal issues, primarily assessment of patentability and prosecution cost. We review our intellectual property
on a regular basis to determine if there are changes in the estimated useful life of issued patents and if any capitalized costs
for unissued patents should be abandoned. Capitalized patent costs related to abandoned patent filings are charged off in the
period of the decision to abandon. During 2019, 2018 and 2017, we abandoned previously capitalized patent and licensing
related charges of $0.2 million, $0.2 million and $0.4 million, respectively.
The carrying amount and accumulated amortization of patents, licenses, and other intangibles is as follows (in
thousands):
Patents, definite life
Patents, pending issuance
Licenses and other amortizable intangible assets
Nonamortizable intangible assets (trademarks)
Total gross carrying amount
Accumulated amortization—patents
Accumulated amortization—licenses and other
Total intangible assets, net
December 31,
2019
2018
10,597
7,266
2,510
399
20,772
(4,912)
(1,439)
14,421
$
$
9,320
5,644
2,011
399
17,374
(4,142)
(1,263)
11,969
$
$
Amortization expense for patents, licenses, and other intangible assets was $0.9 million, $0.9 million and $0.8
million for the years ended December 31, 2019, 2018 and 2017, respectively.
Future amortization expense for patent, licenses, and other intangible assets recorded as of December 31, 2019, and
for which amortization has commenced, is as follows:
2020
2021
2022
2023
2024
Thereafter
Total
Year ended
December 31,
(in thousands)
1,009
912
880
809
647
2,365
6,622
$
$
The above amortization expense forecast is an estimate. Actual amounts of amortization expense may differ from
estimated amounts due to additional intangible asset acquisitions, impairment of intangible assets, accelerated amortization
of intangible assets, and other events. As of December 31, 2019, the Company has $7.3 million of intangible assets which are
in-process and have not been placed in service, and accordingly amortization on these assets has not commenced.
94
Table of Contents
Long-Lived Assets
Management reviews long-lived assets which include fixed assets and amortizable intangibles for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be
recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to
undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the
impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of
the assets.
We did not recognize a loss from impairment for the years ended December 31, 2019, 2018 or 2017.
Income Taxes
We account for income taxes in accordance with accounting guidance which requires an asset and liability approach
to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for
differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible
amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to
affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount
expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during
the period in deferred tax assets and liabilities.
We assess our income tax positions and record tax benefits for all years subject to examination based upon our
evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is
greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may
potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information.
For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has
been recognized in the financial statements. We did not have any material uncertain tax positions at December 31, 2019 or
2018.
Our policy is to recognize interest and penalties on taxes, if any, as a component of income tax expense.
The Tax Cuts and Jobs Act of 2017 (TCJA) was enacted on December 22, 2017 and has several key provisions
impacting the accounting for and reporting of income taxes. The most significant provisions reduced the U.S. corporate
statutory tax rate from 35% to 21%, eliminated the corporate Alternative Minimum Tax (AMT) system, and made changes to
the utilization and carryforward of net operating losses beginning on January 1, 2018. The tax reform provided for a refund
of unused AMT carryforwards for years beginning after December 31, 2017. We recorded an income tax receivable as of
December 31, 2019 and 2018 of $0.8 million and $1.6 million, respectively related to federal AMT carryforwards.
Stock-Based Compensation
We recognize compensation expense using a fair-value-based method for costs related to all share-based payments,
including stock options and shares issued under our Employee Stock Purchase Plan (ESPP). Stock-based compensation cost
related to employees and directors is measured at the grant date, based on the fair-value-based measurement of the award
using the Black-Scholes method, and is recognized as expense over the requisite service period on a straight-line basis. We
account for forfeitures when they occur. We recorded stock-based compensation and expense for stock-based awards to
employees, directors and consultants of approximately $31.9 million, $20.5 million and $13.7 million for the years ended
December 31, 2019, 2018 and 2017 respectively. Included in the 2019, 2018, and 2017 balances for total compensation
expense is $0.7 million, $0.7 million and $0.5 million, respectively, relating to our ESPP.
Options granted to individual service providers that are not employees or directors are accounted for at estimated
fair value using the Black-Scholes option-pricing method and are subject to periodic re-measurement over the period during
which the services are rendered.
95
Table of Contents
Net Income (Loss) Per Share
Basic net income (loss) per common share is computed by dividing the net income or loss by the weighted-average
number of common shares outstanding during the period. Potentially dilutive securities were included in the diluted net
income per common share calculation for 2019. We included 1,923,310 options to purchase shares of common stock and
13,131 shares of restricted stock units (RSUs) in the calculation of the weighted-average common shares outstanding used in
computing diluted net income per common share. We excluded 1,022,623 shares of options and RSUs from the calculation
for 2019 because the inclusion of such shares would have had an antidilutive effect.
In 2018 and 2017, we excluded all options and awards from the calculations because we reported net losses in the
periods and the inclusion of such shares would have had an antidilutive effect.
Basic
Numerator:
Net income (loss) attributable to common stockholders for basic net
income (loss) per share
Denominator:
Weighted-average common shares outstanding
Basic net income (loss) per common share
Diluted
Numerator:
Net income (loss) attributable to common stockholders for diluted net
income (loss) per share
Denominator:
Weighted average number of common shares outstanding used in
computing basic net income (loss) per common share
Dilutive effect of employee stock options and ESPP
Weighted-average number of common shares outstanding used in
computing diluted net income (loss) per common share
Diluted net income (loss) per common share
Segment Reporting
Year Ended December 31,
2018
(in thousands, except share and per share data)
2017
2019
26,875
$
(70,409) $
(38,486)
56,531,439
0.48
53,942,116
$
(1.31) $
46,817,756
(0.82)
26,875
$
(70,409) $
(38,486)
$
$
$
56,531,439
1,936,441
58,467,880
0.46
$
53,942,116
46,817,756
—
—
53,942,116
$
(1.31) $
46,817,756
(0.82)
The Company determines its segment reporting based upon the way the business is organized for making operating
decisions and assessing performance. The Company has only one operating segment related to the development of
pharmaceutical products.
2. Comprehensive Income (Loss)
Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). For the
years ended December 31, 2019 and 2018, the only component of other comprehensive income (loss) is net unrealized gains
on marketable debt securities. There were no material reclassifications out of accumulated other comprehensive loss during
the year ended December 31, 2019.
96
Table of Contents
3. Marketable Securities
The Company’s marketable debt securities held as of December 31, 2019 and 2018 are summarized below:
(in thousands)
Money Market Funds
Corporate Securities
Government Securities
Reported as
Cash and cash equivalents
Marketable securities
Total investments
(in thousands)
Money Market Funds
Corporate Securities
Government Securities
Reported as
Cash and cash equivalents
Marketable securities
Total investments
December 31, 2019
Gross
Amortized
Unrealized
Cost
Gains
Gross
Unrealized
Losses
Fair Value
$
$
32,009
281,586
268,239
581,834
$
$
— $
195
1,006
1,201
$
— $
(30)
—
(30) $
32,009
281,751
269,245
583,005
$
$
32,009
550,996
583,005
December 31, 2018
Gross
Amortized
Unrealized
Cost
Gains
Gross
Unrealized
Losses
Fair Value
$
$
18,270
105,311
399,873
523,454
$
$
— $
1
187
188
$
— $
(345)
(804)
(1,149) $
18,270
104,967
399,256
522,493
$
$
18,270
504,223
522,493
The maturities of the Company’s marketable debt securities as of December 31, 2019 are as follows:
(in thousands)
Mature in one year or less
Mature after one year through five years
Amortized
Cost
Estimated
Fair Value
$
$
478,338
71,487
549,825
$
$
479,470
71,526
550,996
97
Table of Contents
The unrealized losses on available-for-sale investments and their related fair values as of December 31, 2019 and
2018 are as follows:
(in thousands)
Corporate Securities
Government Securities
(in thousands)
Corporate Securities
Government Securities
December 31, 2019
Less than 12 months
12 months or greater
Fair value
Unrealized
losses
Fair value
Unrealized gain
(losses)
46,303
—
46,303
$
$
(24)
—
(24)
$
$
13,992
—
13,992
$
$
(6)
—
(6)
December 31, 2018
Less than 12 months
12 months or greater
Fair value
Unrealized
losses
Fair value
Unrealized
losses
84,666
176,225
260,891
$
$
(310)
(672)
(982)
$
$
17,805
116,830
134,635
$
$
(35)
(132)
(167)
$
$
$
$
The unrealized losses from the listed securities are due to a change in the interest rate environment and not a change
in the credit quality of the securities.
4. Sale of Additional Common Stock
In March 2018, we completed the sale of 8,395,000 shares of commons stock which included shares we issued
pursuant to our underwriters’ exercise of their over-allotment option pursuant to a follow-on financing. We received net
proceeds of $245.5 million, after underwriters’ discounts and offering expenses.
On September 19, 2016, we entered into an Equity Distribution Agreement (the Distribution Agreement) with Piper
Jaffray & Co (Piper Jaffray) pursuant to which we could sell from time to time, at our option, up to an aggregate of $40.0
million of common stock through Piper Jaffray as sales agent. We did not sell any shares under the Distribution Agreement,
and the Distribution Agreement terminated in October 2019.
5. Property and Equipment
Property and equipment consist of the following:
Computers, software and equipment
Furniture and fixtures
Leasehold and tenant improvements
Less accumulated depreciation and amortization
December 31,
2019
2018
(in thousands)
$
21,087 $
492
6,831
28,410
(12,605)
15,805
$
$
16,292
173
4,774
21,239
(9,426)
11,813
Depreciation and amortization expense related to property and equipment in 2019, 2018 and 2017 was $3.4 million,
$2.4 million and $1.2 million, respectively.
98
Table of Contents
6. Income Taxes
Our effective tax rate differs from the statutory federal income tax rate, primarily as a result of the changes in
valuation allowance. The provision for income taxes for the year ended December 31, 2019 was $0.3 million. There was no
tax provision for the year ended December 31, 2018, and the provision for income taxes for the year ended December 31,
2017 was a benefit of $0.5 million. Current tax expense of $0.3 million for the year ended December 31, 2019 represents
state alternative minimum tax.
A reconciliation of the federal statutory income tax to our effective income tax is as follows (in thousands):
Federal statutory income tax
State and local income taxes
Research and development credit
Stock based compensation
Effect of the 2017 Tax Cut and Jobs Act
State credit
Other
Net change in valuation allowance
Income tax provision (benefit)
2019
2017
Year Ended
December 31,
2018
$ 5,709 $ (14,795) $ (13,243)
(1,806)
(5,554)
2,709
19,596
—
720
(2,885)
(463)
2,549
(6,747)
1,927
—
1,725
(301)
(4,550)
312
(4,767)
(6,170)
444
—
—
414
24,874
— $
$
$
The tax effect of temporary differences that give rise to a significant portion of the deferred tax assets and liabilities
at December 31, 2019 and 2018 is presented below (in thousands):
Deferred income tax assets
Net operating loss carryforwards
Research credits
Depreciation
Unrealized loss on securities
Accrued compensation
Deferred revenue
State taxes
Gross deferred income tax assets
Valuation allowance
Net deferred income tax assets
Deferred income tax liabilities
Patent costs
Licensing costs
Capitalized legal costs
Unrealized gain on securities
Gross deferred income tax liabilities
Net deferred income tax asset
99
December 31,
2019
2018
$
$
36,891
28,415
334
—
4,788
11,215
64
81,707
(77,389)
4,318
(3,736)
(229)
(26)
(327)
(4,318)
$
— $
49,889
23,151
207
269
1,097
11,222
—
85,835
(82,537)
3,298
(3,142)
(125)
(31)
—
(3,298)
—
Table of Contents
The Tax Cuts and Jobs Act of 2017 (TCJA) was enacted in December 2017 and made substantial changes in the
U.S. tax system. One of the changes was elimination of the AMT tax system for corporations and allowance of an income tax
refund for AMT tax credit carryforwards as of December 31, 2017. We have reported an income tax receivable of $0.8
million and $1.6 million as of December 31, 2019 and 2018 to reflect the U.S. AMT credit carryforwards we have available,
which do not expire. Due to the uncertainty surrounding the realization of the benefits of our deferred tax assets in future tax
periods, we have placed a valuation allowance against our deferred tax assets at December 31, 2019 and 2018. The Company
recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. The
Company’s net deferred income tax asset is not more likely than not to be realized due to the lack of sufficient sources of
future taxable income and cumulative losses that have resulted over the years. During the year ended December 31, 2019, the
valuation allowance decreased by $5.1 million. Upon analysis, we determined that we experienced an ownership change
under Section 382 of the Internal Revenue Code and related state provisions as a result of our sale of preferred stock and sale
of common stock during 2013. Sections 382 and 383 of the Internal Revenue Code limit the amount of net operating losses
and tax credit forwards that may be available after a change in ownership. The Company has adjusted its net operating loss
and tax credit carryforwards to reflect the impact of the limitation under sections 382 and section 383 of the Internal Revenue
Code. The Company’s tax returns remain open to potential inspection for the years 2015 and onwards for federal purposes
and 2014 and onwards for state purposes.
As of December 31, 2019, we had cumulative net operating loss carryforwards for federal and state income tax
purposes of $144.7 million and $92.8 million respectively, and available tax credit carryforwards of approximately $19.7
million for federal income tax purposes and $11.0 million for state income tax purposes, which can be carried forward to
offset future taxable income, if any. The federal net operating loss carryforwards consists of $68.0 million of losses incurred
prior to January 1, 2018 and which can be used to offset 100% of future taxable income and $76.7 million of losses incurred
after January 1, 2018 which can be used to offset up to 80% of taxable income in subsequent years.
Our federal net operating loss carryforwards expire starting in 2026, state net operating losses expire starting in
2032, and federal tax credit carryforwards began to expire starting in 2019. A total of $0.03 million in federal tax credits
expired in 2019 and an additional $0.3 million will expire over the next five years if not utilized. Utilization of our net
operating loss and tax credit carryforwards are subject to a substantial annual limitation under Section 382 of the Code due to
the fact that we have experienced ownership changes. As a result of these changes, certain of our net operating loss and tax
credit carryforwards may expire before we can use them.
7. Stock-Based Compensation
Our Board of Directors and the requisite stockholders previously approved the 2010 Equity Incentive Plan (the 2010
Plan). In October 2013, our Board of Directors approved the 2013 Equity Incentive Plan (the 2013 Plan) and in
November 2013 our stockholders approved the 2013 Plan. The 2013 Plan provides for the grant of incentive stock options,
nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock
awards, performance cash awards, and other stock awards. The 2013 Plan became effective as of December 2, 2013, the date
of the pricing of the Company’s initial public offering. As of December 2, 2013, we suspended the 2010 Plan and no
additional awards may be granted under the 2010 Plan. Any shares of common stock covered by awards granted under the
2010 Plan that terminate after December 2, 2013 by expiration, forfeiture, cancellation or other means without the issuance
of such shares will be added to the 2013 Plan reserve.
As of December 31, 2019, the total number of shares of common stock available for issuance under the 2013 Plan
was 11,277,816. Unless otherwise determined by the Board, beginning January 1, 2014, and continuing until the expiration
of the 2013 Plan, the total number of shares of common stock available for issuance under the 2013 Plan will automatically
increase annually on January 1 by 4% of the total number of issued and outstanding shares of common stock as of
December 31 of the immediate preceding year. On January 1, 2019, the total number of shares of common stock available for
issuance under the 2013 Plan was automatically increased by 2,251,181 shares, which number is included in the number of
shares available for issuance above. As of December 31, 2019, a total of 8,893,515 options have been granted under the 2013
Plan.
100
Table of Contents
As of December 31, 2019, the Company has awarded 105,499 RSUs to certain employees pursuant to the 2013
Plan. Vesting of these awards will be in three equal annual installments and is contingent on continued employment terms.
The fair value of these awards is determined based on the intrinsic value of the stock on the date of grant and will be
recognized as stock-based compensation expense over the requisite service period.
In November 2013, our Board of Directors and stockholders approved the 2013 Employee Stock Purchase Plan
(ESPP), which became effective as of December 5, 2013. Under the ESPP our employees may elect to have between 1-15%
of their compensation withheld to purchase shares of the Company’s common stock at a discount. The ESPP had an initial
two-year term that includes four six-month purchase periods and employee withholding amounts may be used to purchase
Company stock during each six-month purchase period. The initial two-year term ended in December 2015 and pursuant to
the provisions of the ESPP, the second two-year term began automatically upon the end of the initial term. The total number
of shares that can be purchased with the withholding amounts are based on the lower of 85% of the Company’s common
stock price at the initial offering date or 85% of the Company’s stock price at each purchase date.
We have reserved a total of 581,286 shares of common stock for issuance under the ESPP. Unless otherwise
determined by our Board, beginning on January 1, 2014, and continuing until the expiration of the ESPP, the total number
shares of common stock available for issuance under the ESPP will automatically increase annually on January 1 by the
lesser of (i) 1% of the total number of issued and outstanding shares of common stock as of December 31 of the immediately
preceding year, or (ii) 621,814 shares of common stock. On January 1, 2014, the total number of shares of common stock
available for issuance under the ESPP was automatically increased by 313,545 shares, which number is included in the
number of shares reserved for issuance above. Pursuant to approval by our board, there were no increases in the number of
authorized shares in the ESPP in years from 2015 to 2019. As of December 31, 2019, we have issued a total of 417,277
shares of common stock under the ESPP.
Total employee, director and non-employee stock-based compensation expense recognized was as follows:
(in thousands)
General and administrative
Research and development
(in thousands)
Stock options
ESPP
RSUs
Year Ended
December 31,
2018
2019
7,699 $
8,854 $
22,997
31,851
12,849
$ 20,548
$
Year Ended
December 31,
2018
2019
30,502 $ 19,537 $
$
$
$
687
662
31,851
744
267
$ 20,548
$
$
2017
5,617
8,034
13,651
2017
13,153
498
—
13,651
Information with respect to stock options outstanding is as follows:
Exercisable options
Weighted average exercise price per share of exercisable options
Weighted average grant date fair value per share of options granted during the
year
Options available for future grants
Weighted average remaining contractual life
101
2019
December 31,
2018
3,950,965
3,058,659
$
17.79 $
15.12 $
2017
2,558,941
11.06
20.74 $
$
16.92
3,975,160 3,576,574 3,394,691
7.62
18.06 $
7.51
7.32
Table of Contents
The following table summarizes stock option activity for the years ended December 31, 2019 and 2018:
Balances at December 31, 2017
Options granted
Options forfeited
Options exercised(3)
Balances at December 31, 2018
Options granted
Options forfeited
Options exercised(3)
Balances at December 31, 2019
As of December 31, 2019
Options vested and expected to vest
Exercisable
Weighted-
Average
Exercise
Price
(Per Share)(1)
15.32
27.43
21.66
9.24
19.71
35.80
32.23
17.04
24.03
$
Number of
Shares
5,093,442
1,805,937
(107,720)
(824,731)
5,966,928
2,142,228
(390,950)
(543,887)
7,174,319
7,174,319
3,950,965
$
$
24.03
17.79
Weighted-
Average
Remaining
Contractual
Term
(in years)
7.62
Aggregate
Intrinsic Value
(in thousands)(2)
$
35,495
7.51
$
99,273
7.32
7.32
6.17
$
$
$
79,116
79,116
66,286
(1) The weighted average exercise price per share is determined using exercise price per share for stock options.
(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the option and the fair value of our common
stock for in-the-money options at December 31, 2019 and 2018.
(3) The total intrinsic value of stock options exercised was $11.5 million, $23.6 million and $5.7 million for the years ended
December 31, 2019, 2018 and 2017 respectively.
The stock options outstanding and exercisable by exercise price at December 31, 2019 are as follows:
Stock Options Outstanding
Stock Options Exercisable
Range of
Exercise
Prices
$0.59 – $4.25
$10.28 – $15.51
$15.69 – $23.75
$23.80 – $35.80
$36.03 – $44.19
Number of
Shares
238,621
1,378,151
2,878,221
1,071,704
1,607,622
7,174,319
Weighted-
Average
Remaining
Contractual
Term
(in years)
Weighted-
Average
Exercise Price
Per Share
3.45
5.37
7.04
8.66
9.16
7.32
$
$
$
$
$
$
3.49
12.21
21.37
31.18
37.22
24.03
Number of
Shares
238,621
1,350,781
1,963,376
276,042
122,145
3,950,965
$
$
$
$
$
$
Weighted-
Average
Exercise Price
Per Share
3.49
12.19
20.62
27.64
39.85
17.79
We estimated the fair value of employee and non-employee awards using the Black-Scholes valuation model. The
fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the
awards. Management estimates the probability of non-employee awards being vested based upon an evaluation of the non-
employee achieving their specific performance goals.
Options granted after our initial public offering are issued at the fair market value of our stock on the date of grant.
102
Table of Contents
The fair value of employee stock options was estimated using the following weighted average assumptions for the
years ended December 31, 2019, 2018 and 2017:
Common stock fair value per share
Expected volatility
Risk-free interest rate
Expected dividend yield
Expected term (in years)
Expected term (years)
Expected volatility
Risk-free interest rate
Expected dividend yield
2019
17.37 - 25.14
Options
2018
21.80 - 43.16
$
60.67% - 61.33% 70.97% - 73.10% 77.42% - 96.73%
2.29% - 3.10%
—
5.23 - 6.08
0.96% - 2.37%
—
5.23 - 6.08
2017
19.61 - 25.67
—
5.23 - 6.59
1.37% - 2.60%
$
$
2019
0.5 - 2.0
50.77% - 71.37%
1.47% - 2.70%
—
ESPP
2018
0.5 - 2.0
57.04% - 71.37%
1.47% - 2.70%
—
2017
0.5 - 2.0
67.83% - 79.76%
0.47% - 1.80%
—
The expected term of stock options represents the average period the stock options are expected to remain
outstanding. The expected stock price volatility for our stock options for the year ended December 31, 2019 was determined
using a blended volatility by examining the historical volatility for industry peer companies and the volatility of our stock
from the effective date that our shares were publicly traded on a national stock exchange. For years ended December 31,
2018 and 2017 expected stock volatility was determined by examining the historical volatilities for industry peers and
adjusting for differences in our life cycle and financing leverage. Industry peers consist of several public companies in the
biopharmaceutical industry.
We determined the average expected life of stock options based on the simplified method because our common
stock has not been publicly traded for an extended period, and we do not have a track record of our stock being traded on the
public markets for sufficient time to establish the volatility of our stock.
The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the
expected term of our stock options.
The expected dividend assumption is based on our history and expectation of dividend payouts.
The following table summarizes RSU activity for the years ended December 31, 2019:
Unvested at December 31, 2018
Granted
Vested
Forfeited
Unvested at December 31, 2019
Weighted-
Average
Grant Date
Fair Value
(Per Unit)
27.64
36.68
27.64
31.12
34.66
Number of
Shares
33,933
71,566
(11,311)
(4,182)
90,006
$
$
As of December 31, 2019 and 2018, the unamortized compensation expense related to unvested stock options was
$51.1 million and $42.8 million, respectively. The remaining unamortized compensation expense will be recognized over the
next 2.72 years. At December 31, 2019 and 2018, the unamortized compensation expense was $1.4 million and $0.8 million
respectively under our ESPP. The remaining unamortized expense will be recognized over the next 1.94 years. At December
31, 2019 and 2018, the unamortized compensation expense related to unvested restricted stock units was $2.5 million and
$0.7 million, respectively. The remaining unamortized compensation expense will be recognized over the next 2.43 years.
103
Table of Contents
8. Leases
The Company leases office and laboratory space in Monrovia, CA under a lease that continues through June 2020,
with an option to renew for an additional five years. In July 2017, the Company entered into an amended lease agreement for
additional space in the same building with a lease that continues through September 2022, also with an option to renew for an
additional five years. The Company assesses that it is likely to exercise both options of the lease term extensions.
The Company also leases office space in San Diego, CA through July 2020 which includes an option to renew for
an additional five years. The Company assesses that it is unlikely to exercise the option to extend this lease.
The Company leases additional office space in San Diego, CA through August 2022, with an option to extend for an
additional five years. The Company assesses that it is unlikely to exercise the option to extend the lease term.
The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants. As of
December 31, 2019, the Company did not have additional operating leases that have not yet commenced.
The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2019 to the
operating lease liabilities recorded on the balance sheet (in thousands):
Years ending December 31,
2020
2021
2022
2023
2024
Thereafter
Total undiscounted lease payments
Less: Imputed interest
Present value of lease payments
Lease liabilities - short-term
Lease liabilities - long-term
Total lease liabilities
$
$
$
$
2,703
2,588
2,208
1,352
1,371
2,282
12,504
(1,770)
10,734
2,169
8,565
10,734
Our operating lease cost and the cash payments for operating leases for the year ended December 31, 2019 were
$2.7 million and $2.6 million, respectively. Rent expense for the year ended December 31, 2018 was $2.5 million.
At December 31, 2019, the weighted-average remaining lease term for operating leases was 5.5 years, and the
weighted average discount rate for operating leases is 5.5%.
9. Commitments and Contingencies
Contingencies
From time to time, the Company may be subject to various litigation and related matters arising in the ordinary
course of business. The Company does not believe it is currently subject to any material matters where there is at least a
reasonable possibility that a material loss may be incurred.
104
Table of Contents
We are obligated to make future payments to third parties under in-license agreements, including sublicense fees,
royalties, and payments that become due and payable on the achievement of certain development and commercialization
milestones. As the amount and timing of sublicense fees and the achievement and timing of these milestones are not probable
and estimable, such commitments have not been included on our balance sheet. We have also entered into agreements with
third party vendors which will require us to make future payments upon the delivery of goods and services in future periods.
Guarantees
In the normal course of business, we indemnify certain employees and other parties, such as collaboration partners
and other parties that perform certain work on behalf of, or for the Company or take licenses to our technologies. We have
agreed to hold these parties harmless against losses arising from our breach of representations or covenants, intellectual
property infringement or other claims made against these parties in performance of their work with us.
These agreements typically limit the time within which the party may seek indemnification by us and the amount of
the claim. It is not possible to prospectively determine the maximum potential amount of liability under these
indemnification agreements since we have not had any prior indemnification claims on which to base the calculation.
Further, each potential claim would be based on the unique facts and circumstances of the claim and the particular provisions
of each agreement. We are not aware of any potential claims and we did not record a liability as of December 31, 2019 and
2018.
10. Collaboration and Licensing Agreements
Following is a summary description of the material revenue arrangements, including arrangements that generated
revenue in the period ended December 31, 2019, 2018, and 2017. The revenue reported for each agreement has been adjusted
to reflect the adoption of ASC 606 for each period presented.
Genentech
In February 2019, the Company entered into a collaboration and license agreement (the Genentech Agreement) with
Genentech, Inc. and F. Hoffman-La Roche Ltd (collectively, Genentech) for the development and commercialization of novel
IL-15 collaboration products (Collaboration Products), including XmAb24306, the Company’s IL-15/IL-15Ra candidate.
Under the terms of the Genentech Agreement, Genentech received an exclusive worldwide license to XmAb24306
and other Collaboration Products, including any new IL-15 programs identified during the joint research collaboration.
Genentech and Xencor will jointly collaborate on worldwide development of XmAb24306 and potentially other
Collaboration Products with Genentech maintaining all worldwide commercialization rights, subject to Xencor having an
option to co-promote in the United States. Xencor has the right to perform clinical studies of Collaboration Products in
combination with other therapeutic agents at its own cost, subject to certain restrictions.
The term of the Genentech Agreement will continue on a program-by-program and country-by-country basis until
there are no remaining payment obligations from Genentech to Xencor with respect to Collaboration Products. Genentech
may terminate the Genentech Agreement in its entirety or on a Collaboration Product-by-Collaboration Product basis by
providing prior written notice. Xencor may terminate the Agreement on a Collaboration Product-by-Collaboration Product
basis under certain circumstances. In the event of a termination of any individual Collaboration Product or the Genentech
Agreement in its entirety, the relevant rights revert to Xencor subsequent to negotiation of a termination agreement with
Genentech.
105
Table of Contents
The Company received a $120.0 million upfront payment and is eligible to receive up to an aggregate of $160.0
million in clinical milestone payments for XmAb24306 and up to $180.0 million in clinical milestone payments for each new
Collaboration Product. The Company is also eligible to receive 45% share of net profits for sales of XmAb24306 and other
Collaboration Products, while also sharing in net losses at the same percentage rate. The parties will jointly share in
development and commercialization costs for all programs designated as a development program under the Genentech
Agreement at the same percentage rate, while Genentech will bear launch costs entirely. The initial 45% profit-cost share
percentage is subject to a one-time downward adjustment at the Company’s discretion and convertible to a royalty under
certain circumstances.
Pursuant to the Genentech Agreement, XmAb24306 is designated as a development program and all costs incurred
for developing XmAb24306 from the effective date of the Genentech Agreement are being shared with Genentech under the
initial cost-sharing percentage.
Under the Genentech Agreement, the Company and Genentech will conduct joint research activities for a two-year
period to identify and discover additional IL-15 candidates developed from the Company’s cytokine and bispecific
technologies. The two-year research term may be extended an additional year if both parties agree. The Company and
Genentech are each responsible for their own costs in conducting the research activities. The Company is eligible for clinical
milestone payments for new Collaboration Products identified from the research efforts.
The Company evaluated the Genentech Agreement under the provisions of ASU No. 2014-09, Revenue from
Contracts with Customers and all related amendments (collectively, ASC 606) as well as ASC 808, Collaborative
Arrangements. Certain provisions of the Genentech Agreement including the cost-sharing of development programs are
governed by ASC 808. We have determined that Genentech is a customer for purposes of the delivery of specific
performance obligations under the Genentech Agreement and applied the provisions of ASC 606 to the transaction.
The Company identified the following performance obligations under the Genentech Agreement: (i) the license of
XmAb24306 and (ii) research services during a two-year period to identify up to potentially nine additional IL-15 candidates,
each a separate research program and a separate performance obligation. The Company determined that the license and each
of the potential research programs are separate performance obligations because they are capable of being distinct and are
distinct in the context of the Genentech Agreement. The license to XmAb24306 has standalone functionality as Genentech
has exclusive worldwide rights to the program, including the right to sublicense to third parties. Genentech has significant
experience and capabilities in developing and commercializing drug candidates similar to XmAb24306, and Genentech is
capable of performing these activities without the Company’s involvement. Upon the transfer of the license of XmAb24306,
Genentech could develop and commercialize XmAb24306 without further assistance from the Company. The Company
determined that the research services for each potential additional IL-15 candidate and research program were separate
standalone performance obligations. The Genentech Agreement provides an outline of an integrated research plan for the
programs to be conducted by the two companies, and the research activities are separate and distinct from the license to
XmAb24306.
The Company determined the standalone selling price of the license to be $114.4 million using the adjusted market
assessment approach considering similar collaboration and license agreements and transactions. The standalone selling price
for the research activities for all nine of the potential IL-15 programs to be performed during the research term was
determined to be $8.5 million using the expected cost approach which was derived from the Company’s experience and
information from providing similar research activities to other parties.
The Company determined that the transaction price of the Genentech Agreement at inception was $120.0 million
consisting of the upfront payment. The potential milestones are not included in the transaction price as these are contingent
on future events and the Company would not recognize these in revenue until it is not probable that these would not result in
significant reversal of revenue amounts in future periods. The Company will re-assess the transaction price at each reporting
period and when event outcomes are resolved or changes in circumstances occur.
The Company allocated the transaction price to each of the separate performance obligations using the relative
standalone selling price with $111.7 million allocated to the license to XmAb24306 and $8.3 million allocated to the research
services.
106
Table of Contents
The Company recognized the $111.7 million allocated to the license when it satisfied its performance obligation and
transferred the license to Genentech in March 2019. The license was transferred upon the effective date of the Genentech
Agreement and when the Company subsequently transferred certain data related to the program to Genentech. The $8.3
million allocated to the research activities is being recognized over a period of time through the end of the research term that
services are rendered as we determine that the input method is the appropriate approach to recognize income for such
services. A total of $2.2 million of revenue related to the research activities was recognized in the year ended December
31, 2019.
For the year ended December 31, 2019, we recognized $113.9 million of income from the Genentech Agreement.
As of December 31, 2019, there is a $0.9 million payable related to cost-sharing development activities during the fourth
quarter of 2019 for the XmAb24306 program. There is $6.1 million in deferred revenue as of December 31, 2019 which
reflects our obligation to perform research services during the research term.
Astellas
Effective March 29, 2019, the Company entered into a Research and License Agreement (Astellas Agreement) with
Astellas Pharma Inc. (Astellas) pursuant to which the Company and Astellas will conduct a discovery program to
characterize compounds and products for development and commercialization. Under the Astellas Agreement, Astellas was
granted a worldwide exclusive license, with the right to sublicense products in the field created by the research activities.
Pursuant to the Astellas Agreement, the Company will apply its bispecific Fc technology to research antibodies
provided by Astellas to generate bispecific antibody candidates and will conduct limited testing and characterization of the
bispecific candidates and return the candidates to Astellas for development and commercialization. The activities will be
conducted under a research plan agreed to by both parties to the Astellas Agreement. Astellas will assume full responsibility
for development and commercialization of the antibody candidate. Pursuant to the Astellas Agreement, the Company
received an upfront payment of $15.0 million and is eligible to receive up to $240.0 million in milestones which include
$32.5 million in development milestones, $57.5 million in regulatory milestones and $150.0 million in sales milestones. If
commercialized, the Company is eligible to receive royalties on net sales that range from the high-single to low-double digit
percentages.
We evaluated the Astellas Agreement under ASC 606 and identified the performance obligations under the
Agreement to be (i) delivery of bispecific antibodies to Astellas from the antigen provided by Astellas and (ii) research
activities against the bispecific antibodies as outlined in the research plan. The Company determined that the license to the
bispecific antibodies is not a separate performance obligation because it is not capable of being distinct, the license to the
antibodies cannot be separated from the underlying antibodies.
Astellas will control and benefit from the antibodies that are delivered. The Astellas Agreement provides Astellas
the right to sublicense the antibody to third parties and Astellas has significant experience and capabilities in developing and
commercializing clinical candidates and is capable of performing these activities from the delivered antibodies without the
Company’s involvement.
The Company determined the standalone selling price of the bispecific deliverable to be $17.1 million using the
income approach by calculating a risk adjusted net present value of the potential revenue that could be earned from the
arrangement. The standalone selling price for the research activities to be performed was determined to be $1.4 million using
the expected cost approach which was derived from the Company’s experience and information from providing similar
research activities to other customers.
The Company determined that the transaction price of the Astellas Agreement at inception was $15.0 million
consisting of the upfront payment. The potential milestones are not included in the transaction price as these are contingent
on future events and the Company would not recognize these in revenue until it is not probable that these would not result in
significant reversal of revenue amounts in future periods. The Company will re-assess the transaction price at each reporting
period and when event outcomes are resolved or changes in circumstances occur.
107
Table of Contents
The Company allocated the transaction price to each of the separate performance obligations using the relative
standalone selling price with $13.6 million allocated to delivery of the bispecific antibodies and the remainder of $1.4 million
was allocated to the research activities.
The Company recognized the $13.6 million allocated to the bispecific antibodies when it satisfied its performance
obligation and transferred the bispecific antibodies to Astellas. Astellas transferred the research antibodies to the Company
and the Company applied its bispecific technologies to and transferred the completed antibodies to Astellas in June 2019.
The $1.4 million allocated to the research activities is being recognized as the research services are being completed over the
period of time the Company expects to complete the activities under the research plan.
We recognized $14.0 million of revenue under this arrangement for the year ended December 31, 2019. There is
$1.0 million in deferred revenue as of December 31, 2019 related to our obligation to complete research activities under the
Astellas Agreement.
Novartis
In June 2016, the Company entered into a Collaboration and License Agreement (Novartis Agreement) with
Novartis Institutes for BioMedical Research, Inc. (Novartis), to develop and commercialize bispecific and other Fc
engineered antibody drug candidates using the Company’s proprietary XmAb® technologies and drug candidates. Pursuant
to the Novartis Agreement:
● The Company granted Novartis certain exclusive rights to research, develop and commercialize XmAb14045
and XmAb13676 (plamotamab), two development stage products that incorporate the Company’s bispecific Fc
technology;
● The Company will apply its bispecific technology in up to four target pair antibodies identified by Novartis
(each a Global Discovery Program); and
● The Company will provide Novartis with a non-exclusive license to certain of its Fc technologies to apply
against up to ten targets identified by Novartis.
In December 2018, Novartis notified the Company it was terminating its rights with respect to the plamotamab
program, which became effective June 2019. Under the Novartis Agreement, Novartis is responsible to fund its share of
plamotamab development costs through June 2020. In November 2019, the Company and Novartis amended the Agreement
and Novartis paid the Company $1.4 million in settlement of its projected remaining cost-sharing due for the plamotamab
program.
Pursuant to the Novartis Agreement, the Company will apply its bispecific technology to up to four target pair
antibodies selected, if available for exclusive license to Novartis and not subject to a Company internal program. The
Company will apply its bispecific technology to generate bispecific antibody candidates from starting target pair antibodies
provided by Novartis for each of the four Global Discovery Programs and return the bispecific product candidate to Novartis
for further testing, development and commercialization. Novartis has the right to substitute up to four of the original selected
target pair antibodies during the research term provided that Novartis has not submitted and received allowance for an
Investigational New Drug Application (IND) application with the Company provided bispecific antibody candidate. The
research term is five years from the date of the Novartis Agreement.
We completed delivery of a Global Discovery Program in 2017 and delivery of a second Global Discovery Program
in 2018. In December 2019, Novartis dosed a patient in a Phase 1 study with an undisclosed bispecific antibody that is a
Global Discovery Program, and we received a $10.0 million milestone payment.
Novartis will assume full responsibility for development and commercialization of each product candidate under
each of the Global Discovery Programs.
108
Table of Contents
The Company evaluated the Novartis Agreement under the new revenue recognition standard ASC 606 and
concluded that Novartis is a customer. The Company identified the following performance obligations that it deemed to be
distinct at the inception of the contract:
● License to certain rights to our XmAb14045 and plamotamab;
● Develop four bispecific antibody drug candidates against four targets identified by Novartis; and
● License to our Fc technologies for up to 10 targets identified and selected by Novartis.
The Company considered the licenses as functional intellectual property as Novartis has the right to access its
technology and such technology is functional to Novartis at the time that the Company provides access. Under the Novartis
Agreement, Novartis has substitution rights under each discovery program provided it has not advanced to submitting an
IND. The Company’s obligation to provide services related to the discovery programs, and Novartis’ right to substitute
programs is limited to the five-year period from the date of the Novartis agreement.
The Company determined the transaction price at inception is the $150.0 million upfront payment to be allocated to
the performance obligations. The Novartis Agreement includes variable consideration for potential future milestones and
royalties that were contingent on future success factors for development programs. The Company used the “most likely”
method to determine the variable consideration. In the third quarter of 2019, the Company recorded a $10.0 million
development milestone related to a Global Discovery program, and this amount was included in the transaction price as
uncertainty associated with it has been resolved. None of the development, regulatory or sales milestones or royalties were
included in the transaction price. The Company will re-evaluate the transaction price in each reporting period as uncertain
events are resolved or other changes in circumstances occur.
The Company determined the transaction price at inception of the Novartis Agreement and allocated it to the
various performance obligations using the standalone selling price which is comparable to the relative selling price
methodology used in the original accounting treatment for the transaction.
The transaction price of $160.0 million was allocated to the performance obligations as follows:
*
*
*
*
$27.1 million to certain rights to the XmAb14045 program;
$31.4 million to certain rights to the plamotamab program;
$90.2 million to the four Global Discovery Programs; and
$11.3 million to the Fc licenses.
Under ASC 606, revenue is recognized at the time that the Company’s performance obligation for each Global
Discovery is completed upon delivery of each discovery program to Novartis. The Company delivered a discovery program
to Novartis in 2017 and recognized $20.1 million of revenue in the period of delivery. In the third quarter of 2018, the
Company delivered a second discovery program to Novartis and is recognizing an additional $20.0 million of revenue. In the
third quarter of 2019, Novartis received notice of approval for an investigational new study (IND) from the Federal and Drug
Administration (FDA) for an application submitted for a Global Discovery Program and we recognized $10.0 million of
revenue.
Under ASC 606 the entire amount of revenue allocated to the Fc licenses is being recognized at inception of the
Novartis Agreement, the second quarter of 2016.
During the year ended December 31, 2019, 2018 and 2017, the Company recognized $10.0 million, $20.0 million
and $20.1 million of revenue respectively. As of December 31, 2019, there is a receivable of $12.2 million and $40.1 million
in deferred revenue related to the arrangement.
109
Table of Contents
Amgen Inc.
In September 2015, the Company entered into a research and license agreement (the Amgen Agreement) with
Amgen Inc. (Amgen) to develop and commercialize bispecific antibody product candidates using the Company’s proprietary
XmAb® bispecific Fc technology. Under the Amgen Agreement, the Company granted an exclusive license to Amgen to
develop and commercialize bispecific drug candidates from the Company’s preclinical program that bind the CD38 antigen
and the cytotoxic T-cell binding domain CD3, (the CD38 Program). The Company also agreed to apply its bispecific
technology to five previously identified Amgen provided targets (each a Discovery Program). The Company received a $45.0
million upfront payment and milestones totaling $15.5 million from Amgen and is eligible to receive up to $600.0 million in
future development, regulatory and sales milestones in total for programs in development and is eligible to receive royalties
on any global net sales of products.
Pursuant to the Amgen Agreement, the Company applied its bispecific technology to five Discovery Programs
antibody molecules provided by Amgen that bind Discovery Program targets and returned the bispecific product candidates
to Amgen for further testing, development and commercialization. The initial research term was three years from the date of
the Amgen Agreement, but Amgen, pursuant to its option, requested an extension of one year. The Company received
research funding for the additional services provided during the extended research term.
Amgen will assume full responsibility for development and commercialization of product candidates under each of
the Discovery Programs.
The Company evaluated the Amgen Agreement under ASC 606 and determined that it is a customer and that
delivery of the CD38 Program and each of the five Discovery Programs represent the performance obligations under the
contract.
The Company determined the transaction price at inception is the $45.0 million upfront payment to be allocated to
the performance obligations. The Amgen Agreement includes variable consideration for potential future milestones and
royalties that were contingent on future success factors for development programs. The Company used the “most likely”
method to determine the variable consideration. In the fourth quarter of 2017, the Company received a $10.0 million
development milestone related to the CD38 program, now AMG 424, and this payment was included in the transaction price
as uncertainty associated with it has been resolved. In the fourth quarter of 2018, the Company received a $0.5 million
preclinical milestone related to one of the Discovery Programs. In the third quarter of 2019, the Company recognized a $5.0
million milestone related to one of the Discovery Programs.No other development, regulatory or sales milestones or royalties
were included in the transaction price. The Company will re-evaluate the transaction price in each reporting period and as
uncertain events are resolved or other changes in circumstances occur.
In allocating the transaction price determined at inception, the Company determined that ASC 606 provides the use
of a standalone selling price for the transaction.
The transaction price of $60.5 million was allocated to the performance obligations as follows:
*
*
$23.75 million to the CD38 program and
$36.75 million in total to the five Discovery Programs
Under ASC 606, the amount of revenue recognized for the CD38 program is recognized at the inception of the
contract when delivery of the CD38 program and materials was transferred to Amgen. The $10.0 million milestone revenue
was recognized in the period that the uncertainty regarding the event is resolved, i.e. when the milestone event occurred.
The Company completed performance obligations for the five Discovery Programs in 2016 when all five of the
Discovery Programs were delivered to Amgen. In the fourth quarter of 2018, a $0.5 million milestone payment was received
in connection with a preclinical development of a Discovery Program. In the third quarter of 2019, a $5.0 million milestone
was recognized in connection with a development milestone for a Discovery Program.
110
Table of Contents
In the third quarter of 2018, the Company and Amgen agreed upon additional scope of work to be performed by the
Company; the work was completed in 2018, and the Company recorded additional revenue of $0.1 million for the additional
services provided.
During the years ended December 31, 2019, 2018 and 2017, the Company recognized $5.0 million, $0.6 million and
$10.0 million in revenue, respectively, under this arrangement. As of December 31, 2019, there was a $5.0 million
receivable, and there was no deferred revenue related to the arrangement.
MorphoSys AG
In June 2010, the Company entered into a Collaboration and License Agreement with MorphoSys AG
(MorphoSys), which was subsequently amended in March 2012. The agreement provided us an upfront payment of $13.0
million in exchange for an exclusive worldwide license to the Company’s patents and know-how to research, develop and
commercialize our XmAb5574 product candidate (subsequently renamed MOR208 and tafasitamab) with the right to
sublicense under certain conditions. If certain developmental, regulatory and sales milestones are achieved, the Company is
eligible to receive future milestone payments and royalties.
In June 2017, MorphoSys initiated a Phase 3 clinical trial under the arrangement for which the Company received a
milestone payment of $12.5 million. The Company recognized the payment as revenue in the period that the milestone event
occurred.
The Company recognized $12.5 million of revenue for the year end December 31, 2017. There were no revenues
recognized under this arrangement for the years ended December 31, 2019 and 2018. As of December 31, 2019, the
Company has no deferred revenue related to this agreement.
Alexion Pharmaceuticals, Inc.
In January 2013, the Company entered into an option and license agreement with Alexion Pharmaceuticals, Inc.
(Alexion). Under the terms of the agreement, the Company granted to Alexion an exclusive research license, with limited
sublicensing rights, to make and use our Xtend technology to evaluate and advance compounds against six different target
programs. Alexion exercised its rights to one target program, ALXN1210, which is now marketed as Ultomiris.
The Company is eligible to receive contractual milestones for certain development, regulatory and commercial
achievements. If licensed products are successfully commercialized, the Company is also entitled to receive royalties based
on a percentage of net sales of such products sold by Alexion, its affiliates or its sub licensees, which percentage is in the low
single digits. Alexion’s royalty obligations continue on a product-by-product and country-by-country basis until the
expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country.
In the third quarter of 2018, Alexion completed certain regulatory submissions for Ultomiris, and the Company
received $9.0 million in milestone payments. In the fourth quarter of 2018, Alexion completed certain regulatory
submissions for Ultomiris and also received FDA marketing approval, and the Company received $11.0 million in milestone
payments.
In the second and third quarter of 2019, Alexion completed certain regulatory submissions for Ultomiris, and the
Company received a total of $8.0 million in milestone payments. During 2019, the Company also recorded royalty revenue
of $5.0 million in connection with reported net sales of Ultomiris by Alexion.
The Company determined Alexion to be a customer and the license of the Company’s Xtend intellectual property is
functional intellectual property, distinct and is the only performance obligation under the agreement. Under ASC 606 the
upfront payment was recognized at inception of the agreement when Alexion was provided access to the technology.
111
Table of Contents
The total revenue recognized under this arrangement was $13.0 million and $20.0 million for the years ended
December 31, 2019 and 2018, respectively. There was no revenue recognized for the year ended December 31, 2017. As of
December 31, 2019, there is a receivable of $4.1 million, and there is no deferred revenue related to this agreement.
CSL Limited
In February 2009, the Company entered into a research license and commercialization agreement with CSL Limited
(CSL). Under the agreement, the Company provided CSL with a research license to our Fc Cytotoxic technology and options
to non-exclusive commercial licenses. CSL elected to exercise one commercial license for a compound, CSL362.
In 2013 CSL sublicensed CSL362 (now called talacotuzumab) to Janssen Biotech Inc. (Janssen Biotech). In March
2017, CSL, through its sub-licensee, Janssen Biotech, initiated a Phase 3 clinical trial for CSL362 and the Company received
a milestone payment of $3.5 million.
There was no revenue recognized for the years ended December 31, 2019 and 2018. Total revenue recognized for
the year ended December 31, 2017 was $3.5 million. As of December 31, 2019, there is no deferred revenue related to this
agreement.
INmune Bio, Inc.
In October 2017, the Company entered into a License Agreement with INmune Bio, Inc. (INmune). Under the terms
of the agreement, the Company provided INmune with an exclusive license to certain rights to a proprietary protein,
XPRO1595. Under the agreement the Company received an upfront payment of $100,000, a 19% fully diluted equity interest
in INmune and an option to acquire additional shares of INmune. The Company is eligible to receive a percentage of
sublicensing revenue received for XPRO1595 and also royalties in the mid-single digit percent range on the sale of approved
products.
The equity interest in INmune constituted 1,585,000 shares of common stock, and the option is to purchase an
additional 10% of the fully diluted interest in INmune for $10.0 million.
In 2018, INmune filed a registration statement on a Form S-1 with the Securities and Exchange Commission (SEC)
which was declared effective by the SEC on December 19, 2018.
Under ASC 606, the Company determined that the performance obligation under the agreement was the license to
XPRO1595 and performance occurred at the effective date of the agreement. The total consideration under the agreement
was determined to be $100,000 as the equity interest and the option had an insignificant fair value. The Company recognized
$100,000 as revenue related to the agreement for the year ended December 31, 2017 and did not recognize any revenue
related to the agreement for the years ended December 31, 2019 or 2018. There is no deferred revenue as of December 31,
2019 related to this agreement.
Vir Biotechnology, Inc.
In the third quarter of 2019, the Company entered into a Patent License Agreement (the VirBio Agreement) with
VIR Biotechnology (VirBio) pursuant to which the Company provided a non-exclusive license to its Xtend technology for up
to two targets. Under the terms of the VirBio Agreement, the Company received an upfront payment and is eligible to receive
total milestones of $155.25 million which include $5.25 million of development milestones, $30.0 million of regulatory
milestones and $120.0 million of sales milestones. In addition, the Company is eligible to receive royalties on the net sales of
approved products in the low-single digits.
The Company evaluated the VirBio Agreement and determined that the single performance obligation was access to
a non-exclusive license to certain patents of the Company which were transferred to VirBio upon execution of the VirBio
Agreement in July 2019.
112
Table of Contents
The Company recognized $0.8 million of license and milestone revenue related to the agreement for the year ended
December 31, 2019. There is no deferred revenue as of December 31, 2019 related to this agreement.
Revenue Earned
The $156.7 million, $40.6 million and $46.2 million of revenue recorded for the years ended December 31, 2019,
2018 and 2017, respectively, were earned principally from the following licensees (in millions):
Amgen
Alexion
Astellas
CSL
Genentech
MorphoSys
Novartis
Other
Total
Year Ended
December 31,
2018
2017
2019
$
$
5.0
13.0
14.0
—
113.9
—
10.0
0.8
156.7
$
$
0.6
20.0
—
—
—
—
20.0
—
40.6
$
$
10.0
—
—
3.5
—
12.5
20.1
0.1
46.2
The below table summarizes the disaggregation of revenue recorded for the years ended December 31, 2019, 2018
and 2017 (in millions):
Research collaboration
Milestone
Licensing
Royalties
Total
Year Ended
December 31,
2018
2019
$
$
16.3
23.2
112.2
5.0
156.7
$
$
20.1
20.5
—
—
40.6
$
$
2017
20.1
26.0
0.1
—
46.2
A portion of our revenue is earned from collaboration partners outside the United States. Non-U.S. revenue is
denominated in U.S. dollars. A breakdown of our revenue from U.S. and non-U.S. sources for the years ended December 31,
2019, 2018 and 2017 is as follows (in millions):
U.S. Revenue
Non-U.S. Revenue
Total
Year Ended
December 31,
2018
2019
$
$
142.7
14.0
156.7
$
$
40.6
—
40.6
$
$
2017
30.2
16.0
46.2
Remaining Performance Obligations and Deferred Revenue
Our remaining performance obligations are delivery of two additional Global Discovery Programs under the
Novartis Agreement and conducting research activities pursuant to research plans under the Genentech and Astellas
Agreements. As of December 31, 2019 and 2018, we have deferred revenue of $47.1 million and $40.1 million, respectively.
As of December 31, 2019, $45.2 million of deferred revenue was classified as current liabilities as our obligations to perform
services are due on demand when requested by Novartis and Astellas under the Novartis and Astellas Agreements,
respectively. A total of $1.9 million of deferred liability is classified as long-term for the obligation to perform research
services to Genentech under the Genentech Agreement after one year.
113
Table of Contents
11. 401(k) Plan
We have a 401(k)-plan covering all full-time employees. Employees may make pre-tax contributions up to the
maximum allowable by the Internal Revenue Code. Effective January 1, 2018, the Company contributes 100% of the first 1%
of participating employees’ contribution and 50% of the next 5% of participating employees’ contribution, for a maximum of
3.5% employer contribution. Participants are immediately vested in their employee contributions; employer contributions are
vested over a three-year period with one-third for each year of a participating employee’s service. Employer contributions
made for the year ended December 31, 2019 and 2018 were $0.6 million and $0.5 million, respectively. No employer
contributions were made for the year ended December 31, 2017.
12. Condensed Quarterly Financial Data (unaudited)
The following table contains selected unaudited financial data for each quarter of 2019 and 2018. The unaudited
information should be read in conjunction with the Company’s financial statements and related notes included elsewhere in
this Annual Report. The Company believes that the following information reflects all normal recurring adjustments necessary
for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily
indicative of results for any future period.
Quarterly Financial Data (in thousands, except per share data):
Total revenue
Income (loss) from operations
Net income (loss)
Basic net income (loss) per common share
Diluted net income (loss) per common share
Total revenue
Income (loss) from operations
Net income (loss)
Basic net income (loss) per common share
Diluted net income (loss) per common share
13. Subsequent Event
Gilead and Aimmune Agreements
2019 Quarter Ended
$
$
March 31,
111,939
78,244
80,045
1.42
1.38
June 30,
September 30, December 31,
$
19,485
(19,572)
(16,034)
(0.28)
(0.28)
$
21,760
(14,276)
(10,224)
(0.18)
(0.18)
3,516
(30,572)
(26,912)
(0.47)
(0.47)
2018 Quarter Ended
March 31,
June 30,
$
— $
September 30, December 31,
$
— $
(30,649)
(29,493)
(0.62)
(0.62)
(28,290)
(25,869)
(0.46)
(0.46)
29,039
651
3,150
0.06
0.05
11,564
(21,082)
(18,197)
(0.32)
(0.32)
In January and February 2020, the Company entered into license agreements with Gilead and with Aimmune,
respectively for the license of Company technologies and drug candidates. Under the Gilead agreement, the Company
licensed restricted access to its cytotoxic and Xtend technologies and the Company received a $6.0 million upfront payment
and is eligible to receive additional milestones and potential royalties under the license agreement. Under the Aimmune
agreement, the Company licensed the worldwide exclusive rights to its XmAb7195 drug candidate, and the Company will
receive a $5.0 million upfront payment and common stock of Aimmune with an aggregate value of $5.0 million. Aimmune
will be responsible for all development activities for XmAb7195 and the Company is eligible to receive additional
milestones and potential royalties under the arrangement.
114
Table of Contents
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure
controls and procedures as of December 31, 2019. The term "disclosure controls and procedures," as defined in Rules 13a-
15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure
that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information
is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation our Chief Executive Officer
and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2019 at
the reasonable assurance level.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting
(as defined in Rule 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended). Our management,
Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial
reporting as of December 31, 2019. In making this assessment, our management used the criteria set forth by the Committee
of Sponsoring Organizations of the Treadway Commission (2013 Framework) (COSO) in Internal Control—Integrated
Framework. Based on that assessment and using the COSO criteria, our management, Chief Executive Officer and Chief
Financial Officer have concluded that, as of December 31, 2019, our internal control over financial reporting was effective.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting during the year ended December 31, 2019,
that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations of Controls
Management does not expect that our disclosure controls and procedures or our internal control over financial
reporting will prevent or detect all error and all fraud. Controls and procedures, no matter how well designed and operated,
can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in
evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within
the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be
faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by
the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The
design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and
there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over
time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the
policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or
fraud may occur and not be detected.
115
Table of Contents
Attestation in Internal Control over Financial Reporting
RSM US LLP, our independent registered public accounting firm, has audited our financial statements for the year
ended December 31, 2019 and has issued an audit report on the effectiveness of the Company’s internal control over
financial reporting as of December 31, 2019, which is included in Item 8 of this Annual Report.
Item 9B. Other Information
Not applicable.
Item 10. Directors, Executive Officers and Corporate Governance
PART III
We have adopted a code of ethics for directors, officers (including our principal executive officer, principal financial
officer and principal accounting officer) and employees, known as the Code of Business Conduct and Ethics. The Code of
Business Conduct and Ethics is available on our website at http://www.xencor.com under the Corporate Governance section
of our Investor Relations page. We will promptly disclose on our website (i) the nature of any amendment to the policy that
applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons
performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the policy
that is granted to one of these specified individuals that is required to be disclosed pursuant to SEC rules and regulations, the
name of such person who is granted the waiver and the date of the waiver.
The other information required by this item and not set forth below will be set forth in our 2020 Annual Meeting of
Stockholders (Proxy Statement) to be filed with the SEC within 120 days after the end of the fiscal year ended December 31,
2019, and is incorporated herein by reference.
Audit Committee
The information required by this item will be set forth in the Proxy Statement and incorporated herein by reference.
Item 11. Executive Compensation
The information required by this item will be set forth in the Proxy Statement and is incorporated herein by
reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this item will be set forth in the Proxy Statement and is incorporated herein by
reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this item will be set forth in the Proxy Statement and is incorporated herein by
reference.
Item 14. Principal Accounting Fees and Services
The information required by this item will be set forth in the Proxy Statement and is incorporated herein by
reference.
116
Table of Contents
Item 15. Exhibits, Financial Statement Schedules
1.
Financial Statements. We have filed the following documents as part of this Annual Report:
Report of Independent Registered Public Accounting Firm (RSM US LLP)
Balance Sheets
Statements of Comprehensive Income (Loss)
Statements of Stockholders’ Equity
Statements of Cash Flows
Notes to Financial Statements
Page
82
85
86
87
88
89
Financial Statement Schedules. All schedules have been omitted because they are not applicable or
2.
required, or the information required to be set forth therein is included in the Financial Statements or notes thereto
included in Item 8 of this Annual Report on Form 10-K.
3.
Exhibits.
Exhibit
Number
Description
3.1
Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to
Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2013).
3.2
4.1
4.2*
Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the
Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2013).
Form of Common Stock Certificate of the Company (incorporated by reference to Exhibit 4.1 to the
Company’s Registration Statement on Form S-1, as amended (File No. 333-191689), originally filed with
the SEC on October 25, 2013).
Third Amended and Restated Investor Rights Agreement, dated June 26, 2013, among the Company and
certain of its stockholders incorporated by reference to Exhibit 4.2 to the Company’s Registration
Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 11,
2013).
4.3
Description of the Common Stock of the Company
10.1*
10.2*
10.3*
Form of Indemnity Agreement between the Company and its directors and officers (incorporated by
reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-1, as amended (File
No. 333-191689), originally filed with the SEC on October 11, 2013).
Xencor, Inc. 2010 Equity Incentive Plan, as amended, and Form of Stock Option Grant Notice, Option
Agreement and Form of Notice of Exercise (incorporated by reference to Exhibit 10.2 to the Company’s
Registration Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on
October 11, 2013).
Xencor, Inc. 2013 Equity Incentive Plan and Form of Stock Option Agreement and Form of Stock Option
Grant Notice thereunder (incorporated by reference to Exhibit 10.3 to the Company’s Registration
Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 11,
2013).
117
Table of Contents
10.4*
10.5*
10.6*
10.7*
10.8*
10.9*
10.10*
10.11*
10.12†
10.13†
10.14†
10.15†
Xencor, Inc. 2013 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 to the
Company’s Registration Statement on Form S-1, as amended (File No. 333-191689), originally filed with
the SEC on October 11, 2013).
Second Amended and Restated Executive Employment Agreement, dated January 1, 2007, by and between
the Company and Dr. Bassil I. Dahiyat (incorporated by reference to Exhibit 10.6 to the Company’s
Registration Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on
October 11, 2013).
Offer Letter, dated September 28, 2009, by and between the Company and Dr. Bruce Carter (incorporated
by reference to Exhibit 10.8 to the Company’s Registration Statement on Form S-1, as amended (File
No. 333- 191689), originally filed with the SEC on October 11, 2013).
Amendment to Offer Letter, dated November 18, 2010, by and between the Company and Dr. Bruce Carter
(incorporated by reference to Exhibit 10.9 to the Company’s Registration Statement on Form S-1, as
amended (File No. 333-191689), originally filed with the SEC on October 11, 2013).
Amended and Restated Executive Employment Agreement, dated September 4, 2013, by and between the
Company and Dr. Bassil I. Dahiyat (incorporated by reference to Exhibit 10.12 to the Company’s
Registration Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on
October 11, 2013).
Offer Letter, dated September 5, 2013, by and between the Company and Dr. Edgardo Baracchini, Jr.
(incorporated by reference to Exhibit 10.13 to the Company’s Registration Statement on Form S-1, as
amended (File No. 333-191689), originally filed with the SEC on October 11, 2013).
Amended and Restated Severance Agreement, dated September 5, 2013, by and between the Company and
Dr. John R. Desjarlais (incorporated by reference to Exhibit 10.14 to the Company’s Registration
Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 11,
2013).
Amended and Restated Change in Control Agreement, dated September 5, 2013, by and between the
Company and John J. Kuch (incorporated by reference to Exhibit 10.15 to the Company’s Registration
Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 11,
2013).
Collaboration and License Agreement, dated June 27, 2010, by and between the Company and MorphoSys
AG (incorporated by reference to Exhibit 10.19 to the Company’s Registration Statement on Form S-1, as
amended (File No. 333-191689), originally filed with the SEC on October 11, 2013).
First Amendment to the Collaboration and License Agreement, dated March 23, 2012, by and between the
Company and MorphoSys AG (incorporated by reference to Exhibit 10.20 to the Company’s Registration
Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 11,
2013).
Option and License Agreement, dated January 28, 2013, by and between the Company and Alexion
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.23 to the Company’s Registration Statement
on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 11, 2013).
Collaboration Agreement, dated February 10, 2012, by and between the Company and Boehringer
Ingelheim International GmbH (incorporated by reference to Exhibit 10.24 to the Company’s Registration
Statement on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 11,
2013).
118
Table of Contents
10.16†
Cross-License Agreement, dated December 19, 2012, by and between the Company and
MedImmune, LLC (incorporated by reference to Exhibit 10.26 to the Company’s Registration Statement
on Form S-1, as amended (File No. 333-191689), originally filed with the SEC on October 11, 2013).
10.17
10.18
10.19
10.20†
10.21*
10.22*
10.23*
10.24*
10.25†
10.26†
10.27
10.28
10.29
Lease dated January 1, 2015 by and between the Company and BF Monrovia, LLC (incorporated by
reference to Exhibit 99.1 to the Company’s Form 8-K filed with the SEC on January 5, 2015).
Master Service Agreement dated July 14, 2014 by and between the Company and KBI Biopharma, Inc.
(incorporated by reference to Exhibit 10.26 to the Company’s Form 10-K filed with the SEC on February
20, 2015)
Amendment to Lease dated January 27, 2015 by and between the Company and BF Monrovia, LLC.
(incorporated by reference to Exhibit 10.27 to the Company’s Form 10-K filed with the SEC on February
20, 2015).
Research and License Agreement effective September 15, 2015 between the Company and Amgen Inc.,
(incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed with the SEC on November
4, 2015).
Employment Agreement dated December 16, 2015 by and between the Company and Dr. Paul Foster
(incorporated by reference to Exhibit 10.29 to the Company's Form 10-K filed with the SEC on March 8,
2016).
Severance Agreement, dated May 26, 2016 by and between the Company and Bassil Dahiyat (incorporated
by reference to Exhibit 10.1 to the Company's Form 10-Q filed with the SEC on August 3, 2016).
Severance Agreement, dated May 26, 2016 by and between the Company and John Kuch (incorporated by
reference to Exhibit 10.2 to the Company's Form 10-Q filed with the SEC on August 3, 2016).
Severance Agreement, dated May 26, 2016 by and between the Company and John Desjarlais
(incorporated by reference to Exhibit 10.3 to the Company's Form 10-Q filed with the SEC on August 3,
2016).
Collaboration and License Agreement, dated June 26, 2016, by and between the Company and Novartis
Institutes for BioMedical Research, Inc. (incorporated by reference to Exhibit 10.6 to the Company's Form
10-Q filed with the SEC on August 3, 2016).
Amendment No. 1, dated September 21, 2016, to the Collaboration and License Agreement by and
between the Company and Novartis Institutes for BioMedical Research, Inc. (incorporated by reference to
Exhibit 10.2 to the Company's Form 10-Q filed with the SEC on November 2, 2016).
Office Lease, dated June 21, 2017, by and among the Company and PRII High Bluffs LLC and Collins
Corporate Center Partners, LLC (incorporated by reference to Exhibit 99.1 to the Company’s Form 8-K
filed with the SEC on June 26, 2017).
Second Amendment to Lease, dated July 5, 2017, by and between the Company and 111 Lemon Investors
LLC (incorporated by reference to Exhibit 99.1 to the Company’s Form 8-K filed with the SEC on July 10,
2017).
Transition and Separation Agreement, executed July 31, 2018, by and between the Company and Edgardo
Baracchini, Jr. (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed with the SEC
on August 7, 2018).
119
Table of Contents
10.30†
10.31
Collaboration and License Agreement, dated February 4, 2019, by and between the Company and
Genentech, Inc. and F. Hoffman-La Roche LTD (incorporated by reference to Exhibit 10.1 to the
Company’s Form 10-Q filed with the SEC on May 9, 2019).
Transition and Separation Agreement and Release, executed June 21, 2019, by and between the Company
and Paul Foster (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed with the
SEC on August 6, 2019).
10.32*
Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy (incorporated by
reference to Exhibit 10.1 to the Company’s Form 10-Q filed with the SEC on November 5, 2019).
10.33*
Employment Agreement dated August 5, 2019 by and between the Company and Celia Eckert.
10.34*
Employment Agreement dated November 13, 2019 by and between the Company and Dr. Allen Yang,
M.D., Ph.D.
23.1
31.1
31.2
32.1**
32.2**
Consent of Independent Registered Public Accounting Firm (RSM US LLP).
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities
Exchange Act of 1934.
Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities
Exchange Act of 1934.
Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
XBRL Instance Document – The instance document does not appear in the Interactive Data File because its
XBRL tags are embedded within the inline XBRL document.
101.SCH
XBRL Taxonomy Extension Schema Document.
101.CAL
XBRL Taxonomy Extension Schema Document.
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB
XBRL Taxonomy Extension Label Linkbase Document.
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document.
104
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
† We have received confidential treatment for certain portions of this agreement, which have been omitted and filed
separately with the SEC pursuant to Rule 406 under the Securities Act of 1933, as amended.
* Indicates management contract or compensatory plan.
** These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350,
and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be
incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless
of any general incorporation language in such filing.
120
Table of Contents
Item 16. Form 10-K Summary
None.
121
Table of Contents
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: February 24, 2020
Xencor, Inc.
By:
/s/ BASSIL I. DAHIYAT, PH.D.
Bassil I. Dahiyat, Ph.D.
President & Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and
appoints Bassil I. Dahiyat, Ph.D. and John J. Kuch, and each of them, his true and lawful attorneys-in-fact, each with full
power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to
file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange
Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do
or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the Company and in the capacities and on the dates indicated.
Signature
Title
Date
/s/ BASSIL I. DAHIYAT, PH.D.
Bassil I. Dahiyat, Ph.D.
Director, President & Chief Executive
Officer (Principal Executive Officer)
February 24, 2020
/s/ JOHN J. KUCH
John J. Kuch
Sr. Vice President & Chief Financial Officer
(Principal Financial and Accounting
Officer)
/s/ A. BRUCE MONTGOMERY, M.D.
A. Bruce Montgomery, M.D.
/s/ KURT GUSTAFSON
Kurt Gustafson
/s/ YUJIRO S. HATA
Yujiro S. Hata
/s/ KEVIN C. GORMAN, PH.D.
Kevin C. Gorman, Ph.D.
/s/ RICHARD RANIERI
Richard Ranieri
/s/ ELLEN G. FEIGAL, M.D.
Ellen G. Feigal, M.D.
/s/ DAGMAR ROSA-BJORKESON
Dagmar Rosa-Bjorkeson
Director
Director
Director
Director
Director
Director
Director
122
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
DESCRIPTION OF COMMON STOCK
Exhibit 4.3
The following summary description of the common stock of Xencor, Inc. (we, our or us) is based on the provisions of our amended
and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware
General Corporation Law. This information is qualified entirely by reference to the applicable provisions of our amended and restated
certificate of incorporation, our amended and restated bylaws and the Delaware General Corporation Law. Our amended and restated
certificate of incorporation and amended and restated bylaws have previously been filed as exhibits with the Securities and Exchange
Commission.
Voting. Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders,
including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of
our common stock entitled to vote in any election of directors can elect all of the directors standing for election.
Dividends. Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are
entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.
Liquidation. In the event of our liquidation, dissolution or winding-up, holders of our common stock will be entitled to share ratably
in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to
the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.
Rights and Preferences. Holders of our common stock have no preemptive, conversion or subscription rights, and there are no
redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our
common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock
that we may designate and issue in the future.
Fully Paid and Nonassessable. All of our outstanding shares of common stock are fully paid and nonassessable.
The laws of the State of Delaware, the state of our incorporation, provide that the holders of preferred stock will have the right to vote
separately as a class on any proposal involving fundamental changes in the rights of holders of such preferred stock. This right is in
addition to any voting rights that may be provided for in the applicable certificate of designation.
The issuance of preferred stock could adversely affect the voting power, conversion or other rights of holders of common stock and
reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. Preferred stock could
be issued quickly with terms designed to delay, deter or prevent a change in control of our company or make removal of management
more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock.
Delaware Anti-Takeover Law and Provisions of Our Amended and Restated Certificate of Incorporation and Amended and
Restated Bylaws
Our amended and restated certificate of incorporation and our amended and restated bylaws contain certain provisions that could have
the effect of delaying, deterring or preventing another party from acquiring control of us, and therefore could adversely affect the
market price of our common stock. These provisions and certain provisions of Delaware General Corporation Law (DGCL) which are
summarized below, may also discourage coercive takeover practices and inadequate takeover bids, and are designed, in part, to
encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of
increased protection of our potential ability to negotiate more favorable terms with an unfriendly or unsolicited acquirer outweigh the
disadvantages of potentially discouraging a proposal to acquire us.
Delaware Anti-Takeover Law
We are subject to Section 203 of the Delaware General Corporation Law (Section 203). Section 203 generally prohibits a public
Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years
following the time that such stockholder became an interested stockholder, unless:
·
prior to such time the board of directors of the corporation approved either the business combination or the transaction which
resulted in the stockholder becoming an interested stockholder;
·
·
upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced,
excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested
stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which
employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in
a tender or exchange offer; or
at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special
meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 /3% of the outstanding voting stock
which is not owned by the interested stockholder.
2
Section 203 defines a business combination to include:
·
any merger or consolidation involving the corporation and the interested stockholder;
·
·
·
·
any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;
subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to
the interested stockholder;
subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the
stock of any class or series of the corporation beneficially owned by the interested stockholder; and
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits
provided by or through the corporation.
In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws
Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:
·
permit our Board of Directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as
they may designate (including the right to approve an acquisition or other change in our control);
·
·
·
·
·
·
provide that the authorized number of directors may be changed only by resolution of the board of directors;
provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the
affirmative vote of a majority of directors then in office, even if less than a quorum;
require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders
and not be taken by written consent;
provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as
directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the
form and content of a stockholder's notice;
do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to
vote in any election of directors to elect all of the directors standing for election, if they should so choose); and
provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or
by our Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors.
The amendment of any of these provisions, with the exception of the ability of our Board of Directors to issue shares of preferred
stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66 /3% of our
then-outstanding common stock.
2
The provisions of the DGCL and the provisions of our amended and restated certificate of incorporation and amended and restated
bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they might also inhibit
temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts.
These provisions might also have the effect of preventing changes in our management. It is possible that these provisions could make
it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar's
address is 250 Royall Street, Canton, MA, 02021.
Listing on The Nasdaq Global Market
Our common stock is listed on The Nasdaq Global Market under the symbol "XNCR".
Exhibit 10.33
revised
August 5, 2019
Ms. Celia Eckert
Dear Ms. Eckert,
Congratulations! I am pleased to confirm our offer of a position as Vice President, General Counsel and Corporate
Secretary reporting to the President & CEO. The specifics of this offer, subject to approval by the Board of Directors,
are as follows:
·
·
·
·
·
Start date of September 3 , 2019
rd
Annual base salary of Three Hundred Seventy Five Thousand dollars ($375,000), less standard withholdings
and deductions, payable in accordance with the Company’s standard payroll procedures.
Eligibility for discretionary increases and performance bonuses (target 40%) in accordance with the Company’s
programs less standard withholdings and deductions, with metrics dependent upon corporate and individual
performance. You are eligible for a prorated portion of the 40% target in 2019 and will be eligible for the full
40% target in 2020. Any bonus you earn will be paid out in cash and/or stock in accordance with the
Company’s standard practice.
Options for Ninety One Thousand Two Hundred Ninety Two (91,292) shares of Xencor Common Stock valued
at approximately $1.9MM (based on the 6/30/2019 Black-Scholes value of $21.36) vesting over the
Company’s standard vesting schedule; (i) twenty five percent (25%) of the options shall vest on the one-year
anniversary of the Start Date: (ii) the balance of the option shares shall vest at the rate of 1/48 on the final date
of each month thereafter: and (iii) you must be employed by the Company on each applicable vesting date. The
exercise price of the option shares is equal to the fair market value of the Common Stock on the grant date. The
options shall be subject to and governed by the Company’s 2013 Equity Plan (the “Plan”).
th
The Company shall reimburse you the amount of the following expense you incur on or before 24 months from
your start date, up to One Hundred Thousand dollars ($100,000) (the “Relocation Payments”): (i) reasonable
costs associated with the sale of your current primary residence, including reimbursement of payment of real
estate commissions to your real estate agent; but specifically excluding any “loss” as a result of your sale of
your primary residence (as determined by comparing the original purchase price paid by you for your primary
residence, compared to the price at which you sell your primary residence) and (ii) relocation costs (including
temporary housing, move and travel). All such Relocation Payments that are subject to taxation will be grossed
up accordingly upon submission of expense receipts for reimbursement set forth below. The Relocation
Payments (and related tax gross up) are an advance and will be paid to you, as applicable, prior to being earned
by you.
If you cease to be employed by the Company for any reason prior to the twelve (12) month anniversary of the
Commencement Date, you must repay to the Company all Relocation Payments that the Company had provided
to you as of the employment termination date.
·
·
·
·
·
·
·
Eligibility to participate in the Company Employee Stock Purchase Plan (ESPP). The Plan allows for purchase
of Company stock at a discount less than the fair market value of the Company’s stock on the purchase date,
subject to certain limitations.
Eligibility for participation in the Company’s employee benefits plan including medical, dental and life
insurance, subject to the terms, conditions and limitations of the plans. The Company reserves the right to
modify its benefits plan as needed.
401(k) plan (matching by Xencor)
Paid Personal Leave (PPL) accrual at 18 days/year
9 holidays/year
Termination without Cause:
In the event the Company terminates your employment without Cause, you shall be eligible for the following
benefits: (i) a cash payment equivalent to twelve (12) months of your base salary at the rate in effect as of the
effective date of such termination and (ii) if you are eligible for and timely elect continued group health plan
coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) following your
termination, the Company will pay your COBRA group health insurance premiums for you and your eligible
dependents until the earliest of (A) the close of the twelve (12) month period following the termination of your
employment (the “COBRA Payment Period”), (B) the expiration date of your eligibility for the continuation
coverage under COBRA, or (C) the date when you become eligible for substantially equivalent health insurance
coverage in connection with new employment or self-employment. References to COBRA premiums shall not
include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement
plan. Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it
cannot pay the COBRA premiums without potentially incurring financial costs of penalties under applicable
law (including, without limitation, Section 2716 of the Public Health Service Act), then regardless of whether
you elect continued health coverage under COBRA, in lieu of providing the COBRA premiums, the Company
will instead pay you on the last day of each remaining month of the COBRA Payment Period, a fully taxable
cash payment equal to the COBRA Premiums of that month, subject to applicable tax withholdings (such
amount, the “Special Severance Payment”), which payments shall continue on until the earlier of expiration of
the COBRA Payment Period or the date when you become eligible for the substantially equivalent health
insurance coverage in connection with new employment or self-employment. As a condition to receipt of these
severance-related benefits, you must provide to the Company a fully-executed and non-revocable release of
claims in a form acceptable to the Company.
Change of Control:
In the event the Company terminates your employment without Cause in connection with a Change in Control
of the Company (for purposes of this Agreement, “Change in Control” shall have the meaning specified in the
Plan) which occurs prior to the one year anniversary of the Start Date, the number of vested option shares
available for you to immediately exercise shall be calculated as if you had remained employed by the Company
for one (1) additional year. In the event the Company terminates your employment in connection with a
Change in Control which occurs after the one year anniversary of the Start Date, all (100%) of the option shares
shall be fully vested and immediately exercisable. A termination of employment shall be deemed to be in
connection with a Change in Control if it is initiated by the Company and is effective within ninety (90) days
prior to twelve (12) months after the effective date of the Change in Control of the Company. As a condition to
this accelerated vesting you must provide to the Company a fully-executed and non-revocable release of claims
in a form acceptable to the Company.
This offer is contingent upon your executing a Proprietary Information and Inventions Agreement to be prepared by
Xencor and completing a Federal Employment Eligibility Verification form (INS I-9).
By signing this letter, you understand and agree that your employment with Xencor is at-will. Therefore, your
employment can terminate, with or without cause, and with or without notice, at any time, at your option or Xencor’s
option, and Xencor can terminate or change all other terms and conditions of your employment, with or without cause,
and with or without notice, at any time. This at-will relationship will remain in effect throughout your employment at
Xencor or any of its subsidiaries or affiliates. This letter constitutes the entire agreement, arrangement and
understanding between you and Xencor on the nature and terms of your employment with Xencor. This letter
supersedes any prior or contemporaneous agreement, arrangement or understanding on this subject matter.
By executing this letter as provided below, you expressly acknowledge the termination of any such prior agreement,
arrangement or understanding. Also, by your execution of this letter, you affirm that no one has made any written or
verbal statement that contradicts the provisions of this letter. The at-will nature of your employment, as set forth in this
paragraph, can be modified only by a written agreement signed the Chief Executive Officer and you, which expressly
alters it. This at-will relationship may not be modified by any oral or implied agreement, or by any Company policies,
practices or patterns of conduct.
If this offer is suitable, please sign and date this letter and retain the copy for your records.
Sincerely,
/s/ Bassil Dahiyat
Bassil I. Dahiyat
President & CEO
I have read and understand the terms of employment described in this letter and consent to all of the terms and
provisions contained herein.
/s/ Celia Eckert
Signature of acceptance
August 6, 2019
Date
Exhibit 10.34
November 12, 2019
Dr. Allan S. Yang
Dear Dr. Yang,
Congratulations! I am pleased to confirm our offer of a position as Senior Vice President and Chief Medical Officer
reporting to the President & CEO. The specifics of this offer, subject to approval by the Board of Directors, are as
follows:
·
·
·
·
·
·
·
Annual base salary of Four Hundred Sixty Five Thousand dollars ($465,000), less standard withholdings and
deductions, payable in accordance with the Company’s standard payroll procedures.
Eligibility for discretionary increases and performance bonuses (target 40%) in accordance with the Company’s
programs less standard withholdings and deductions, with metrics dependent upon corporate and individual
performance. You will not be eligible for the Q1 2020 annual increase and bonus but will be eligible for the Q1
2021 annual program. Any bonus you earn will be paid out in cash and/or stock in accordance with the
Company’s standard practice.
Options for Sixty Two Thousand Three Hundred (62,300) shares of Xencor Common Stock valued at
approximately $1.605MM (based on the 9/30/2019 Black-Scholes value of $25.76) vesting over the
Company’s standard vesting schedule; (i) twenty five percent (25%) of the options shall vest on the one-year
anniversary of the Start Date: (ii) the balance of the option shares shall vest at the rate of 1/48 on the final date
of each month thereafter: and (iii) you must be employed by the Company on each applicable vesting date. The
exercise price of the option shares is equal to the fair market value of the Common Stock on the grant date. The
options shall be subject to and governed by the Company’s 2013 Equity Plan (the “Plan”).
th
You will be granted restricted stock units (“RSU”) of Thirty One Thousand Nine Hundred (31,900) shares of
the Company’s common stock pursuant to the Plan valued at approximately $1.07MM. The RSU will vest over
a period of three (3) years following the Commencement Date with 1/3 of such units vesting on each of one
(1), two (2) and three (3) year anniversaries of the Commencement Date, so long as you remain continuously
employed by the Company.
rd
Signing bonus of One Hundred Eighty Thousand dollars ($180,000). If you cease to be employed by the
Company for any reason prior to the twenty four (24) month anniversary of your start date, you must repay to
the Company the Signing Bonus that the Company had provided to you as of the employment termination date.
The Company shall reimburse you the amount of reasonable costs associated with travel and lodging expenses
incurred for work at the San Diego office. All such payments that are subject to taxation will be grossed up
accordingly upon submission of expense receipts for reimbursement.
Eligibility to participate in the Company Employee Stock Purchase Plan (ESPP). The Plan allows for purchase
of Company stock at a discount less than the fair market value of the Company’s stock on the purchase date,
subject to certain limitations.
·
·
·
·
·
·
Eligibility for participation in the Company’s employee benefits plan including medical, dental and life
insurance, subject to the terms, conditions and limitations of the plans. The Company reserves the right to
modify its benefits plan as needed.
401(k) plan (matching by Xencor)
Paid Personal Leave (PPL) accrual at 18 days/year
9 holidays/year
Termination without Cause:
In the event the Company terminates your employment without Cause, you shall be eligible for the following
benefits: (i) a cash payment equivalent to twelve (12) months of your base salary at the rate in effect as of the
effective date of such termination and (ii) if you are eligible for and timely elect continued group health plan
coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) following your
termination, the Company will pay your COBRA group health insurance premiums for you and your eligible
dependents until the earliest of (A) the close of the twelve (12) month period following the termination of your
employment (the “COBRA Payment Period”), (B) the expiration date of your eligibility for the continuation
coverage under COBRA, or (C) the date when you become eligible for substantially equivalent health insurance
coverage in connection with new employment or self-employment. References to COBRA premiums shall not
include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement
plan. Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it
cannot pay the COBRA premiums without potentially incurring financial costs of penalties under applicable
law (including, without limitation, Section 2716 of the Public Health Service Act), then regardless of whether
you elect continued health coverage under COBRA, in lieu of providing the COBRA premiums, the Company
will instead pay you on the last day of each remaining month of the COBRA Payment Period, a fully taxable
cash payment equal to the COBRA Premiums of that month, subject to applicable tax withholdings (such
amount, the “Special Severance Payment”), which payments shall continue on until the earlier of expiration of
the COBRA Payment Period or the date when you become eligible for the substantially equivalent health
insurance coverage in connection with new employment or self-employment. As a condition to receipt of these
severance-related benefits, you must provide to the Company a fully-executed and non-revocable release of
claims in a form acceptable to the Company.
Change of Control:
In the event the Company terminates your employment without Cause in connection with a Change in Control
of the Company (for purposes of this Agreement, “Change in Control” shall have the meaning specified in the
Plan) which occurs prior to the one year anniversary of the Start Date, the number of vested option shares and
RSU shares available for you to immediately exercise shall be calculated as if you had remained employed by
the Company for one (1) additional year. In the event the Company terminates your employment in connection
with a Change in Control which occurs after the one year anniversary of the Start Date, all (100%) of the option
shares and RSU shares shall be fully vested and immediately exercisable. A termination of employment shall
be deemed to be in connection with a Change in Control if it is initiated by the Company and is effective within
ninety (90) days prior to twelve (12) months after the effective date of the Change in Control of the
Company. As a condition to this accelerated vesting you must provide to the Company a fully-executed and
non-revocable release of claims in a form acceptable to the Company.
This offer is contingent upon your executing a Proprietary Information and Inventions Agreement to be prepared by
Xencor and completing a Federal Employment Eligibility Verification form (INS I-9).
By signing this letter, you understand and agree that your employment with Xencor is at-will. Therefore, your
employment can terminate, with or without cause, and with or without notice, at any time, at your option or
Xencor’s option, and Xencor can terminate or change all other terms and conditions of your employment, with or
without cause, and with or without notice, at any time. This at-will relationship will remain in effect throughout your
employment at Xencor or any of its subsidiaries or affiliates. This letter constitutes the entire agreement, arrangement
and understanding between you and Xencor on the nature and terms of your employment with Xencor. This letter
supersedes any prior or contemporaneous agreement, arrangement or understanding on this subject matter.
By executing this letter as provided below, you expressly acknowledge the termination of any such prior agreement,
arrangement or understanding. Also, by your execution of this letter, you affirm that no one has made any written or
verbal statement that contradicts the provisions of this letter. The at-will nature of your employment, as set forth in this
paragraph, can be modified only by a written agreement signed the Chief Executive Officer and you, which expressly
alters it. This at-will relationship may not be modified by any oral or implied agreement, or by any Company policies,
practices or patterns of conduct.
If this offer is suitable, please sign and date this letter and retain the copy for your records.
Sincerely,
/s/ Bassil Dahiyat
Bassil I. Dahiyat
President & CEO
I have read and understand the terms of employment described in this letter and consent to all of the terms and
provisions contained herein.
/s/ Allen Yang
Signature of acceptance
November 14, 2019
Date
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Nos. 333-192635 and 333-216365) on Form
S-8 and the Registration Statement (No. 333-213700) on Form S-3 of Xencor, Inc. of our reports dated February 24,
2020, relating to our audits of the financial statements and the effectiveness of internal controls over financial reporting
of Xencor, Inc., appearing in this Annual Report on Form 10-K of Xencor, Inc. for the year ended December 31, 2019.
Exhibit 23.1
/s/ RSM US LLP
Los Angeles, California
February 24, 2020
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE
I, Bassil I. Dahiyat, Ph.D., certify that:
SARBANES‑OXLEY ACT OF 2002
Exhibit 31.1
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10‑K for the fiscal year ended December 31, 2019 of Xencor, Inc. (the
“Company”);
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the Company as of,
and for, the periods presented in this report;
The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d) – 15(f) for the Company and have:
a)
b)
c)
d)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the Company, including its
consolidated subsidiaries, is made known to us by others within those entities particularly during the period
in which this report is being prepared;
Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;
Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and
Disclosed in this report any change in the Company’s internal control over financial reporting that occurred
during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an
annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s
internal control over financial reporting; and
5.
The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of
directors (or persons performing the equivalent functions):
a)
b)
All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process,
summarize and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Company’s internal control over financial reporting.
Date: February 24, 2020
/s/ Bassil I. Dahiyat
Bassil I. Dahiyat, Ph.D.
President & Chief Executive Officer
Exhibit 31.2
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE
SARBANES‑OXLEY ACT OF 2002
I, John J. Kuch, certify that:
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10‑K for the fiscal year ended December 31, 2019 of Xencor, Inc. (the
“Company”);
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the Company as of,
and for, the periods presented in this report;
The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d) – 15(f)) for the Company and have:
a)
b)
c)
d)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the Company, including its
consolidated subsidiaries, is made known to us by others within those entities particularly during the period
in which this report is being prepared;
Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;
Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and
Disclosed in this report any change in the Company’s internal control over financial reporting that occurred
during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an
annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s
internal control over financial reporting; and
5.
The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of
directors (or persons performing the equivalent functions):
a)
b)
All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process,
summarize and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Company’s internal control over financial reporting.
/s/ John J. Kuch
John J. Kuch
Chief Financial Officer (Principal Financial Officer)
Date: February 24, 2020
Exhibit 32.1
CERTIFICATION
Pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
In connection with the Annual Report on Form 10‑K of Xencor, Inc. (the “Company”) for the period ended
December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bassil I.
Dahiyat, Ph.D., as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that to my knowledge:
1.
2.
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
1934, as amended; and
the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.
Date: February 24, 2020
/s/ Bassil I. Dahiyat
Bassil I. Dahiyat, Ph.D.
President & Chief Executive Officer
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is
not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated
by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided
to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff
upon request.
Exhibit 32.2
CERTIFICATION
Pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
In connection with the Annual Report on Form 10‑K of Xencor, Inc. (the “Company”) for the period ended
December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John J.
Kuch, as Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes‑Oxley Act of 2002, that to my knowledge:
1.
2.
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
1934, as amended; and
the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.
Date: February 24, 2020
/s/ John J. Kuch
John J. Kuch
Chief Financial Officer
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is
not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated
by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided
to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff
upon request.